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Hypertension 
Prevalence of hypertension 
High blood pressure (hypertension) is the major risk factor for cardiovascular disease, 
chronic kidney disease and overall increased risk of mortality (36, 81, 87, 90). With a 
prevalence of 1.4 billion people worldwide, representing 1 in every 4 adults, it has become 
the most critical and expensive public health problem (81). Global prevalence is predicted to 
increase to 1.6 billion by 2025 (21, 30, 53, 81, 87). Strikingly, ~50% of hypertensive patients 
are unaware of their condition (21) and hypertension is therefore often referred to as “the 
silent killer”. Around 90% of hypertensive patients have primary or essential hypertension, 
which means that the origin of their disorder  is unknown (16, 80). Hypertension is a complex 
disease, likely resulting from the combination of an inherited susceptibility and the exposure 
to environmental factors, such as a typical diet that is high in sodium (Na+) and low in 
potassium (K+) (40, 130). 
 
Essential hypertension 
Adults are usually diagnosed with hypertension when the systolic blood pressure is above 
140 mmHg and/or diastolic blood pressure is greater than 90 mmHg (56, 58). Essential 
hypertension is defined as high blood pressure in which the secondary causes such as 
monogenic diseases, renal failure, aldosteronism and renovascular disease are not present. 
To date, the primary cause of hypertension is determined in less than 10% of hypertensive 
patients, leaving the vast majority of patients with an undefined cause of their hypertension. 
Usually a cluster of factors are involved, including high Na+ intake in salt-sensitive patients 
(72, 131, 132), low K+ intake (129-131), obesity (42, 54, 84, 131, 132), diabetes (24), 
adaptive immunity (68), high alcohol intake (20, 131, 145), sedentary lifestyle (20, 59, 64, 
96), stress (95), hyperlipidaemia (80), and probably low calcium (Ca2+) (3), magnesium 
(Mg2+) and fiber intake (7, 118).  
 
Salt-sensitive essential hypertension 
Salt sensitivity is characterized by an increase or decrease in blood pressure in response to 
high or low dietary Na+ intake, respectively. This is observed in ~30% of normotensives and 
~65% hypertensives (1, 63). The interplay of genetic and environmental factors contributes 
to the development of salt sensitivity (63, 76). Declining glomerular filtration rate, aging, 
African descent, and obesity are associated with salt sensitivity (1). Salt-sensitive individuals 
consuming a high Na+ diet retain more Na+ than salt-resistant subjects (13). Additionally, in 
salt-sensitive patients the blood pressure response to Na+ is modified by other components 
in their diet such as K+, Ca2+ and Mg2+ (3, 63). Low dietary intake of K+, Ca2+ and Mg2+ 
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potentiates the salt sensitivity of blood pressure regulation (3, 7, 63, 118, 129-131). 
Conversely, high dietary intake of these minerals can attenuate the development of Na+-
induced hypertension (7, 118, 129-131). Dietary K+ exerts a powerful, dose-dependent 
inhibitory effect, as increased dietary K+ can even abolish salt sensitivity in both 
normotensives and hypertensives (1, 85). The proper knowledge on the dietary intervention 
provides an important opportunity for further improvement of the blood pressure control in 
our society. Adequate intake of K+, Ca2+ and Mg2+, besides limiting the Na+ consumption, is a 
viable health recommendation to reduce the risk of Na+-induced hypertension (78). 
Therefore, adherence to dietary patterns similar to the DASH (Dietary Approaches to Stop 
Hypertension) diet can be beneficial to salt-sensitive individuals (109). However, the majority 
of hypertensive patients will need treatment with antihypertensive drugs to normalize their 
blood pressure (20). Despite the availability of effective and safe antihypertensive drugs, 
hypertension and its concomitant risk factors remain uncontrolled in most patients. Hence, 
there is a need to decode and understand the molecular mechanisms underlying the 
pathogenesis of hypertension, in order to develop effective diagnostic tools, advance 
prevention, and improve treatment strategies. 
 
The kidneys are key to the regulation of blood pressure 
Na+ balance 
Blood pressure is intimately associated with extracellular fluid volume homeostasis, which 
itself is determined by Na+ content (86). Na+ homeostasis is achieved by balancing the 
intake and excretion of Na+. The kidneys are the principal route for Na+ excretion and are 
therefore central to long-term stability of blood pressure (9, 22, 25, 86). Studies of Guyton 
and other investigators were particularly instrumental to linking Na+ intake and kidney 
function to the pathogenesis of salt-sensitive hypertension (11, 38, 39, 68). Several 
physiological, genetic, and clinical studies have shown that an increased blood pressure is 
driven by a failure of the kidneys to excrete excess Na+ in a typical high Na+-low K+ diet. Na+ 
balance is, therefore, key to the homeostatic control of blood pressure. Na+ is freely filtered 
at the glomerulus, with ~99% of the filtered load being reabsorbed by Na+ transporters along 
the nephron, the smallest functional unit of the kidney (Fig 1) (86). The tubular system starts 
with the proximal tubule (PT), where ~65% of Na+ is both passively (~15%) and actively 
(~50%) reabsorbed (8). In the PT, active Na+ transport is mainly facilitated by the Na+/H+ 
exchanger type 3 (NHE3) and a variety of solute-specific symporters that reabsorb Na+ 
together with phosphate (NaPi’s) or organic solutes such as amino acids (SLC6A19), 
glucose (SLC5A2) and citrate (SLC13A1) (117). In the thick ascending limb of Henle’s loop 
(TAL), ~25% of the filtered Na+ load is reabsorbed by the furosemide-sensitive NaKCl 
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cotransporter (NKCC2). Fine-tuning (~7%) of Na+ reabsorption primarily takes place in the 
distal convoluted tubule (DCT) by the thiazide-sensitive NaCl cotransporter (NCC) (29). This 
fine regulation of Na+ is possible here because it is not affected by tubuloglomerular 
feedback (33). NCC is apically localized in epithelial cells lining DCT, with a robust 
expression in the early part of the DCT (DCT1) that decreases into the later part of the DCT 
(DCT2) (29, 69, 70, 91). Finally, residual Na+ (~2%) is reabsorbed in the connecting tubule 
(CNT) and collecting duct (CD) by amiloride-sensitive epithelial Na+ channel (ENaC) (86). 
The ENaC abundance increases gradually along the DCT2 and is highly expressed in the 
CNT and CD (10, 69, 115). The Na+ reabsorption is an energy consuming process, which is 
mainly driven by the Na+/K+ pump (Na/K-ATPase) localized in the basolateral membrane of 
all epithelial cells along the nephron (Fig. 1) (116). The Na/K-ATPase transports Na+ out of 
the cell and K+ into the cell by consuming adenosine triphosphate (ATP) (116). Na+ extrusion 
from the cell provides the chemical gradient, necessary as driving force for the Na+ 
transporters in the apical plasma membrane. 
 
NCC in health and disease 
NCC isoforms 
Although only ~7% of filtered Na+ is reabsorbed by NCC, this transport is essential for blood 
pressure control. The influence of the NCC on blood pressure has been elucidated through 
observations of diseases that  increase or decrease the abundance and/or activity of NCC 
(12, 35, 122, 143). The presence of NCC was first suggested in urinary bladder of the winter 
flounder (Pseudopreuronectes americanus) (100, 101). Later studies in this tissue 
demonstrated that the cotransporter was inhibited by thiazide diuretics (124) and the cDNA 
encoding NCC was cloned and characterized (32). NCC is encoded by the SLC12A3 gene, 
which consists of 26 exons (55 kb). In humans, alternate splicing of SLC12A3 gives rise to 
three separate isoforms (133), namely NCC1 (121), NCC2 (37), and NCC3 (75). NCC3 
(NP_001119580.1) consists of 1021 amino acids and is the shortest and most extensively 
studied isoform, as the other two isoforms are not present in rodents (37). NCC1 
(NP_000330.2) is the longest isoform in which splicing of exon 20 results in nine extra amino 
acids compared to NCC3 (Fig. 2) (121). NCC2 (NP_001119579.1) is only one amino acid 
shorter than NCC1 by missing glutamine (Q)95 (Fig. 2) (133). Subsequent studies confirmed 
the presence of both long and short forms of the exon 20 (20a and 20b respectively) as a 
result of splicing (74). Both NCC1 and NCC2 are similar in structure and were shown 
indistinguishable in experimental assays. Therefore, in this thesis, they will be referred to as 
NCCSV. Interestingly, NCCSV are only present in humans and higher primates. The 
importance of NCCSV in (patho)physiological conditions remains unknown. Therefore, the 
Chapter 1                                                                 The role of NaCl cotransporter in hypertension | 13 
present thesis aims to investigate the role of NCCSV as well as NCC3 in several 
(patho)physiological conditions. 
 
 
 
Figure 1 | Na+ reabsorption in the kidney.  
Na+ transporters along the nephron are responsible for ~99% Na+ reabsorption. Principal mechanisms 
of Na+ reabsorption are shown in the different nephron segments. Basolateral extrusion of Na+ to the 
blood occurs by the Na+/K+ pump (Na/K-ATPase). This provides the Na+ gradient, which is the driving 
force for secondary Na+ transporters, such as Na+/H+ exchanger type 3 (NHE3) and solute-specific 
symporters in proximal tubule (PT), furosemide-sensitive NaKCl cotransporter (NKCC2) in thick 
ascending limb of Henle’s loop (TAL), thiazide-sensitive NaCl cotransporter (NCC) in distal convolute 
tubule (DCT) and amiloride-sensitive epithelial Na+ channel (ENaC) that is localized in the apical 
membrane of connecting tubule (CNT) and collecting duct (CD). 
 
Chapter 1                                                                 The role of NaCl cotransporter in hypertension | 14 
 
Figure 2 | Splicing of NCC gene.  
Schematic representation of the SLC12A3 gene including exon 20a that encodes for the NCC splice 
variant (NCCSV, NCC isoform 1 and 2). Topological representation of NCCSV with 12 transmembrane 
domains and large amino- and carboxy-terminal domains. Serine (S811) is highlighted as putative 
phosphorylation site in the carboxyl-terminal domain. Left panel shows a multiple alignment of the 
human NCC1, NCC2, and NCC3 protein sequence. Lower panel shows a multiple sequence alignment 
of human, mouse, and rabbit NCC to demonstrate the additional nine amino acids in NCCSV. 
 
Genetic factors determining blood pressure 
 Gitelman syndrome 
All hereditary diseases associated with increased or decreased arterial blood pressure are 
due to mutations in genes encoding renal ion transporters or their regulators (23, 44, 121, 
143). Gitelman syndrome (OMIM 263800) is an autosomal recessive disease that results 
from loss of function mutations in the NCC gene. To date, more than 180 mutations 
throughout the whole NCC protein have been identified (134, 135, 139). Mutations identified 
in Gitelman syndrome can affect the function of NCC at different levels, including protein 
synthesis, trafficking, and activity (26). Gitelman syndrome is the most frequent hereditary 
tubular disorder (1:40,000), characterized by Na+ wasting, hypokalemic metabolic alkalosis, 
hypomagnesemia, hypocalciuria and patients have lower blood pressure compared to their 
age-matched unaffected relatives (35, 122). However, the disease is usually asymptomatic 
or presents with mild symptoms, of which the most frequent are muscle weakness, desire for 
Na+ intake, thirst, urge to urinate during the night and abdominal pain (62). A closely related 
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tubular salt wasting disorder is Bartter syndrome that results from mutations in the genes 
SLC12A1 and KCNJ1 encoding for NKCC2 and the renal outer medullary K+ channel 
(ROMK), respectively (120, 122). Both syndromes are characterized by impaired Na+ 
reabsorption that causes mild volume depletion, leading to prominent stimulation of the 
renin-angiotensin-aldosterone system (RAAS). In Bartter syndrome, this results from a 
defect in the TAL, while Na+ transport in the DCT is disturbed in Gitelman syndrome. In both 
disorders, patients have a normal to low blood pressure despite high RAAS activation. This 
might conceivably blunt the hypertensive phenotype in patients with essential hypertension, 
secondary forms of hypertension or environmental factors leading to hypertension.  
 
 Familial hyperkalemic hypertension  
Familial Hyperkalemic Hypertension (FHHt), also known as pseudohypoaldosteronism type 
II or Gordon syndrome (OMIM 145260), is a form of hypertension that results from gain of 
function of NCC. This is a consequence of mutations in WNK1, WNK4 (encoding the with no 
lysine [WNK] kinases) (143), KLHL3, or CUL3 (respectively coding for the Kelch-like 3 and 
Cullin 3 components of cullin–RING E3 ligase complexes that ubiquitinate substrates) (12). 
FHHt is an autosomal dominant or recessive disease, which is characterized by increased 
renal Na+ reabsorption, arterial hypertension, hyperkalemia, metabolic acidosis, and 
hypercalciuria, low plasma renin levels, with normal or low serum aldosterone levels (65, 
110, 143, 146). High blood pressure, hyperkalemia and metabolic acidosis in the absence of 
chronic renal failure are clinical clues to the diagnosis of FHHt that commonly presents at 
early age, during childhood or adolescence. Patients with these symptoms and clinical 
abnormalities can be tested for the known FHHt-causing mutations. Genetic screening can 
be useful to support the administration of thiazides, which act by blocking NCC (53, 77, 99). 
Strikingly, the hypertension as well as the hyperkalemia and metabolic disorders can be 
corrected by a low dose of thiazide-type diuretics (53, 77, 99). Therefore, several guidelines 
for management of hypertension in FFHt patients consider thiazide-type diuretics as first-line 
therapeutic tool to correct clinical manifestations and laboratory abnormalities caused by this 
syndrome (51, 53, 99). Hence, genetic testing is key for targeted treatment and can enable 
personalized control of blood pressure, thereby diminishing target organ damage and 
ultimately preventing cardiovascular events (108). Both Gitelman syndrome and FHHt 
demonstrate the relevance of NCC in the (patho)physiology of blood pressure.  
 
Renin-angiotensin-aldosterone system 
Aldosterone has been reported as the major regulatory hormone in the transport of Na+ in 
the DCT segment of the kidney. The DCT together with CNT and CD are collectively termed 
the aldosterone-sensitive distal nephron (6, 19, 137). Remarkably, the effects of either Na+ 
Chapter 1                                                                 The role of NaCl cotransporter in hypertension | 16 
or K+ abnormality on the RAAS components can be divergent. Aldosterone is produced by 
the adrenal gland in two physiological conditions namely hypovolemia and hyperkalemia. 
During hypovolemia aldosterone stimulates Na+ reabsorption; during hyperkalemia, 
aldosterone enhances secretion of K+ (6). The observation that a single hormone, i.e. 
aldosterone, has different effects on the Na+ and K+ transport has been termed the 
“aldosterone paradox”. Remarkably, aldosterone is elevated in both hypovolemic and 
hyperkalemic states but leads to distinct physiological responses in the kidney (6). Since 
RAAS activation is the hallmark of volume depletion but angiotensin II is not affected by 
changes in the plasma K+ concentration, it is suggested that angiotensin II plays an 
important role in discriminating between hypovolemic and hyperkalemic states.  
 Angiotensin II is known to regulate ENaC and ROMK directly via a complex interactive 
kinase network involving the WNK kinases (6). Angiotensin II stimulated K+ deficiency driven 
by ENaC and ROMK results in increased activity of NCC (141). Recently, it has been shown 
that plasma K+ levels directly modulates the WNK kinases in the DCT (130). There are four 
abundant WNK kinases along the aldosterone-sensitive distal nephron, namely WNK1, 
kidney-specific WNK1 (KS-WNK1), WNK3, and WNK4 (88). They can affect the Na+ and K+ 
transporters by modulating their trafficking to or from the plasma membrane and by 
modulating transport activity via phosphorylation. The latter involves the intermediary 
kinases SPAK (STE20/SPS1-related, proline alanine-rich kinase) and OSR1 (oxidative 
stress responsive protein type 1) that are phosphorylated and activated by WNK kinases. 
Subsequently, SPAK and OSR1 can phosphorylate NCC resulting in increased transport 
activity (28, 126, 151). While the exact mode of action of the different WNK kinases is still 
under debate, it is generally believed that WNK4 inhibits NCC activity by reducing its plasma 
membrane abundance. Angiotensin II can directly activate NCC and ENaC (138), but it is 
also shown to block the inhibitory effect of WNK4 that allows trafficking of NCC to the 
plasma membrane (150), ultimately increasing Na+ reabsorption in DCT (113, 114). 
Furthermore, the WNK kinases can interact with the serum and glucocorticoid-inducible 
kinase 1 (SGK1) (89), which is known as an important kinase in the regulation of NCC and 
ENaC (5, 18, 50). Clinically, RAAS is activated in various disease states, including some 
forms of hypertension (142). Angiotensin receptor blockers are well-known anti-hypertensive 
drugs that reduce blood pressure by antagonizing angiotensin II type I receptors (43). This 
shows the clinical relevance of angiotensin II in regulation of the blood pressure (127). The 
presence of angiotensin II receptors in the basolateral and luminal membranes of DCT 
epithelial cells offers a potential role for angiotensin II to indirectly regulate Na+ transport (41, 
82).  
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Posttranslational modifications  
Posttranslational modifications including glycosylation, ubiquitylation, and phosphorylation 
have been extensively investigated and play a crucial role in the regulation of NCC activity 
(34, 49). These cascades of processing can control the trafficking of the transporter to the 
plasma membrane and affect its stability at the plasma membrane (34, 49, 60).  
 Glycosylation 
NCC is a membrane glycoprotein and contains 12 transmembrane segments (S) with large 
intracellular amino- and carboxy-terminal regions, and a large hydrophilic extracellular loop 
between S7 and S8 (Fig. 2) (32). This loop between S7 and S8, contains glycosylation sites 
that are essential for the cell surface expression of NCC, thiazide sensitivity and NCC 
activity (49). It has been suggested that NCC forms functional dimers (27, 33). 
 Ubiquitylation 
Adding the ligands of ubiquitin to lysine residues of a target protein, marks the protein for 
degradation (34, 140). Ubiquitylation is a powerful way to modulate the activity of NCC 
protein and was suggested to be involved in endocytosis of the protein at the plasma 
membrane (Fig. 3) (2, 61). A well-known example of ubiquitin-mediated protein degradation 
occurs with ENaC, which is ubiquitylated by Nedd4-2 ubiquitin ligase (34). Liddle syndrome, 
a monogenic hypertensive disease, is caused by mutations in different subunits of ENaC 
that prevent binding to the Nedd4-2 ubiquitin ligase (34) or affecting the extracellular domain 
of ENaC (111). As a consequence the ENaC expression in the apical membrane or intrinsic 
channel activity is increased, resulting in enhanced Na+ reabsorption that leads to 
hypertension (31, 123). Interestingly, it has also been shown that Nedd4-2 can interact with 
NCC, postulating a role for Nedd4-2-mediated ubiquitylation in NCC regulation (61). The 
SGK1-Nedd4-2 pathway that modulates ENaC activity might also be linked to NCC (5). 
Generally, aldosterone increases SGK1 expression, which in turn phosphorylates Nedd4-2, 
thereby promoting interaction with 14-3-3 proteins. Subsequently, this interaction reduces 
the ligase activity of Nedd4-2 towards ENaC (18, 50). There is increasing evidence that 
aldosterone and SGK1 also modulate NCC by the ubiquitin ligase Nedd4-2 (5). In vitro, 
Nedd4-2 activity induced a reduction in NCC surface expression and it was observed that 
activation of SGK1 disrupted the Nedd4-2-NCC interaction (5). In an inducible knockout 
model of Nedd4-2, knockdown of the ubiquitin ligase Nedd4-2 provoked a dramatic increase 
in NCC expression (5, 18). In addition, there are several studies indicating that 
phosphorylation of NCC could interfere with its ubiquitylation, thereby playing a dual role in 
modulating NCC function (107, 148).  
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Figure 3 | NCC regulation by kinases. 
Regulation of NCC by with no lysine (WNKs) kinases. The various interactions of the NCC regulatory 
pathway are shown as green arrows (stimulatory) or red lines (inhibitory). Phosphorylation is indicated 
with the symbol P. WNK4 is capable of activating SPAK (STE20/SPS1-related, proline alanine-rich 
kinase) and OSR1 (oxidative stress responsive protein type 1). WNK4 regulates Nedd4-2-mediated 
ubiquitylation of NCC. Kelch-like 3 (KLHL3) and Cullin 3 (CUL3), components of cullin–RING E3 
ligase complexes, ubiquitinate WNK1 and WNK4 resulting in degradation of WNK1 and WNK4. The 
K+ channel, comprising Kir4.1, likely with Kir5.1, appears to be the predominant conductive pathway 
for K+ exit along the basolateral membrane. Cl- channel (CLC-Kb) is responsible for efflux of Cl-. 
Plasma K+ levels regulate intracellular Cl- concentration via modulating the basolateral membrane 
voltage. Low intracellular Cl- stimulates WNK-SPAK/OSR1. Downstream, NCC is phosphorylated, 
activated, by SPAK/OSR1. 
 
 Phosphorylation of NCC  
Phosphorylation is considered one of the most important posttranslational modification 
processes in the regulation of NCC activity. Therefore, protein phosphorylation mechanisms 
have been comprehensively investigated (102, 103, 147). The amino-terminal domain of 
NCC contains several key phosphorylation sites including threonines 48, 55 and 60 and 
serines 73 and 91 (T48, T55, T60, S73, S91 in humans, and T46, T53, T58, S71, S91 in 
rodents, respectively) (34). These residues are targets of the serine-threonine kinases SPAK 
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and OSR1, which are activated by WNK kinases (92, 110). Several studies have shown an 
increase in NCC activity by augmented phosphorylation at these sites (28, 92, 126, 151). To 
investigate the role of these residues, the sites of phosphorylation were eliminated by site-
directed mutations, by changing T48; T55; T60; S73 and S91 to alanine (T48; T55A; T60A; 
S73A; S91A), representing the inactive form of the NCC protein as a non-phosphorylable 
amino acid. Eliminating T48, T55, T60, as well as S73 and S91, decreased basal activity of 
NCC and prevented activation of NCC (34, 102, 148). Interestingly, several studies have 
shown that changing T60 to a non-phosphorylated amino acid (T60A) prevented or reduced 
the phosphorylation at the other sites (T48, T55, S73 or S91), suggesting that T60 is a key 
modulator in the regulation of NCC activity (34, 102, 148). Table 1 shows a compilation of 
studies where different NCC phosphorylation sites have been analyzed under different 
conditions and stimuli. All three human NCC isoforms contain the T55 and T60 residues that 
are essential mediators of NCC activity. Recently, a new phosphorylation site located at 
S811 in NCCSV was identified (37). For decades, NCC3 has been extensively investigated in 
patho(physiological) conditions, leaving NCCSV unexplored. To date, most studies measuring 
NCC activity used conventional models such as rodents, Xenopus laevis and renal cell lines. 
The lack of NCCSV in these models and non-invasive method to investigate human NCC 
hampered studying the role of NCCSV in renal Na+ handling and blood pressure. 
 
Calcineurin inhibitor-induced NCC activity  
The calcineurin inhibitors (CNIs) cyclosporine A (CsA) and tacrolimus (Tac) are widely used 
to prevent rejection of transplanted organs (48). Although both CsA and Tac exert their 
principal immunosuppressive effects through inhibition of the same target protein, 
calcineurin, they differ in cytoplasmic-binding proteins, namely cyclophilins and FKBP12 for 
CsA and Tac, respectively (48). A common side effect of CNIs is hypertension, although 
CsA appears more hypertensinogenic than Tac (14, 15, 73). The clinical characteristics of 
CNI-treated patients sometimes resemble that of FHHt (4, 93). Several studies have shown 
that CNIs increase NCC activity possibly contributing to hypertension (47, 66). Some reports 
suggest that CNIs do not activate NCC directly, but it activates NCC via the WNKs, and that 
inhibition of calcineurin is required for this effect (66, 79). Recently, it was demonstrated in 
mice that acute Tac treatment increases the NCC activity, and this acute regulatory system 
mediated by calcineurin is shown to be independent of the WNK-SPAK signaling cascade 
(119). 
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Table 1 | Phosphorylation of NCC at specific phosphorylation sites under various experimental 
conditions. 
Experimental 
model 
Stimulus Effect Phosphorylation 
site* 
Kinase involved Ref 
COS7 cells T55D T60D and S73D NCC 
mutants 
         T55, T60, S73 ? (60) 
Xenopus 
laevis oocytes 
Angiotensin II  T55 WNK4-SPAK (113) 
Rat ACEI   T55, T60 SPAK (67) 
Rat Angiotensin II   T55, T60 SPAK (67) 
Xenopus 
laevis oocytes 
Low concentration of Cl-  T55, T60, S73 ? (92) 
Rat Vasopressin  T55, T60 WNK4-SPAK/OSR1 (94) 
HEK 293 cells  Hypotonic with low 
concentration of Cl- 
 T48, T55, T60, S91 WNK1-SPAK/OSR1 (102) 
Mouse Low NaCl diet  S73 WNK4-SPAK/OSR1 (19) 
Mouse Low NaCl and K+ diet  T55, S73 SGK1 (136) 
Mouse Wnk4D561A/+ Knockin  T60 WNK4 (149) 
Mouse Angiotensin II / Aldosterone  T55, T60, SPAK (137) 
Rat  Aldosterone / low Na+ diet   T55, T60, S124 ? (106) 
Mouse  T60M NCC Knockin  T55, T60, S73 independent of 
WNK4-SPAK  
(148) 
MDCK Cells T60A and T60M NCC mutants  T55, T60, S73 independent of 
WNK4-SPAK  
(148) 
COS7 / HEK 
293 cells 
Angiotensin II / Forskolin  ? PKC- and PKA-
WNK4-SPAK  
(17) 
Mouse Angiotensin II / vasopressin  T60 PKC- and PKA-
WNK4  
(17) 
*Number corresponds to the human NCC sequence. T55D, T60D and S73D, constitutively phosphorylated NCC 
mutants; T55A, T60A, and T60M, non-phosphorylated NCC mutants; HEK293 cells, Human embryonic kidney 293 
cells; DCT, distal convoluted tubule; WNK, with no lysine; SPAK, Ste20-related proline-alanine-rich kinase; 
OSR1, oxidative stress response 1; ACEI, angiotensin-converting enzyme inhibitor; SGK1, glucocorticoid 
inducible kinase 1; MDCK, Madin-Darby canine kidney cells. 
The current comprehensive model of NCC regulation 
NCC is processed in the endoplasmic reticulum and Golgi apparatus, and trafficked to the 
plasma membrane, where it is activated by phosphorylation. For thiazide-sensitive Na+ 
reabsorption to occur in the DCT, two processes must take place (125). First, a sufficient 
number of NCC must be present at the DCT apical membrane, which is regulated by many 
kinases that regulate the forward-trafficking and degradation process of the NCC protein. 
Second, NCC present at the DCT lumen must be switched on by phosphorylation (125). Two 
related serine-threonine kinases, SPAK (55) and OSR1 (128), phosphorylate NCC directly, 
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by transferring phosphate groups from ATP to serine and threonine residues present in the 
intracellular amino-terminal domain of NCC (102). Phosphorylation at these residues 
enhances the ability of the cotransporter to transport Na+, presumably by altering its protein 
conformation. SPAK and OSR1 are the two downstream substrates of WNK1, WNK3 and 
WNK4 (40, 83, 88, 102). WNKs appear to modulate both the trafficking and phosphorylation 
of NCC by separate mechanisms (45). These intracellular signaling cascade that controls 
NCC abundance and activity has been extensively investigated in the past decade (Fig. 3). 
Proteins involved in ubiquitylation including Nedd4-2 (5, 105), KLHL3 (12, 71) and CUL3 
(12) were also found to regulate NCC. Although, WNK1 and WNK4 mutations were the first 
to be implicated in the pathogenesis of FHHt, most FHHt-affected individuals harbor 
mutations in two other genes: the CUL3 and its adaptor, KLHL3 (12, 71). Together Cullin3 
and KLHL3 form a Cullin-RING type E3 ubiquitin ligase complex that targets WNK kinases 
for ubiquitination to promote their proteasomal degradation (88). Additionally, SGK1 was 
also found to regulate NCC. However it is suggested that SGK1 does not interact directly 
with NCC, but rather through WNK4 and Nedd4-2 (5, 104, 110, 136). This pathway seems to 
be translated, at least in part, by SGK1-induced WNK4 phosphorylation that results in 
reduced inhibition of WNK4 on NCC (104, 110). Cell shrinkage or a decrease in intracellular 
Cl- concentration, or both, triggers the phosphorylation of NCC. WNK1 crystal structure 
showed that WNK1 binds Cl- near the catalytic lysine in subdomain 1, inhibiting its 
autophosphorylation and, in turn, activity (97). In low Cl- conditions, this WNK1 auto-
phosphorylation results in OSR1/SPAK-NCC phosphorylation cascade (88, 97). Recently, it 
has been shown that plasma K+ levels regulate NCC through changes in intracellular Cl- 
thereby modulating WNK kinases (130). Lower plasma K+ concentration can enhance Cl- 
efflux from DCT cells through both electrogenic and electroneutral mechanisms (129, 130). 
The extracellular K+ levels, independent of hormonal effects, directly modulates the WNK-
SPAK-OSR1-NCC cascade. This may explain, in part, the hypertension and cardiovascular 
mortality observed in individuals who consume a low K+ diet and suggests that dietary K+ 
deficiency activates NCC leading to hypertension. 
 
Urinary extracellular vesicles  
Almost all cells in our body release vesicles as way of intercellular communication. They are 
formed when multivesicular bodies within the cell merge with the plasma membrane and 
release internal vesicles into the extracellular space (Fig. 4) (46). In the kidney, these 
vesicles can be shed into the urine and are termed urinary extracellular vesicles (uEVs). 
uEVs, which also includes urinary exosomes, are nanosized vesicles (30-120 nm) that 
contain membrane and cytosolic protein, DNA and RNA that are conserved and protected 
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from degradation (98, 112). These uEVs contain membrane and cytosolic protein, DNA and 
RNA that are conserved and protected from degradation (112). The cargo of uEVs reflects 
changes in the expression of different proteins present in the epithelial cells of the DCT, 
including total NCC and phosphorylated form of NCC (Fig. 4) (52, 133, 137). Hence, urine 
provides a non-invasive source to study the regulation of NCC in the kidney (37, 137, 144). 
Indeed, it has been shown that patients with Gitelman syndrome display a decreased NCC 
abundance in uEVs (23, 57). Inversely, patients with FHHt demonstrate higher NCC levels in 
the kidney and this increased abundance was also observed in uEVs of patients with FHHt 
(137). Furthermore, administration of a mineralocorticoid like aldosterone rapidly increased 
the abundance of total and phosphorylated NCC in uEVs (144). This suggests that NCC 
abundance in uEVs reflects the actual state of NCC expression in the kidney. Together, the 
uEVs provide a unique novel tool to study the regulation of the three NCC isoforms in the 
human kidney, and may have clinical utility for biomarker investigation of a variety of 
physiological and pathological conditions. 
 
Figure 4 | Release of urinary extracellular vesicles in distal convoluted tubule (DCT). 
The plasma membrane buds inward, forming a membrane-bound vacuole, an endosome. This 
endosome goes through several changes as it matures from an early endosome to a late endosome. 
Most notably, the endosomal membrane buds inward and pinches off to make membrane-bound 
vesicles inside the endosome and the endosome is now titled a multivesicular body. The 
multivesicular body travel to and fuse with the plasma membrane, releasing its contents, which, once 
existing outside the cell, are called exosomes (size 30–120 nm). 
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Aims of the thesis  
The paragraphs above have illustrated the importance of NCC function in the 
(patho)physiology of hypertension. While the third isoform, NCC3 has been the focus of 
intense research over the last decades, the regulation and function of NCCSV in blood 
pressure control remained largely unexplored. To date, the detailed localization of NCCSV in 
human kidney, the regulatory network, the relationship with NCC3 and its relevance in renal 
Na+ handling remains to be elucidated. A better understanding of these isoforms is critical to 
unravel the molecular events underlying the pathogenesis of essential hypertension, and to 
develop effective therapeutic strategies to combat the dysregulation of blood pressure. 
Therefore, this thesis aims to study the role of all three NCC isoforms in various 
(patho)physiological conditions. The goal of Chapter 2 is to determine the abundance and 
localization of previously underrepresented NCC isoforms compared to NCC3 in the human 
kidney. Additionally, the functional properties of the NCCSV as well as its regulation in 
physiological conditions is studied. In Chapter 3 the aim is to study the effect of various anti-
hypertensive treatments on the abundance and phosphorylation of all three NCC isoforms in 
uEVs of essential hypertensive patients, and to explore the relationship between NCC 
abundance in uEVs and changes in blood pressure. The aim of Chapter 4 is to investigate 
the role of the new S811 phosphorylation site in NCCSV function, determine the interaction of 
NCCSV with NCC3 and to study the effect of NCCSV S811 phosphorylation on the function of 
NCC3. In Chapter 5 of this thesis a large-scale study is performed to investigate the effect of 
CNIs, including cyclosporine A and tacrolimus on the abundance of both total and 
phosphorylated NCC in uEVs, and assessed whether NCC abundance in uEVs predicts the 
blood pressure response to thiazide diuretics. In order to confirm the effect of CNIs on NCC 
in the kidney, an ex vivo study is conducted in mice cortical tubules exposed to cyclosporine. 
In Chapter 6, in mice, the effect of high Na+-low K+ diet was not only investigated on NCC 
regulation, but its affect was also studied on Mg2+, Ca2+ and phosphate (Pi) homeostasis. 
Finally, the results of this thesis are summarized and discussed in Chapter 7. 
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Abstract 
The thiazide-sensitive NaCl cotransporter (NCC) is an important pharmacological target in 
the treatment of hypertension. Human SLC12A3 gene, encoding NCC, gives rise to three 
isoforms. Only the 3rd isoform has been extensively investigated. The aim of the present 
study was, therefore, to establish the abundance and localization of the almost identical 
isoforms 1 and 2 (NCC1/2) in the human kidney and to determine their functional properties 
and regulation in physiological conditions. Immunohistochemical analysis of NCC1/2 in the 
human kidney revealed that NCC1/2 localizes to the apical plasma membrane of the distal 
convoluted tubule. Importantly, NCC1/2 mRNA constitutes ~44% of all NCC isoforms in the 
human kidney. Functional analysis performed in the Xenopus laevis oocyte revealed that 
thiazide-sensitive 22Na+ transport of NCC1 was significantly increased in comparison to 
NCC3. Mimicking a constitutively active phosphorylation site at residue 811 (S811D) in NCC1 
further augmented Na+ transport, while a non-phosphorylatable variant (S811A) of NCC1 
prevented this enhanced response. Analysis of human urinary exosomes demonstrated that 
water loading in human subjects significantly reduces the abundance of NCC1/2 in urinary 
exosomes. The present study highlights that previously underrepresented NCC1/2 is a fully 
functional thiazide-sensitive NaCl-transporting protein. Being significantly expressed in the 
kidney it may constitute a unique route of renal NaCl reabsorption and could, therefore, play 
an important role in blood pressure regulation.  
 
Keywords: Hypertension / WNK4 / Aldosterone-sensitive distal part of the nephron / Sodium 
/ Kidney 
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Introduction 
Hypertension is a global disease with an overall prevalence around 30-45% in the general 
population (18, 21). The kidneys play a key role in chronic blood pressure homeostasis by 
maintaining appropriate renal salt reabsorption. It is of critical importance to understand the 
molecular mechanisms governing renal NaCl transport in physiological and 
pathophysiological conditions in order to exploit them as therapeutic targets. 
The 2014 evidence-based guideline for the management of high blood pressure in 
adults recommends thiazide-type diuretics as initial therapy for hypertension (18). Thiazide-
type diuretics act by blocking the NaCl cotransporter (NCC) in the distal convoluted tubule 
(DCT), highlighting the importance of NCC in blood pressure regulation. Mutations in NCC-
encoding gene (SLC12A3) cause Gitelman’s syndrome (OMIM 263800), a condition 
characterized by salt wasting and hypotension (13, 22). A mirror image of Gitelman’s 
syndrome with increased renal reabsorption of NaCl and a resultant increase in systemic 
blood pressure can be observed in patients with Pseudohypoaldosteronism type II (PHAII, 
also known as Gordon syndrome (OMIM 145260) (10). PHAII results from mutations in the 
WNK [with-no-K(Lys)] kinases (members WNK1 and WNK4) (47), as well as kelch-like 3 
(KLHL3) and cullin 3 (CUL3) (2, 14), which play an instrumental role in regulating NaCl 
reabsorption in the distal part of the nephron (20, 29, 31, 45, 47, 48). The amino- (N)-
terminal domain of NCC contains several phosphorylation sites being of critical importance 
for NCC function. These residues are targets of the serine-threonine kinases, Ste20-related 
proline-alanine-rich kinase (SPAK) and oxidative stress response 1 (OSR1) (27, 31). In 
addition, kinases in the WNK family as well as the serum- and glucocorticoid-inducible 
kinase 1 (SGK1) interact within the network of SPAK and OSR1, thereby affecting the 
phosphorylation status of NCC (7, 38, 39, 49).  
The SLC12A3 gene encoding the human NCC yields three separate isoforms as a 
result of an alternative splicing. An mRNA sequence encoding a 1,030 amino acid NCC 
protein was first deposited in the GenBank by Simon et al. (35) representing isoform 1 
(NCC1) (accession no. NP_000330.2). Subsequently, Mastroianni et al. (23) reported an 
mRNA sequence encoding a protein of 1,021 amino acids representing isoform 3 (NCC3) 
(accession no. NP_001119580.1), in which exon 20 is nine amino acids shorter than in 
NCC1. Following studies confirmed the presence of both long and short form of the exon 20 
(20a and 20b respectively) as a result of a possible cryptic splicing donor site (22). 
Moreover, cDNA analysis indicated that NCC3 constitutes the predominant form in the 
human kidney (22). Isoform 2 (NCC2) (accession no. NP_001119579.1) is only one amino 
acid shorter than NCC1. Recently, Gonzales et al.(15) used a proteomic approach to analyze 
human urinary exosomes and identified a novel phosphorylation site at serine (Ser811). This 
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residue is present only in NCC1 and NCC2. Interestingly, mouse and rat SLC12A3 genes do 
not contain the segment coded by human exon 20, hence NCC1 and NCC2 are not present 
in these animals. The lack of NCC1 and NCC2 in rodents hampered the progress and 
interest towards further investigations and until now NCC3 has predominantly been studied 
(8, 12). At present, detailed localization of NCC1 and NCC2 proteins in human kidney, their 
regulatory network, and relevance in renal Na+ handling remain to be elucidated.  
The goal of the present study was, therefore, to determine the abundance and 
localization of previously underrepresented NCC isoforms in comparison to NCC3 in the 
human kidney as well as their functional properties and regulation in physiological 
conditions. To this end, the presence of NCC1, NCC2, and NCC3 in the human urinary 
exosomes was assessed by mass spectrometric analysis. The localization and regulation of 
NCC isoforms was investigated by immunohistochemical analysis in human kidney biopsies 
and by immunoblotting of kidney membrane fractions and urinary exosomes with newly 
developed isoform specific antibodies. Functional capacity to transport Na+ by NCC1 was 
determined using the Xenopus oocytes expression system. Furthermore, to evaluate 
physiological regulation of NCC isoforms during acute water loading of human subjects was 
chosen as a model, since hormones maintaining water balance are known to regulate NCC 
(5, 28, 30-34, 41, 42).  
 
Materials and Methods  
Isolation and sequencing of NCC variants from human kidney 
Human kidney cDNA was amplified using primers against the C-terminal domain of NCC. 
The PCR product was isolated, cloned into the pGEM®-T Easy Vector System (Promega), 
and transformed into DH5-E. Coli bacteria. Colonies were isolated, plasmid DNA was 
extracted, and submitted for Sanger sequencing. The resulting chromatograms from the 
sequencing confirmed the presence of NCC1/2 and NCC3 in the human kidney.  
 
Real-time relative RT-PCR quantification  
All 7 donors gave permission for donating their kidneys after death. In case the kidney 
appeared not suitable for transplantation the donor gave permission to use the kidneys for 
research purposes, which is registered in the Dutch Donor registry. Relative amount of 
NCC1/2 and NCC1-3 mRNA in the human kidney was determined by a real-time RT-PCR 
based on the standard curve method (46). RNA from 7 healthy humans kidney cortex was 
isolated with Trizol Reagent (Life Technologies, Grand Island, NY, USA) and cDNA was 
synthesized with moloney murine leukemia virus (M-MLV) revers transcriptase (Invitrogen, 
Grand Island, NY, USA). Following primers amplifying specifically NCC1/2 as well as primers 
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against N-terminal fragment recognizing both NCC1/2 and NCC3 combined (NCC1-3) were 
used: NCC1/2 Fw: GTGCCAGGCCATCAGTCT; NCC1/2 Rev: TATGGTCTTCTTGCCCTGCT; 
NCC1-3 Fw: TGTTTGGGGCTATCATCTCC; NCC1-3 Rev:  GAGGAGCCCCAATTTACCTC. 
Standard curve was prepared based on mixed DNA plasmids containing both NCC1/2 and 
NCC3 dilutions ranging from 2.5 × 105 – 5.12 × 108. Quantification was performed with iQ 
SYBR Green supermix system (Bio-Rad, Hercules, CA, USA) according to manufacturer’s 
instructions. The products of the RT-PCR were verified by sequencing. The absolute copy 
number per µg of mRNA isolated form the human cortex was defined and the ratio of NCC1/2 
to NCC1-3 was determined.   
 
Mutagenesis and constructs 
Human NCC in pT7Ts has been previously described.(7) The human NCC1 fragment was 
generated by site directed mutagenesis using the QuikChange site-directed mutagenesis kit 
(Stratagene, La Jolla, CA, USA) with the following primers: Fw GCGCCAGAGGTGCCAGGC 
CATCAGTCTCTGGCGCTTTGGACCCCAAGGC; Rev: GCCTTGGGGTCCAAAGCGCCAG 
AGACTGATGGCCTGGCACCTCTGGCGC; and subsequently inserted in the NCC3-pT7Ts. 
The NCC1 phosphomutants mimicking the active (S811D) and the inactive (S811A) 
phosphorylation sites were generated by site directed mutagenesis. Primers: S811D Fw: 
GTGCCAGGCCAGACGTCTCTGGCGCTTTG; Rev: CAAAGCGCCAGAGACGTCTGGCCT 
GGCAC; S811A Fw: GTGCCAGGCCAGCAGTCTCTGGCGCTTTG; Rev: CAAAGCGCCAG 
AGACTGCTGGCCTGGCAC. eGFP-NCC in pT7Ts was described previously.(7) The C-
terminal part of human NCC1 in pT7Ts was subcloned into the eGFP-NCC construct. For 
expression in mammalian systems, human eGFP-NCC3 fragment described previously(7) 
was subcloned into empty pCMV-SPORT6 vector. Human NCC1 and NCC1 phosphorylation 
site mutants (S811A and S811D) fragments were subcloned to eGFP-NCC3 pCMV SPORT6 
construct. All the constructs were confirmed by sequence analyses. 
 
In vitro cRNA translation for functional assays 
Microinjection of cRNA and 22Na+ uptake experiments were performed essentially as 
described previously (7). Briefly, constructs encoding the NCC variants were linearized, 
transcribed in vitro using the mMESSAGE mMACHINE® T7 Kit (Ambion, Austin, TX, USA). 
The integrity of the product was confirmed on 1% w/v agarose, 37% v/v formaldehyde gels 
and cRNA aliquots were stored at –80°C. 
 
Oocyte harvesting and animal experimentation  
All animal experiments received the approval from the animal ethics board of Radboud 
university medical center, Nijmegen, The Netherlands. Xenopus laevis oocytes were 
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processed based on previous established protocols (7). Mature oocytes were selected and 
microinjected with 5 ng of cRNA encoding the human NCC1, NCC3, NCC1 S811D, NCC1 
S811A or co-injected with 10 ng of WNK4 cRNA. 22Na+ uptake was corrected for the surface 
expression of the corresponding microinjected variant and expressed as a percent of WT 
uptake. All the experiments using 22Na+ radioisotope were approved and monitored by the 
Environmental Health and Radiation Safety office, Radboud university medical center. 
 
Quantification of eGFP-NCC in the oocyte membrane  
Surface expression analyses were performed as described in detail previously (7). Briefly, 
oocytes were microinjected with 5 ng of cRNA encoding eGFP-NCC1, eGFP-NCC3, or 
eGFP-NCC1 phosphorylation site mutants. All images were acquired on an Olympus FV1000 
laser-scanning microscope (Center Valley, PA, USA) using a 10 x water objective. 
Densitometry analysis of fluorescence was done using Image J software (image processing 
program, NIH, Bethesda, MA, USA). Autofluorescence of water-injected oocytes was 
subtracted from the fluorescence of all injected variants. 
 
Cell culture, transfection, and isolation of enriched plasma membrane 
HEK293 cells were cultured on 100 mm dishes and grown in DMEM supplemented with 10% 
v/v fetal bovine serum, nonessential amino acids, and 2 mM L-glutamine. Cells were 
transfected with eGFP-NCC3 pCMV SPORT6, eGFP-NCC1 pCMV SPORT6, eGFP-NCC1 
S811D pCMV SPORT6 and eGFP-NCC1 S811A pCMV SPORT6 vector using 32 µg of DNA 
and 96 µl of polyethylenimine (Polysciences, Inc., Warrington, PA, USA). Cells transfected 
with empty vector were used as controls (mock). At 48 hours post-transfection the cells were 
lysed in 1 ml of ice-cold dissection buffer per dish (300 mM sucrose, 25 mM imidazole, 1 mM 
EDTA, 1 µg/ml pepstatin, 1 mM phenylmethylsulfonyl fluoride (PMSF), 5 µg/ml leupeptin and 
5 µg/ml apropotin). Lysed cells were centrifuged at 4,000 x g for 8 minutes and subsequently 
the supernatant was centrifuged at 16,000 x g for 40 minutes. The pellet was resuspended 
in ice-cold dissection buffer and 1x Laemmli (0.4% w/v SDS, 2% v/v glycerol, 12 mM Tris-
HCl pH 6.8, 40 mM DTT and 0.002% w/v bromophenol blue) was added. Samples were 
incubated in 65°C for 15 minutes. BCA Protein Assay Kit (Pierce, Thermo Scientific, 
Rockford, IL, USA) was used to determine the protein concentration. 
 
Kidney membrane preparations for NCC immunoblots 
All three donors gave permission for donating their kidneys after death. In case the kidney 
appeared not suitable for transplantation the donor gave permission to use the kidneys for 
research purposes, which is registered in the Dutch Donor registry. Harvested kidneys were 
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snap-frozen immediately after isolation and homogenized in detergent-free lysis buffer 
containing 50 mM Tris-HCl pH 7.5, 1 mM EDTA, 1 mM EGTA, 1 mM sodium orthovanadate, 
5 mM sodium fluoride, 5 mM sodium pyrophosphate, 0.27 M sucrose, 0.1% v/v 2-
mercaptoethanol and protease inhibitors (Roche, 1 tablet per 50 ml) with a homogenizer 
(VWR VDI 12 Adaptable Homogenizers, OpticsPlanet, Inc., Commercial Avenue Northbrook, 
IL, USA). Nuclei and debris were pelleted by centrifugation at 1,500 x g for 5 minutes at 4°C. 
Next, supernatants were centrifuged at 100,000 x g for 1 hour at 4°C. The pellet was 
washed with 1 vol. of lysis buffer without reducing agent and centrifuged again at 100,000 x 
g for 15 minutes to remove any remaining cytosolic particles. The pellet was then 
resuspended in lysis buffer including 1% v/v Nonidet P40. BCA Protein Assay Kit (Pierce, 
Thermo Scientific, Rockford, IL, USA) was used to determine the protein concentration. 
Finally, samples were stored at -80°C for the immunoblotting. 
 
Immunoblotting  
Exosome and kidney membrane samples were loaded on a gradient SDS-PAGE gel (4-15% 
v/v Criterion™ TGX™ Precast Gel, Bio-Rad, The Netherlands) and cell membrane proteins 
(10 µg) were loaded on an 8% v/v SDS-PAGE gel. Proteins were transferred to PVDF 
membranes (Immobilon-P, Millipore Corporation, Bedford, MA, USA) by electroelution. 
PVDF membranes were incubated for 16 hours with primary antibodies in 4°C, washed and 
subsequently incubated with secondary antibody for two hours in room temperature. 
Proteins were visualized using enhanced chemiluminescence (Thermo Fischer Scientific, 
Waltham, MA, USA) and a gel imaging system (ChemiDoc XRS, Bio-Rad Laboratories, 
Hercules, CA, USA). Densitometry was performed using Image J software (image 
processing program, NIH, Bethesda, MA, USA). 
 
Immunohistochemistry 
Immunohistochemical staining was performed on cryosections of snap-frozen tissue. Briefly, 
2 μm serial sections of frozen human kidney were fixed with acetone for 10 minutes at -
20°C. The sections were incubated for 1 hour at room temperature with primary antibody 
diluted in TNB buffer (0.1 M Tris-HCl, pH 7.5, 0.15 M NaCl, 0.5% w/v, Blocking Reagent, 
#FP1020, Perkin Elmer, Groningen, The Netherlands). For detection, kidney sections were 
incubated with Alexa flour-conjugated secondary antibodies. Images were taken with an 
Axio Imager camera and ZEN Lite software (Zeiss, Sliedrecht, The Netherlands). 
 
Antibodies 
Anti NCC1/2 rabbit polyclonal antibody was manufactured by 21st Century Biochemicals 
(Marlborough, MA, USA).  Briefly, peptide corresponding to the sequence NH2-
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ARGARPSVSGALDP-COOH was manufactured by Fmoc chemistry and after 
cleavage/deprotection was HPLC purified to >90%, and the mass and sequence verified by 
nanospray MS and CID MS/MS, respectively.  This peptide was conjugated to carrier protein 
and used to immunize two New Zealand rabbits.  After multiple boosts and bleeds, the 
serum was immunodepleted by affinity purification of the antibody specific to NCC1/2 with 
affinity column containing the immunizing peptide. The antibody was used at the following 
dilution rates: IB 1:1,000, IHC 1:50. Rabbit polyclonal antibody against the N-terminal portion 
of rat NCC (Millipore, Billerica, MA, USA, #AB3553; IB 1:2,000, IHC 1:50). Rabbit polyclonal 
antibody against rat (R7) AQP2 (kindly provided by Dr. Peter Deen; IB 1:3,000).(6) Mouse 
monoclonal antibody against amino acids 101-210 of CD9 of human origin (C4, Santa Cruz 
Biotechnology, Inc., CA, USA; IB 1:500). Secondary antibodies were as follows: peroxidase 
conjugated goat anti-rabbit (Sigma-Aldrich, St. Luis, MO, USA, #A4914; IB 1:10,000), goat 
anti-rabbit Alexa Fluor® 488 (Molecular Probes, Eugene, OR, USA, #A-11029, IHC 1:300). 
 
Acute water loading 
The study was conducted according to the principles expressed in the declaration of 
Helsinki. All participants gave written informed consent and the study protocol was approved 
by the Institutional Review Board of the Radboud university medical center, Nijmegen, The 
Netherlands (approval number NL47178.091.13). Healthy males between 25 to 35 years old 
and with a body weight below 100 kg body weight were included in the study. Subjects were 
asked to refrain from coffee, tea, alcohol intake and any vigorous exercise for 24 hours 
before and during the study. Subjects did not drink or eat for 12 hours before the first urine 
collection to achieve maximal urine concentration. Each subject ingested 20 ml/kg body 
weight of water in 30 minutes. Midstream urine was collected before (time 0 minutes) and 
after water ingestion in 30 minutes intervals up to 150 minutes. Collected urine samples 
were supplemented with a final concentrations of protease inhibitors of 50 µM 
phenylmethylsulfonyl (PMSF), 20 µM aprotinin, 10 µM pepstatin A, 20 µM leupeptin, and 
stored at -80°C. 
 
Urinary exosome isolation 
The urine samples were collected from healthy subjects after acute water loading (see 
Supplement). Ten ml of collected urine was centrifuged at 17,000 × g for 15 minutes at 24°C 
in ultracentrifuge (Sorvall™ WX Floor Ultra Centrifuges, Thermo Scientific, Asheville, NC, 
USA) with 70.1Ti rotor. Supernatant was stored at room temperature for 25 minutes. The 
pellet was resuspended in 200 μl isolation solution (250 mM sucrose and 10 mM 
triethanolamine-HCl, pH 7.6) and 50 μl 3.24 M dithiothreitol (DTT), subsequently centrifuged 
at 17,000 × g for 15 minutes at 24°C. Thereafter, the supernatant was collected, combined 
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with supernatant obtained from the previous step and centrifuged at 200,000 × g for 2 hours 
at 24°C. Exosome pellet was dissolved in 50 µl of 1.5 × Laemmli (0.6% w/v SDS, 3% v/v 
glycerol, 18 mM Tris-HCl pH 6.8 and 0.003% w/v bromophenol blue). All the samples were 
stored in -20°C for further use. 
 
Mass spectrometry 
Gel slices were cut from the Coomassie-stained and washed SDS PAGE gel on a clean 
glass plate and were further diced in 1 mm3 cubes using a scalpel and were transferred to a 
1.5 ml reaction tube for further processing. ¼ gelband equivalent was processed for trypsin 
digestion and ¾ gelband was processed for Lys-C digestion. Gel cubes were vortexed in 
400 µl 50 mM NH4HCO3 for 10 minutes. Supernatant was removed and the gel cubes were 
vortexed in 400 µl 50 mM NH4HCO3, 50% v/v acetonitrile for 10 minutes. After removal of 
the supernatant this wash-step was repeated once. Gel cubes were reduced in 10 mM DTT 
in 50 mM NH4HCO3 at 56°C in a heating block for 60 minutes. After cooling down the 
supernatant was removed and gel cubes were alkylated with 54 mM iodoacetamide in 50 
mM NH4HCO3 for 45 minutes in the dark at RT. Supernatant was removed and gel cubes 
were vortexed in 400 µl 50 mM NH4HCO3 for 10 minutes. Supernatant was removed and the 
gel cubes were vortexed in 50 mM NH4HCO3/50% v/v acetonitrile. After removal of the 
supernatant this wash-step was repeated once. Supernatant was removed and gel cubes 
were dried in a vacuum centrifuge at 50°C for 10 minutes. Dried gel slices were covered with 
trypsin solution or Lys-C solution (6.25 ng/µl in 50 mM NH4HCO3), after rehydration of the 
cubes excess protease was removed and gel cubes were covered with 50 mM NH4HCO3. 
Digestion proceeded overnight at 25°C in a heating block. After digestion, peptides were 
extracted from the gel cubes with 100 µl 1% v/v formic acid by vortexing. Supernatant was 
transferred to a 1.5 ml tube and gel cubes were extracted with 100 µl 5% v/v formic acid 
50% v/v acetonitrile. Supernatant was pooled with the first eluate. The second extraction 
was repeated once and the supernatant was pooled with previous extracts. Extracts were 
concentrated in a vacuum centrifuge at 50°C and volumes were adjusted to 50 µl by adding 
0.05% v/v formic acid. 
 
LC-MS/MS 
Peptides were separated by an Ultimate 3000 nanoLC-MS/MS system (Dionex LC-
Packings, Amsterdam, The Netherlands) equipped with a 20 cm × 75 μm ID fused silica 
column custom packed with 1.9 μm 120 Å ReproSil Pur C18 aqua (Dr Maisch GMBH, 
Ammerbuch-Entringen, Germany). After injection (15/50 µl Lys-C digest; 20/50 µl trypsin 
digest), peptides were trapped at 6 μl/minute on a 10 mm × 100 μm ID trap column packed 
with 5 μm 120 Å ReproSil Pur C18 aqua at 2% buffer B (buffer A: 0.5% v/v acetic acid in 
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MQ; buffer B: 80% v/v ACN + 0.5% v/v acetic acid in MQ) and separated at 300 nl/minute in 
a 10–40% buffer B gradient in 60 minutes (90 minutes inject-to-inject) at 50˚C. Eluting 
peptides were ionized at a potential of +2 kVa into a Q Exactive mass spectrometer (Thermo 
Fisher, Bremen, Germany). Intact masses were measured at resolution 70.000 (at m/z 200) 
in the orbitrap using an AGC target value of 3 × 106 charges. The top 10 peptides signals 
(charge-states 2+ and higher) were submitted to MS/MS in the HCD (higher-energy collision) 
cell (1.6 amu isolation width, 25% normalized collision energy). MS/MS spectra were 
acquired at resolution 17,500 (at m/z 200) in the orbitrap using an AGC target value of 1 × 
106 charges, an underfill ratio of 0.1%, and a maximum injection time (IT) of 60 milliseconds. 
Dynamic exclusion was applied with a repeat count of 1 and an exclusion time of 30 
seconds.   
 
Protein identification 
MS/MS spectra were searched against the Uniprot human reference proteome FASTA file, 
release January 2014, no fragments; 42104 entries using MaxQuant 1.5.2.8. Enzyme 
specificity was set to trypsin or Lys-C, depending on the protease used, and up to two 
missed cleavages were allowed. Cysteine carboxamidomethylation (Cys, +57.021464 Da) 
was treated as fixed modification and methionine oxidation (Met, +15.994915 Da), Gln-
>pyroglutamate (pyr-Gln, -17.026549 Da) and N-terminal acetylation (N-terminal, 
+42.010565 Da) as variable modifications. Peptide precursor ions were searched with a 
maximum mass deviation of 4.5 ppm and fragment ions with a maximum mass deviation of 
20 ppm (default MaxQuant settings). Peptide and protein identifications were filtered at an 
FDR of 1% using the decoy database strategy. Proteins that could not be differentiated 
based on MS/MS spectra alone were grouped to protein groups (default MaxQuant settings).  
 
Measurement of urinary creatinine and osmolality. 
Urinary creatinine was measured according to Jaffe’s method with the use of colorimetric 
assay (Labor und Technik, Berlin, Germany).(37) Osmolality of urine samples was 
measured by freezing point depression using a Micro-osmometer  (Advanced Instrument 
model 3320, Nordwood, MA, USA). 
 
Statistical analysis  
In the oocyte analysis all depicted data are averages of at least 2 independent experiments, 
each containing a minimum of 10-15 oocytes per group. Overall statistics between groups 
was determined by one-way ANOVA. In case of significance, multiple comparisons between 
groups were performed by Bonferroni post-hoc tests. Immunoblot data were analyzed by 
comparing integrated optical densities of bands by one-way ANOVA followed by Dunnett's 
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Multiple Comparison post-hoc test. Values are mean ± SEM in acute water loading: 
normalized to time 0 minutes levels, n = 6. For all experiments P value <0.05 was 
considered statistically significant. All the data were analyzed using Prism 5 software 
(GraphPad Software Inc, La Jolla, CA, USA).  
 
Results 
NCC splicing and the S811 phosphorylation site 
Fig. 1A displays the protein sequence alignment encompassing the fragment specific for 
NCC1 and NCC2. NCC1 contains one extra amino acid as compared to NCC2, which is 
localized outside the exon 20 region. Therefore, NCC1/2 will refer to the combined presence 
of NCC1 and NCC2, as these are indistinguishable in several of the experimental assays 
performed in this study. The NCC1/2 is present and preserved between some mammalian 
species (human and rabbit), but is not present in rodents (mouse and rat). In humans, the 
NCC splice site is encoded by exon 20 (Fig. 1B). Remarkably, this exon is absent in mouse 
and rat due to the lack of splice sites. Fig. 1B shows the exon prearrangement of NCC1/2. 
Sequence analysis of cDNA fragments isolated from human kidney showed that both NCC1/2 
and NCC3 are present (Fig. 1C). NCC1/2 is longer than NCC3 due to the presence of nine 
extra amino acid residues in the C-terminal domain (Fig. 1D). The phosphorylation site 
identified in the additional fragment corresponds to residue S811 (Fig. 1D). Constructs 
encoding NCC3 and NCC1 as well as the phosphorylation site mutants (S811D and S811A) 
(Fig. 1D) were subcloned into appropriate plasmid vectors for heterologous expression in 
Human Embryonic Kidney (HEK293) cells and Xenopus laevis oocytes. Quantitative PCR 
analysis revealed that NCC1/2 mRNA constitute 44 ± 6% (n = 7) of all NCC isoforms present 
in the human kidney cortex biopsies (Table 1). 
 
Mass spectrometric identification of human NCC isoforms 
The presence of the NCC isoforms in the human urinary exosomes on the protein level was 
investigated by mass spectrometry. Data are available via ProteomeXchange with identifier 
PXD002279 (http://www.proteomexchange.org; Username: reviewer55274@ebi.ac.uk; 
Password: QI1g6xJe) (44). Overall 51 peptides were detected for SLC12A3 by tryptic 
digestion and 15 peptides by Lys-C digestion yielded sequence coverage of 14 and 39%, 
respectively. Two regions in the amino-acid sequence allow distinction between the 
isoforms: Peptides correlated to V807L and 9 amino-acid deletion peptides indicating the 
presence of both NCC3 as well as NCC1/2 were identified. Isoform-specific peptides spanning 
residues 781-838 are shown in Table 2. Specifically, Lys-C digestion yields 
MMQAHINPVFDPAEDGKEASARGARPSVSGALDPK (NCC1/2 res 785-820, Andromeda 
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score 49.2) and MMQAHINPVFDPAEDGKEASA RVDPK (NCC3 res 785-811, Andromeda 
score 70.3), as well as EASARGARPSVSGALDPK (NCC1/2 res 802-820, Andromeda score 
57.5) and EASARVDPKALVK (NCC3 res 802-815, Andromeda score 32.9). Tryptic digestion 
additionally yielded GARPSVSGALDPK (NCC1/2 res 807-820, Andromeda score 122.5) and 
PSVSGALDPK (NCC1/2 res 810-820, Andromeda score 104.8). Identification of multiple 
overlapping peptides of both NCC3 as well as NCC1/2 firmly indicated that in exosomes, the 
SCL12A3 gene product is present as a mixture of NCC3 and at least one and possibly both 
NCC1 and NCC2. 
 
Generation of specific antibodies against NCC1/2 
NCC1/2-specific peptide epitope (ARGARPSVSGALDP) was used to generate anti-NCC1/2 
antibodies. Specificity of the antibody was tested using isolated membranes from HEK293 
cells transfected with corresponding plasmids. A commercially available antibody against the 
N-terminal portion of NCC detected NCC3 as well as NCC1/2, as all are carrying the 
recognized epitope (Fig. 2A). Therefore, in the present study expression of NCC, detected 
by the antibody against the N-terminal NCC, refers to the combined expression of NCC3 and 
NCC1/2 hence denoted as NCC1-3. The antibody specific for NCC1/2 recognized only NCC1/2, 
but not NCC3 and NCC1/2 mutants (S811A and S811D) (Fig. 2B). This demonstrates the high 
specificity of the newly generated antibody against the NCC1/2 epitope. Immunoreactivity 
was not present in cells transfected with mock vector or in the presence of specific blocking 
peptides (Fig. 2C). 
 
Immunoblot identification of human NCC isoforms 
Immunoblots of kidney membrane fractions and urinary exosomes of three subjects showed 
two immunopositive protein bands of ~260 and 130 kDa, representing the dimeric and 
monomeric form of the NCC1-3 transporter, respectively (Fig. 2D). Importantly, the NCC1/2 
protein was also detected in kidney membrane fractions and urinary exosomes as two bands 
of ~260 and 130 kDa as evidence for the dimeric and monomeric form, respectively (Fig. 
2E). This indicates that NCC isoforms are present in oligomeric structures in the human 
kidney and urinary exosomes. 
 
NCC1/2 localizes to apical membrane of DCT 
Immunohistochemical staining of human kidney serial sections revealed expression of NCC1-
3 (Fig. 3A and B) and NCC1/2 (Fig. 3C and D) at the apical membrane of epithelial cells lining 
the DCT. Expression of both NCC1-3 and NCC1/2 was restricted to the same tubular sites. 
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Figure 1 | Splicing of NaCl cotransporter (NCC) gene.  
(A) Multiple protein alignment analysis of NCC against diverse species as stated. (B) Schematic 
representation of gene SLC12A3 and the exon 20a, in light grey box, that encodes for the splice 
variant. (C) DNA multiple alignment and chromatogram sequence analysis of the region encoding the 
human NCC1/2 and NCC3. (D) Topological representation of NCC1/2 within the N-terminal domain, in 
light grey shadow, shows alignment of all three human NCC isoform sequences (NCC3, NCC2, and 
NCC1) and carboxyl-terminal domain, in light grey shadow, shows the phosphorylation site at S811. 
Lower panel shows a multiple alignment of the human NCC protein sequence depicted the additional 
nine amino acids in NCC1/2, including the phosphorylation mutant constructs (S811D and S811A). 
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Table 1 | Ratio of NCC1/2 to NCC1-3 mRNA expression in seven human kidney cortex biopsies 
determined by Real-time relative RT-PCR quantification. 
 
Table 2 | Peptides identified from the isoform-specific region of SLC12A3 aligned to the 
protein amino acid sequence. 
In red NCC3 specific residues and in green NCC1/2 specific residues. In the middle the aligned amino 
acid sequences of NCC3 and NCC1/2. 
 
Functional characterization of NCC1 
In order to compare the functional abilities of NCC1 and NCC3, cRNA of the respective 
variants was microinjected into Xenopus laevis oocytes and thiazide-sensitive 22Na+ uptake 
was measured (Fig. 4). It has been shown previously that cumulative amounts of eGFP-
NCC correlate dose-dependently with the eGFP-NCC fluorescence at the oocyte membrane 
and with thiazide-sensitive 22Na+ uptake (7). For the analysis, day 4 after cRNA injection was 
chosen. Thiazide-sensitive 22Na+ transport was significantly increased in the NCC1 
compared to the NCC3 (Fig. 4A). To further evaluate whether this increase in transport was 
dependent on the phosphorylation at S811 the effect of substituting the serine residue by an 
aspartic acid to mimic constitutive phosphorylation was tested. The S811D mutant exhibited 
a significant increase in thiazide-sensitive 22Na+ uptake in comparison to NCC3 and NCC1. 
Moreover, the S811A mutant mimicking a constitutively inactive phosphorylation site showed 
a significant decrease in thiazide-sensitive 22Na+ uptake, as compared to NCC1 S811D 
variants (Fig. 4A).  
Volunteer # % NCC1/2 
1 52 
2 46 
3 19 
4 29 
5 42 
6 59 
7 63 
  
Average % 44 
SEM ± 6 
Isoform Nomen-clature Protease Sequence of identified peptides 
  Lys-C                                                                                             811/820ALVKEEQATTIFQSEQGK829/838 
  Lys-C           785MMQAHINPVFDPAEDGK802 
  Lys-C           785MMQAHINPVFDPAEDGKEASAR -----------VDPK811 
  Lys-C                                                     802EASAR -----------VDPKALVK815 
SLC12A3-3 NCC3  781NVSKMMQAHINPVFDPAEDGKEASAR -----------VDPKALVKEEQATTIFQSEQGK829 
SLC12A3-1/2 NCC1/2  781NVSKMMQAHINPVFDPAEDGKEASARGARPSVSGALDPKALVKEEQATTIFQSEQGK838 
  Trypsin           785MMQAHINPVFDPAEDGKEASAR807 
  Lys-C           785MMQAHINPVFDPAEDGKEASARGARPSVSGALDPK820 
  Trypsin                                                     802EASARGARPSVSGALDPK820 
  Trypsin                                                                 807GARPSVSGALDPK820 
  Trypsin                                                                         810PSVSGALDPK820 
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Figure 2 | Verification of NCC1/2 antibody specificity.  
(A) Immunoblot of total membrane fraction isolated from HEK293 cells transfected with empty vector 
(mock), NCC3, NCC1 and NCC1 phosphorylation site mutants (S811A and S811D) probed with an 
antibody against NCC1-3. (B) Immunoblot of total membrane fraction isolated from HEK293 cells 
transfected with empty vector (mock), NCC3, NCC1, and NCC1 mutants (S811A and S811D) probed 
with an antibody recognizing specifically NCC1/2. (C) Immunoblot of total membrane fraction isolated 
from HEK293 cells transfected with empty vector (mock), NCC3, NCC1 and NCC1 mutants (S811A 
and S811D) probed with the NCC1/2 antibody pre-absorbed with NCC1/2 immunizing peptide. (D) 
Expression of NCC1-3 and (E) NCC1/2 in kidney membrane fractions and urinary exosomes of three 
subjects depicting two bands of ~260 and 130 kDa. 
 
WNK4 has previously been shown to reduce forward trafficking of NCC in the oocyte 
system, by diverting the cotransporter to the lysosomal compartment (38, 49). Additionally, 
WNK 4 modulates SPAK/OSR1 phosphorylation and hence NCC activity (4, 43). To 
elucidate whether WNK4 has similar effects on NCC1, cRNA encoding the NCC variants 
were co-injected with WNK4. WNK4 reduced NCC-dependent 22Na+ uptake to similar levels 
in all conditions, suggesting that the majority of NCC1 activity is sensitive to WNK4 inhibition 
in S811 independent manner (Fig. 4A). In each condition 22Na+ uptake was thiazide-sensitive 
(Fig. 4A, black bars). To determine surface expression of injected cRNA, fluorescent 
intensity of eGFP-tagged NCC3, NCC1, NCC1 S811D or NCC1 S811A was quantified (Fig. 
4B and C). 
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Figure 3 | Immunolocalization of NCC1/2 in the human kidney.  
Representative serial sections of human kidney depicting NCC1-3 (A and B) and NCC1/2 (C and D). 
Immunofluorescence colocalizes at the apical membrane domains of epithelial cells lining DCT. As 
the antibody against NCC1-3 also binds to NCC1/2, immunofluorescence in A and B may partially 
originate from NCC1/2. The bar represents a scale of 20 or 50 µm as indicated. 
 
Acute water loading 
Acute water loading was performed in six healthy subjects to determine the effect of 
hypervolemia on the renal expression of NCC isoforms. Urine was collected before (time 0) 
and after acute water loading in 30-minute intervals up to 150 minutes. Urinary exosomes of 
each subject were loaded according to the urine creatinine concentration onto the gel and to 
confirm equal loading of the samples, the abundance of the exosomal marker CD9 was 
determined (1, 11). Our study demonstrated the existence of NCC in dimeric and monomeric 
forms in urinary exosomes using immunoblotting. Therefore, both dimeric and monomeric 
forms were analyzed separately. Immunoblots probed for NCC1/2 showed a significant 
decrease of NCC1/2 monomer and dimer expression 60 minutes after acute water loading, 
which returned to the baseline levels at 150 minutes (Fig. 5A, C and E). Expression of NCC1-
3 monomer and dimer significantly dropped 60 minutes after acute water loading and 
restored after 150 minutes (Fig. 5B, D and F). The exosomes were also probed for the 
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expression of aquaporin 2 (AQP2) since water loading is known to downregulate AQP2 (36). 
Indeed, AQP2 expression in urinary exosomes was significantly reduced 60 minutes after 
acute water loading (Fig. 6A and B). CD9 expression levels within urinary exosomes did not 
change significantly at different time points, suggesting equal loading of exosomes (Fig. 5G, 
5H, 6C, respectively). Urine osmolality decreased significantly 30 minutes after acute water 
loading (Fig. 6D). 
 
 
Figure 4 | Expression and functional analysis of eGFP tagged NCC variants in the oocyte 
membrane.  
(A) 22Na+ uptakes in Xenopus laevis oocytes microinjected with 5 ng of cRNA encoding the human 
NCC3, NCC1, NCC1 S811D, NCC1 S811A or co-injected with 10 ng of WNK4 cRNA. The 22Na+ uptake 
experiments were performed in the absence (white bars) or presence (black bars) of 0.1 mM HCT. 
22Na+ uptakes were corrected for surface expression of the corresponding variants. NCC1 vs. NCC3 
(§) as well as NCC1 S811D vs. NCC1 (#) had significantly increased 22Na+ uptake. NCC1 S811A had 
significantly reduced 22Na+ uptake in comparison to NCC1 S811D (†). Each variant co-injected with 
WNK4 had significantly decreased 22Na+ uptake in comparison to its corresponding variant without 
WNK4 (*). (B) Three representative confocal images of oocytes that were injected with GFP-NCC3, 
GFP-NCC1, GFP-NCC1 S811D or GFP-NCC1 S811A cRNA. (C) Surface expression analyses were 
performed on oocytes four days after microinjection with corresponding cRNA. *P<0.05 was 
considered statistically significant. 
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Figure 5 | Expression of NCC1/2 and NCC1-3 in human urinary exosomes after acute water 
loading.  
Immunoblot of urinary exosomes isolated before (0 minute) and after water loading probed for NCC1/2 
(A) and NCC1-3 (B). Both NCC1/2 and NCC1-3 abundance was significantly reduced 60 minutes after 
acute water loading and returned to the baseline level after 150 minutes. Densitometry analysis of 
NCC1/2 (C) and NCC1-3 (D) monomer abundance in urinary exosomes. Densitometry analysis of 
NCC1/2 (E) and NCC1-3 (F) dimer abundance in urinary exosomes. (G and H) Densitometry analysis of 
CD9 expression levels showed no significant changes. Values are mean ± SEM (n = 6) normalized to 
time 0 levels. *P<0.05 was considered significant. 
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Figure 6 | Expression of AQP2 in human urinary exosomes after acute water loading.   
(A) Immunoblot of urinary exosomes isolated before (0 minute) and after water loading probed for 
AQP2. AQP2 abundance was significantly decreased 60 minutes after acute water loading and 
maintained significantly lower levels up to 150 minutes. (B) Densitometry analysis of AQP2 
abundance in urinary exosomes. (C) Densitometry analysis of CD9 expression levels corrected to 
urine creatinine concentration showed no significant changes. (D) Urinary osmolality was significantly 
decreased from 30 to 150 minutes after acute water loading. Values are mean ± SEM (n = 6) 
normalized to time 0 minute levels. *P<0.05 was considered significant. 
 
Discussion  
Since 1996, when human NCC was cloned, it has been shown that three isoforms of NCC 
are present in the human kidney (22, 23, 35). However, all NCC studies have focused on the 
shorter isoform, NCC3, leaving the alternative splice variants unexplored. In the presented 
study, we delineated for the first time the localization, abundance, and functionality of NCC1/2 
in the human kidney by showing that: i) mRNA of NCC1/2 constitutes ~44% of all NCC 
(NCC1-3) transcripts in the human kidney; ii) NCC1/2 is clearly detectable in human urinary 
exosomes by mass spectrometry and immunoblot analysis; iii) NCC1/2 is, like the shorter 
NCC3 isoform, present at the apical membrane of DCT; iv) phosphorylation at S811 
regulates NCC1 function; v) the abundance of NCC1/2 is regulated in response to 
physiological stimuli such as acute water loading. 
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Generation of new antibodies specifically recognizing NCC1/2 allowed us to demonstrate 
the presence of NCC1/2 at the apical membrane of the DCT, present in the human kidney as 
well as monomeric and dimeric complexes in kidney membrane fractions and urinary 
exosomes. The presence of NCC1/2 in the exosomes was confirmed by mass spectrometry. 
Noteworthy, all antibodies raised against NCC3 recognize also NCC1/2. Thus, in previously 
performed studies on endogenous human NCC also NCC1/2 may have been detected. 
Because human NCC1 and NCC2 differ only by one amino acid it was impossible to 
differentiate between both isoforms with the immunodetection methods. Therefore, it was 
addressed as a combined expression of both isoforms, NCC1/2. We demonstrated that 
NCC1/2 mRNA constitutes a substantial amount (44%) of total NCC mRNA in the human 
kidney. Nevertheless, the relative protein abundance of each isoform depends on the 
translation and quality control of the proteins. Therefore, the expression level of mRNA does 
not always mirror the abundance of the protein. Moreover, presented mRNA analysis 
characterizes a combined expression of NCC1 and NCC2 since they were indistinguishable. 
Hence, the ratio of each isoform is not strictly determined.  
Functional characterization of NCC1 and the role of its phosphorylation site S811 were 
investigated by using Xenopus oocytes. As NCC3, NCC1 demonstrated thiazide-sensitive 
22Na+ transport. Additionally, NCC1 activity can also be modified by changes in 
phosphorylation status. Splicing and subsequent single point directed mutagenesis to mimic 
constitutively active phosphorylation sites of NCC1 (S811D) led to an increased activity of 
NCC1 compared to NCC3. We demonstrated that once the S811 residue is substituted by an 
alanine (S811A) mimicking inactive site, the activity of the splice variant is significantly 
decreased. The fact that inhibition of S811 phosphorylation reverts transporter capability 
only to basal levels implies that the NCC1/2 and its phosphorylation is introduced in order to 
augment transport of NCC over the baseline level when needed. Our functional experiments 
demonstrated that WNK4 is a strong inhibitor of both NCC1 and NCC3. However, the effect 
of WNK4 is not mediated via S811 phosphorylation, since the constitutively active S811D 
mutant is not protected from the inhibitory effects of WNK4. This suggests that in both 
isoforms, NCC1 and NCC3, the effect of WNK4 is mediated via regulation at the N-terminus. 
Additionally, phosphorylation at S811 may depend on simultaneous regulation of the 
phosphorylation at the N-terminal residues.  
In order to determine NCC1/2 expression in vivo, human urinary exosomes were 
analyzed. Exosomes are frequently used as biomarkers for renal tubular disorders as they 
reflect changes in the expression of different proteins present in the tubular epithelial cells 
(16, 40). For instance, it has been demonstrated that patients with Gitelman syndrome do 
not express NCC in their urinary exosomes (19). In contrast, patients with familial 
hyperkalemic hypertension characterized by enhanced activity of NCC, have increased NCC 
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expression in their urinary exosomes (17, 24). This substantiates the notion that NCC 
abundance in urinary exosomes reflects the actual state of NCC expression in the DCT as 
postulated previously (16, 40). We hypothesized that the activity of NCC1/2 can be modified 
by changes in the protein abundance at the plasma membrane. Depending on a stimulus 
(hormones, electrolyte concentration, etc.) NCC expression throughout the DCT can be 
altered by the insertion of a more potent isoform (NCC1/2) into the apical membrane, in order 
to maximize NaCl transport and vice versa. Consequently, we showed that NCC1/2 and 
NCC1-3 abundance in urinary exosomes is robustly down regulated in response to water 
loading (Fig. 5). Increased activity and expression of NCC in response to changes in the 
renin-angiotensin-aldosterone system and vasopressin has been well documented (5, 28, 
30-34, 41, 42). Hence, decreased NCC abundance at the apical plasma membrane in water-
loaded subjects is likely a result of hypervolemia, hyponatremia, and a subsequent decline in 
vasopressin release.  
Thus far, signaling pathways regulating NCC1/2 are unknown. However, prediction 
software (pkaPS) from the IMP-IMBA Bioinformatics group (26) suggested that the 
phosphorylated sequence around S811 of NCC1/2 shows high similarity to a PKA consensus 
site. Therefore, potential hormones regulating the cAMP-PKA pathway might be involved in 
regulating transport via this kinase. Several hormonal systems have been shown to activate 
the cAMP-PKA pathway in the DCT (3, 9). Our water loading study substantiates the 
regulatory effect of vasopressin not only on NCC1-3 but also specifically on NCC1/2 
abundance in the kidney. Since S811 may contain PKA consensus site we hypothesized 
that a PKA-dependent mechanism could be occurring for the phosphorylation at S811 in 
response to vasopressin stimulation. Nevertheless, recent studies demonstrated a potential 
role for vasopressin in modulating NCC N-terminal phosphorylation in the DCT (25, 28, 34), 
which may constitute the main regulatory mechanism for all NCC isoforms since all variants 
contain the same N-terminal phosphorylation sites. 
Our data clearly demonstrates that NCC1/2 is not a redundant transcription product, but 
it merely constitutes a fully functional thiazide-sensitive NaCl-transporting protein. In parallel, 
we propose a novel way of NCC regulation by phosphorylation at the C-terminal S811 
residue that adds to the complex system governing the regulation of NCC. Future 
experiments developing S811 phospho-specific antibodies and samples from different 
human pathological states could aid in determining the precise regulation of NCC1/2. A better 
understanding of the regulation of NCC in the kidneys may be critical to help to elucidate the 
molecular events underlying the pathogenesis of essential hypertension. 
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Abstract 
The thiazide-sensitive NaCl cotransporter (NCC), located apically in distal convoluted tubule 
epithelia, regulates the fine-tuning of renal sodium excretion. Three isoforms of NCC are 
generated through alternative splicing of the transcript, of which the third isoform has been 
the most extensively investigated in pathophysiological conditions. The aim of this study was 
to investigate the effect of different anti-hypertensive treatments on the abundance and 
phosphorylation of all three NCC isoforms in urinary extracellular vesicles (uEVs) of 
essential hypertensive patients. In uEVs isolated from patients (n=23) before and after 
hydrochlorothiazide or valsartan treatment the abundance and phosphorylation of the NCC 
isoforms was determined. Additionally, clinical biochemistry and blood pressure of the 
patients was assessed. Our results show that NCC detected in human uEVs has a 
glycosylated and oligomeric structure, comparable to NCC present in human kidney 
membrane fractions. Despite the inhibitory action of hydrochlorothiazide on NCC activity, 
immunoblot analysis of uEVs showed significantly increased abundance of NCC isoforms 1 
and 2 (NCC1/2), total NCC (NCC1-3), and the phosphorylated form of total NCC (pNCC1-3-
T55/T60) in essential hypertensive patients treated with hydrochlorothiazide, but not with 
valsartan. This study highlights that NCC1/2, NCC1-3, and pNCC1-3-T55/T60 are upregulated 
by hydrochlorothiazide, and the increase in NCC abundance in uEVs of essential 
hypertensive patients correlates with the blood pressure response to hydrochlorothiazide. 
 
Keywords: Hypertension / NaCl cotransporter / Thiazide diuretics / Urinary extracellular 
vesicles / kidney  
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Introduction  
Hypertension is a major risk factor for stroke, myocardial infarction, heart failure and chronic 
kidney disease (CKD) (16). According to the latest report from the American Heart 
Association, 78 million American adults (representing 33 % of the population) have 
increased blood pressure (16), of which ~90 % present with primary or essential 
hypertension (4, 28). Anti-hypertensive medications, such as valsartan (Val) and thiazide-
type diuretics are, therefore, prescribed to achieve blood pressure control. Although the 
pathogenesis of essential hypertension is multifactorial, the kidneys play a key role in blood 
pressure regulation by modulating renal sodium excretion (24). Several guidelines for 
management of hypertension in adults consider thiazide-type diuretics as a fundamental 
therapeutic tool (21, 36). Thiazide-type diuretics act by blocking the thiazide-sensitive NaCl 
cotransporter (NCC), apically localized in epithelial cells lining the distal convoluted tubule 
(DCT) (20). Loss of function mutations in NCC cause Gitelman syndrome (OMIM 263800), a 
condition characterized by sodium wasting, hypokalemic metabolic alkalosis, 
hypomagnesemia, hypocalciuria and hypotension when compared to their age-matched 
unaffected relatives (15, 39). Activation of NCC, through mutations in WNK [with no lysine 
(K)] kinases, mainly WNK1 and WNK4 (45), KLHL3 or Cullin3 (3) results in 
pseudohypoaldosteronism type II (PHAII) (also known as familial hyperkalemic hypertension 
(OMIM 145260)), which is characterized by increased renal sodium reabsorption, 
hyperkalemic metabolic acidosis, hypercalciuria and hypertension (32). The known 
involvement of NCC in these disease states suggests a role in the physiological regulation of 
blood pressure. 
In humans, alternate splicing of the SLC12A3 gene gives rise to three separate 
isoforms of the NCC (43); namely NCC1 (39), NCC2 (17), and NCC3 (26). Our previous work 
delineated the abundance and localization of NCC1 and NCC2 (NCC1/2) in the human kidney 
as well as its functional properties in physiological conditions (43). Significantly expressed in 
human kidney, NCC1/2 may constitute a unique route of renal NaCl reabsorption and 
therefore might play an important role in human blood pressure regulation (43). Rodents 
express NCC3, but they lack NCC1/2 (43), which has hampered progress towards further 
investigating the role of NCC1/2 in the pathophysiology of hypertension. 
In humans, urinary extracellular vesicles (uEVs) can be used as a non-invasive tool to 
study the regulation of NCC in the kidney (17, 44, 46). uEVs, including exosomes, are 
nanosized vesicles (30-120 nm) that form when multivesicular bodies within the cell merge 
with the cell membrane and release internal vesicles into the extracellular space or pro-urine 
(35). The cargo of uEVs reflects changes in the expression of different proteins present in 
the epithelial cells of the DCT, including total NCC (NCC1-3) and phosphorylated form of total 
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NCC (pNCC1-3-T55/T60) (43, 44). It has been shown that patients with Gitelman syndrome 
have decreased NCC abundance in uEVs (7, 22), while patients with PHAII have increased 
NCC abundance in uEVs (27, 44).  
Val reduces blood pressure by antagonizing angiotensin II type I receptors and thereby 
prevents the actions of angiotensin II (47). Despite the divergent mechanisms of action of 
thiazides and Val, both anti-hypertensive medications result in a reduction of blood pressure 
(18). Importantly, angiotensin II is a well-known direct activator of NCC (38), making Val a 
suitable anti-hypertensive drug to compare with thiazides. Unlike thiazides, Val does not 
directly bind to NCC, but it might alter NCC activity by effects on NCC phosphorylation and 
abundance. The anti-hypertensive effects of these drugs are well investigated; however, in 
humans their response to NCC expression has not been studied. The aim of this study was, 
therefore, to investigate the effect of different anti-hypertensive treatments on the 
abundance and phosphorylation of all three NCC isoforms in uEVs of essential hypertensive 
patients, and to explore the relationship between NCC abundance in uEVs and changes in 
blood pressure. 
 
Materials and Methods 
Patients, design and setting 
The study was conducted according to the principles expressed in the Declaration of 
Helsinki. The Nijmegen Anti-hypertensive Management Improvement Study (NAMIS) was 
approved by the local Ethics Committee of the Radboud university medical center, Nijmegen, 
The Netherlands (clinicaltrials.gov; trial registration no. NCT00457483). Patients with newly 
diagnosed hypertension, aged 18-65 years and listed in general practices affiliated with the 
Radboud university medical center were screened for eligibility to participate in a prospective 
open-label and blinded end-point (PROBE) crossover study. Patients with a confirmed 
diagnosis of hypertension and who gave written consent were included in the study (n=23). 
Exclusion criteria were the following: use of anti-hypertensive medication; blood pressure 
higher than 200 mmHg systolic or 120 mmHg diastolic; presence of cardiovascular co-
morbidity (diabetes mellitus, peripheral arterial disease, ischemic heart disease, stroke, 
transient ischemic attack and atrial fibrillation) and the inability to speak or understand Dutch. 
 
Figure 1 shows a schematic view of the study design. After a two weeks run-in period, 
untreated (Unt) patients used hydrochlorothiazide (HCT) for four weeks (12.5 mg, once 
daily), followed by a four weeks washout period and then Val treatment for four weeks (80 
mg, once daily). At the run-in, age, sex and menopausal state were also recorded. After the 
run-in period and at the end of each medication, ambulatory blood pressure, plasma sodium, 
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potassium and renin concentrations, amino (N)-terminal of the prohormone brain natriuretic 
peptide (NT-proBNP), estimated glomerular filtration rate (eGFR), urinary albumin excretion, 
body mass index and waist circumference were measured.  
 
 
Figure 1 | Schematic view of the Nijmegen Anti-hypertensive Management Improvement Study 
(NAMIS) design.  
Twenty-three patients with blood pressure ≥ 140/90 mmHg were included in the study. After a two 
weeks run-in period (Unt), patients used HCT for four weeks (12.5 mg, once daily), followed by a four 
weeks washout period and then Val treatment for four weeks (80 mg, once daily). After the run-in and 
at the end of each medication, ambulatory blood pressure, plasma sodium, plasma potassium, 
plasma renin and urine creatinine concentrations were measured and urinary extracellular vesicles of 
patients were isolated for immunoblot analysis. 
 
Blood pressure measurements and laboratory tests 
During eligibility screening performed by the local staff of the general practices, a diagnosis 
of hypertension (≥ 140/90 mmHg) was given based on the mean of all blood pressure 
measurements taken by trained practice nurses at three different clinic visits. The data of the 
blood pressure levels were presented as mean arterial pressure (MAP). All practices were 
provided with oscillometric blood pressure monitors (Stabil-O-Graph, I.E.M. GMBH, Stolberg, 
Germany).  
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All 24-hour ambulatory blood pressure recordings were taken on weekdays and patients 
were asked to keep a standardized diary of their daily activities. Practices used the same 24-
hour ambulatory blood pressure monitor device (Mobil-O-Graph, I.E.M. GMBH, Stolberg, 
Germany) for each patient. The measurement interval was 20 minutes from 7 a.m. to 11 
p.m. and 1 hour from 11 p.m. to 7 a.m. We defined the mean day ambulatory blood pressure 
from 9 a.m. to 9 p.m. and used this as our primary blood pressure outcome. Only recordings 
with 70 % or more valid readings were used. Ambulatory blood pressure values were not 
communicated to the patient, prescribing physician and researcher until after completion of 
the study protocol. Furthermore, the following laboratory tests were used: creatinine (CREA 
plus, Roche Diagnostics, IN, USA), renin (DSL-25100 ACTIVE Renin IRMA kit, Diagnostic 
Systems Laboratories, TX, USA), NT-proBNP (Elecsys, Roche Diagnostics, Zug, 
Switzerland), potassium (ISE Indirect, Roche Diagnostics, IN, USA) and urinary albumin 
(COBAS, Roche Diagnostics, Zug, Switzerland). For comparison of NCC abundance with 
blood pressure, patients were considered responders if they exhibited a decrease of ≥5 
mmHg in blood pressure, n=14. The remainder were considered non-responders, n=9. 
 
Urine collection and measurement of urinary creatinine 
For the patient study, second morning mid-stream urine was collected after the run-in period, 
and at the termination of both HCT and Val treatment. Urine samples were collected 
between 8.30 a.m. and 9.30 a.m. to minimize the effects of circadian rhythm on NCC 
abundance. Additionally, second morning mid-stream urine was collected from 4 healthy 
subjects (males, aged 25-35 years old) solely for the purpose to characterize NCC. uEVs of 
healthy subjects were subjected to N-glycosidase F (PNGase F) and endoglycosidase H 
(Endo H) treatment. All healthy subjects gave written informed consent, and the study 
protocol was approved by the Institutional Review Board of the Radboud University Medical 
Center (approval no. NL47178.091.13). Protease inhibitors (50 μmol/L phenylmethylsulfonyl 
fluoride (PMSF), 20 μmol/L aprotinin, 10 μmol/L pepstatin A and 20 μmol/L leupeptin) were 
added immediately after collecting urine samples to prevent degradation of proteins in uEVs. 
Urinary creatinine was measured according to Jaffe’s method, via a colorimetric assay 
(Labor und Technik, Berlin, Germany) (40). The urine samples were subsequently stored at -
80 °C until required. 
 
Urinary extracellular vesicle isolation 
uEVs were isolated as previously described (43). Briefly, 5 ml of collected urine was 
centrifuged at 17,000 × g for 15 minutes at 24 °C in a Sorvall™ WX Floor Ultra Centrifuge 
(Thermo Scientific, Asheville, NC, USA) with a 70.1Ti rotor. 4 ml of the supernatant was 
removed and incubated at room temperature for 25 minutes. The pellet with remaining 1 ml 
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of the supernatant was resuspended in 200 μl isolation solution (250 mmol/L sucrose and 10 
mmol/L triethanolamine-HCl, pH 7.6) and 50 μl 3.24 mol/L dithiothreitol (DTT), and 
subsequently centrifuged at 17,000 × g for 15 minutes at 24 °C. This supernatant was 
collected and combined with supernatant obtained from the previous step and centrifuged at 
200,000 × g for 2 hours at 24 °C. The uEV pellet was dissolved in 50 µl of Laemmli buffer 
(0.6 % w/v SDS, 3 % v/v glycerol, 18 mmol/L Tris-HCl pH 6.8 and 0.003 % w/v bromophenol 
blue), and stored at -20 °C for further use. 
 
Kidney membrane preparations 
Kidneys were obtained for research purposes through either donation after death, or due to 
unsuitability for transplantation. Membrane fractions of human kidney were isolated as 
described previously (43). In brief, harvested kidneys were snap-frozen immediately after 
isolation and homogenized in detergent-free lysis buffer, containing 50 mmol/L, Tris-HCl 
pH 7.5, 1 mmol/L ethylene diamine tetraacetic acid (EDTA), 1 mmol/L ethylene glycol tetra-
acetic acid (EGTA), 1 mmol/L sodium orthovanadate, 5 mmol/L sodium fluoride, 5 mmol/L 
sodium pyrophosphate, 0.27 mol/L sucrose, 0.1 % v/v β-mercaptoethanol (β-met) and 
protease inhibitors (Roche, 1 tablet per 50 ml), with a homogenizer (VWR VDI 12 Adaptable 
Homogenizers, OpticsPlanet, Inc., Commercial Avenue Northbrook, IL, USA). Nuclei and 
debris were pelleted by centrifugation at 1,500 x g for 5 minutes at 4°C. Next, supernatants 
were centrifuged at 100,000 x g for 1 hour at 4°C. The pellet was washed with 1 volume of 
lysis buffer without reducing agent and centrifuged again at 100,000 x g for 15 minutes to 
remove any remaining cytosolic particles. The pellet was subsequently resuspended in lysis 
buffer including 1 % v/v nonidet P40. Bicinchoninic acid protein assay kit (Pierce, Thermo 
Scientific, Rockford, IL, USA) was used to determine the protein concentration. Finally, 
samples were stored at -80°C for the immunoblotting. 
 
Immunoblotting 
uEV pellets resuspended in Laemmli buffer were incubated at 60 °C for 15 minutes. The 
volume of uEV suspension per lane was adjusted according to the urinary creatinine 
concentration and loaded on 4–15 % v/v Criterion™ TGX™ Precast Gels (Bio-Rad, The 
Netherlands) for protein separation. Proteins were subsequently transferred to 
polyvinylidene difluoride (PVDF) membranes (Immobilon-P, Millipore Corporation, Bedford, 
MA, USA) and incubated with the appropriate primary antibody overnight at 4 °C.  After 
washing, the PVDF membrane was incubated with the appropriate secondary antibody for 
one hour at room temperature, and immunoreactive bands were visualized using 
chemiluminescence (Thermo Fischer Scientific, Waltham, MA, USA). Immunoblots of uEVs 
from hypertensive patients were first probed for the presence of NCC1-3. Subsequently, 
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PVDF membranes were stripped using stripping buffer (100 mmol/L β-met, 2 % w/v SDS, 
62.5 mmol/L Tris-HCl pH 6.8, and 0.1 % v/v Tween-20) and reprobed for pNCC1-3-T55/T60. 
Membrane stripping was performed once for each PVDF membrane that was probed for 
NCC1-3. Immunoreactive band volumes were quantified using Quantity One software (Bio-
Rad, CA, USA).  
 
Dithiothreitol and β-mercaptoethanol treatment 
To reduce dimeric NCC into the monomeric form, the reducing agents DTT and β-met were 
used, in addition to incubation of uEV-samples at 100 °C for 5 minutes. uEV-samples of 
healthy subjects in Laemmli buffer were treated with 0.1 mol/L DTT or 5, 10 and 20 % v/v β-
met. This mixture was continuously mixed for 2 hours at 37 °C with agitation at 0.3 x g in a 
benchtop orbital shaker (Eppendorf, Thermomixer Compact, Gelderland, The Netherlands). 
Subsequently, uEV-samples were incubated at 100 °C for 5 minutes and/or at 60 °C for 15 
minutes (control) and then used for immunoblotting, as previously described in this section. 
 
N-glycosidase F and endoglycosidase H treatment 
Two µl glycoprotein denaturing buffer (New England Biolabs, MA, USA) was added to 18 µl 
of uEVs of healthy subjects in Laemmli buffer. The samples were heated at 60 °C for 15 
minutes and treated with either N-glycosidase F (PNGase F) or endoglycosidase H (Endo H) 
(New England Biolabs, MA, USA) at the final concentration of 9,800 units/ml and 9,800 
units/ml, respectively. This mixture was continuously mixed for 2 hours at 37 °C with 
agitation at 0.3 x g in a benchtop orbital shaker (Eppendorf, Thermomixer Compact, 
Gelderland, The Netherlands) and subsequently used for immunoblotting, as previously 
described in this section. 
 
Antibodies 
The following primary antibodies were used: anti-N-terminal human total NCC (Millipore, 
Billerica, MA, USA, #AB3553; 1:2,000); anti-carboxy (C)-terminal human NCC1/2, generated 
by one of the authors (RJMB, 1:2,000) (43); anti-N-terminal phosphorylated total NCC (anti-
pT55/T60-NCC in human or anti-pT53/T58-NCC in mice; 1:2,000) kindly provided by Prof. R. 
Fenton, Aarhus University, Denmark (33) and anti-amino acid 101-210 of the uEV marker 
CD9 of human origin (C4, Santa Cruz Biotechnology, Inc., CA, USA; 1:500). Secondary 
antibodies used were peroxidase-conjugated goat anti-rabbit (Sigma-Aldrich, St. Louis, MO, 
USA; 1:10,000), and anti-mouse (Sigma-Aldrich, St. Louis, MO, USA; 1:10,000).  
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Statistical analysis 
All data are expressed as mean ± standard error of the mean (SEM). Comparisons were 
made between groups using one-way ANOVA with Tukey’s multiple comparisons test as 
post hoc test. Comparisons between responders and non-responders were made by non-
parametric Student’s t-tests. A P-value of < 0.05 was considered statistically significant. All 
data were analyzed using Prism 5 software (GraphPad Software Inc, La Jolla, CA, USA). 
 
Results 
Structural characterization of NCC in uEVs of healthy subjects 
Figure 2 shows representative immunoblots of uEVs from a healthy subject probed for the 
presence of NCC1-3. In uEVs, NCC protein is present in oligomeric structures, shown in 
Figure 2 as two immunoreactive bands of ~260 (dimer) and ~130 kDa (monomer). The 
molecular size of NCC in uEVs is in agreement with NCC expressed in human kidney (Fig. 
2C) and mouse renal tissue (19). Treatment with the reducing agents β-met, and DTT and/or 
incubation at 100 °C did not reduce the dimeric NCC into the monomeric form (Fig. 2, A and 
B), indicative of the complex oligomeric structure of NCC in human uEVs.  
Resuspended uEV pellets were subjected to Endo H and PNGase F treatment to 
determine glycosylation. Endo H cleaves high-mannose and a limited number of hybrid 
oligosaccharides from N-linked glycoproteins, but does not cleave complex glycans, 
whereas PNGase F removes all N-glycans from glycoproteins, and was used as a control (9, 
19). Both dimeric and monomeric immunoreactive bands of NCC were insensitive to Endo H 
treatment (Fig. 2C). However, PNGase F treatment resulted in migration of both dimeric and 
monomeric immunoreactive bands of NCC to a lower molecular weight (Fig. 2C), 
demonstrating the complex glycosylated structure of NCC. 
Table 1 depicts the clinical and laboratory characteristics of the study population of 
patients with essential hypertension, demonstrating no significant differences in any of these 
parameters between groups. Both HCT and Val treatment significantly reduce arterial blood 
pressure of hypertensive patients (Fig. 3A). Plasma sodium levels did not change after both 
treatments (Fig. 3B). Plasma potassium concentrations were significantly reduced after HCT 
treatment, but not following Val treatment (Fig. 3C), and plasma renin levels were 
significantly increased after both HCT and Val treatment (Fig. 3D). 
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Figure 2 | The structure of NCC in human uEVs and human kidney membrane fractions is 
presented as an oligomeric and glycosylated complex.  
Representative immunoblots of NCC1-3 within uEVs of a healthy subject show band sizes of ~260 and 
~130 kDa. (A) Lane 1- Control (uEVs incubated at 60 °C for 15 minutes prior to immunoblotting); 
Lane 2- Samples treated with dithiothreitol (DTT) (0.1 mol/L) prior to incubation at 60 °C for 15 
minutes; Lane 3- Samples incubated at 100 °C for 5 minutes; Lane 4- Samples treated with DTT (0.1 
mol/L) prior to incubation at 100 °C for 5 minutes. (B) Lane 1- Control; Lane 2, 3 and 4- Samples 
treated with 5, 10 and 20 % v/v β-mercaptoethanol (β-met) respectively prior to incubation at 60 °C for 
15 minutes. (C) Lane 1- untreated uEVs (Control); Lane 2- uEVs treated with N-glycosidase F 
(PNGase F) 9,800 units/mL; Lane 3- untreated uEVs (Control); Lane 4- uEVs treated with 
endoglycosidase H (Endo H) 9,800 units/mL; Lane 5- untreated human kidney membrane fractions 
(Control); Lane 6- human kidney membrane fractions treated with PNGase F 9,800 units/ml; Lane 7- 
untreated human kidney membrane fractions (Control) and Lane 8- human kidney membrane 
fractions treated with Endo H 9,800 units/mL.  
Efficacy of anti-hypertensive medications 
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Table 1 | Clinical and laboratory characteristics of 23 patients with essential hypertension.  
Average age of the patients summarized above was 52 ± 2 years. Data are presented as the mean ± 
SEM. All parameters in HCT or valsartan groups are compared with untreated and found statistically 
not significant.  
Unt: untreated; HCT: hydrochlorothiazide; Val: valsartan (treatment protocol depicted in Fig. 1); 
Menopause 4: 4 out of 6 women were in menopausal state; eGFR: Estimated glomerular filtration 
rate; HDL: High-density lipoprotein in blood; LDL: Low-density lipoprotein in blood; NT-ProBNP: 
amino (N)-terminal of the prohormone brain natriuretic peptide.	 
 
NCC abundance in uEVs of hypertensive patients is increased by the treatment of HCT, but 
not Val 
The volume of uEV suspension per sample was adjusted according to urinary creatinine 
concentration prior to immunoblot analysis. Figure 4A shows representative immunoblots of 
uEVs from three hypertensive patients probed for the presence of NCC1/2, NCC1-3, pNCC1-3-
T55/T60, and the uEV marker CD9, to confirm equal loading (1, 35, 43). Densitometric 
analysis of the immunoreactive bands of 23 hypertensive patients representing dimeric and 
monomeric NCC isoforms and pNCC1-3-T55/T60 was performed together (Fig. 4). The 
abundance of NCC1/2, NCC1-3, and pNCC1-3-T55/T60 was significantly increased in uEVs of 
HCT, but not Val-treated patients (Fig. 4). No difference in CD9 abundance was observed 
between the three groups suggesting that normalization by urinary creatinine results in 
comparable uEV-numbers (Fig. 4, E and F). Finally, the ratio of pNCC1-3-T55/T60 to NCC1-3 
was not significantly different after HCT or Val treatment (Fig. 5G). Additional normalization 
by CD9 abundance led to similar results (data not shown). 
 
Physiological parameters Unt HCT Val 
Body Weight (Kg) 81 ± 3 81 ± 3 81 ± 3 
Body Mass Index (Kg/m2) 
Men/women 
Menopause 
27.8 ± 0.7 
17/6 
4 
27.9 ± 0.8 
17/6 
4                     
27.9 ± 0.8 
     17/6 
  4 
Serum creatinine (μmol/L) 75 ± 3 73 ± 3 74 ± 3 
eGFR (mL/min/1.73 m2) 81 ± 3 81 ± 3 82 ± 3 
HDL (mmol/L) 1.2 ± 0.1 1.2 ± 0.1 1.1 ± 0.1 
LDL (mmol/L) 4.0 ± 0.2 4.2 ± 0.2 4.1 ± 0.2 
Blood glucose (mmol/L) 5.9 ± 0.2 5.8 ± 0.2 5.9 ± 0.2 
Blood NT-ProBNP (pmol/L) 7 ± 1 6 ± 1 14 ± 8 
Urinary creatinine (mmol/L) 11 ± 1 12 ± 1 11 ± 1 
Urinary albumin (mg/L) 15 ± 5 12 ± 3 11 ± 2 
Urinary albumin/Urinary creatinine (mg/mmol) 1.1 ± 0.2 0.9 ± 0.2 1.0 ± 0.2 
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Figure 3 | Effect of anti-hypertensive drugs on systolic blood pressure, plasma sodium, 
potassium, and renin levels in patients with essential hypertension.  
White bars represent, untreated (Unt), grey bars following four weeks of hydrochlorothiazide (HCT) 
treatment and black bars following four weeks of valsartan (Val) treatment. (A) Both HCT and Val 
treatment vs. Unt (*) as well as HCT vs. Val treatment (#) significantly reduced arterial blood pressure. 
(B) Plasma sodium levels did not significantly change after HCT or Val treatment. (C) HCT vs. both 
Unt (*) and Val (§) treatment significantly decreased plasma potassium levels. (D) Plasma renin levels 
were significantly increased following both treatments. The data on arterial blood pressure levels are 
presented as mean arterial pressure (MAP). Values are mean ± SEM. Comparisons were made 
between groups using one-way ANOVA with Tukey’s multiple comparisons test as post hoc test. 
*,#,§P<0.05, n=23. 
 
Efficacy of anti-hypertensive medications in responders and non-responders 
During analysis of the data presented in Figure 3, we observed that with respect to HCT 
administration, the subjects could be divided into responders (Fig. 5, A-E) and non-
responders (Fig. 5, F-J). Responders displayed a decrease of ≥5 mmHg in blood pressure, 
with the remainder considered non-responders. In responders (Fig. 5A), compared to non-
responders (Fig. 5F), the abundance of NCC1/2, NCC1-3, and pNCC1-3-T55/T60 was 
significantly increased (3-4 fold higher) upon HCT, but not Val treatment. In responders, 
arterial blood pressure was significantly reduced after HCT as well as Val treatment, and in 
the non-responder group, arterial blood pressure was significantly reduced in only the Val 
treated group (Fig. 5, B and G). Plasma sodium levels were not significantly different 
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between the responders and non-responders of the treatment groups (Fig. 5, C and H). In 
the responder group, plasma potassium levels of HCT treated patients significantly 
decreased when compared to both Unt and Val treatment, however in the non-responder 
group no significant change in plasma potassium levels were observed between the three 
treatment groups (Fig. 5, D and I). Plasma renin levels were significantly increased in the 
responder group following both HCT and Val treatment and in the non-responder group 
plasma renin concentrations were significantly increased after Val, but not HCT treatment 
(Fig. 5, E and J). 
 
 
Figure 4 | Expression of NCC1/2, NCC1-3, pNCC1-3-T55/T60, and CD9 in uEVs of patients with 
essential hypertension before (Unt) and after treatment with hydrochlorothiazide (HCT) or 
valsartan (Val).  
(A) Representative immunoblots of 3 patients depicting abundance of NCC1/2, NCC1-3, pNCC1-3-
T55/T60, and CD9 in uEVs. In all immunoblots, lane 1 represents protein expression prior to the 
treatment (Unt), and lanes 2 and lane 3 represent protein expression after HCT and Val treatment, 
respectively. Densitometric analysis of the immunoblots of 23 patients depicting the abundance of 
NCC1/2 (B), NCC1-3 (C), pNCC1-3-T55/T60 (D) and the ratio of pNCC1-3-T55/T60 to NCC1-3 (G). 
Densitometric analysis of CD9 expression of the immunoblots of 23 patients for NCC1/2 (E) and NCC1-
3 and pNCC1-3-T55/T60 (F) showed no significant difference between the three groups. Values are 
mean ± SEM (n=23) normalized to Unt levels. Comparisons were made between groups using one-
way ANOVA with Tukey’s multiple comparisons test as post hoc test. *P<0.05, n=23. 
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Figure 5 | Effect of anti-hypertensive drugs on the expression of NCC1/2, NCC1-3 and pNCC1-3-
T55/T6 and systolic blood pressure, plasma sodium, potassium, and renin levels in 
responders compared to non-responders.  
Densitometric analysis of the immunoblots of 23 patients depicting the abundance of NCC1/2, NCC1-3 
and pNCC1-3-T55/T60 and arterial blood pressure, plasma sodium levels, plasma potassium levels 
and plasma renin levels of hypertensive patients after treatment with hydrochlorothiazide (HCT) of 
responders (A-E, n=14) and non-responders (F-J, n=9) have been analyzed separately. White bars 
represent untreated (Unt), grey bars following four weeks of hydrochlorothiazide (HCT) treatment and 
black bars following four weeks of valsartan (Val) treatment. The abundance of NCC1/2, NCC1-3, and 
pNCC1-3-T55/T60 was significantly increased in uEVs of responders (A), compared to non-responders 
(F), upon HCT-, but not Val-treatment. In responders (B), both HCT and Val treatment vs. Unt (*) 
significantly reduced arterial blood pressure, while in non-responders (G) only Val treatment vs. Unt 
(*) and HCT treatment (#) significantly reduced arterial blood pressure. Plasma sodium levels showed 
no significant difference in both responders (C) and non-responders (H) between the groups. (D) In 
responders, plasma potassium levels of HCT vs. both Unt (*) and Val (§) treatment significantly 
decreased, however (I) in the non-responder group plasma potassium levels did not significantly 
change after HCT or Val treatment. (E) In the responder group plasma renin levels were significantly 
increased following both treatments however (J) in non-responder group plasma renin concentrations 
were significantly increased only after Val treatment. The data on arterial blood pressure levels are 
presented as mean arterial pressure (MAP). Values are mean ± SEM. Comparisons were made 
between groups using one-way ANOVA with Tukey’s multiple comparisons test as post hoc test. 
*,#,§P<0.05, n=23. 
 
Blood pressure correlates with NCC abundance in uEVs and plasma potassium of 
hypertensive patients treated with HCT 
To determine if HCT-induced reduction in blood pressure is correlated with NCC abundance, 
the blood pressure response of hypertensive patients to HCT was plotted against NCC 
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abundance for both responder and non-responder groups. As shown in Figure 6, A and B, 
both NCC1-2 and NCC1-3 abundance was significantly higher in patients who responded to 
HCT treatment than non-responders, after normalization to pretreatment. There was no 
significant difference of pNCC1-3-T55/T60 abundance between responders and non-
responders (Fig. 6C, P>0.2).   
 
Figure 6 | Blood pressure correlates with plasma potassium and NCC abundance in uEVs of 
essential hypertensive patients treated with HCT.  
The abundance of NCC1/2 (A), NCC1-3 (B) and pNCC1-3-T55/T60 (C) in uEVs of hypertensive patients 
after treatment with hydrochlorothiazide (HCT) of both responders (n=14) and non-responders (n=9) 
normalized to untreated (Unt). The increase of both NCC1/2 (A) and NCC1-3 (B) in uEVs was 
significantly higher in responders compared to non-responders. (C) pNCC1-3-T55/T60 abundance in 
uEVs showed no significant difference between responders and non-responders. Correlation of ∆ 
blood pressure with ∆ plasma potassium levels of HCT minus Unt (D, r=0.32, P<0.05) or Val minus 
Unt (E, r=0.07, P>0.2). Circles represent responders and triangles represent non-responders. 
Correlation data from one responding patient from panel D, and one non-responding patient from 
panel E is not shown as plasma potassium values are not available. Values are mean ± 
SEM normalized to untreated (Unt) levels. Comparisons between responders and non-responders 
were made by using non-parametric t-test. *P<0.05, n=23. 
 
To determine if changes in plasma potassium levels are associated with a reduction in 
blood pressure following anti-hypertensive treatment, the correlation between plasma 
potassium and blood pressure was assessed. Positive correlation (r=0.32, P<0.05) was 
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observed between plasma potassium and blood pressure when hypertensive patients were 
treated with HCT (Fig. 6D). As depicted in Figure 6E, similar correlation was not observed in 
the group of patients treated with valsartan. 
 
Discussion 
This study demonstrates that chronic HCT treatment, in contrast to Val, enhances the 
abundance of NCC1/2, NCC1-3, and pNCC1-3-T55/T60 in uEVs derived from essential 
hypertensive patients (Fig. 4), indicative of such changes in the DCT (43, 44). Additionally, 
we show that blood pressure correlates with NCC abundance in uEVs and plasma 
potassium levels of essential hypertensive patients treated with HCT, but not with Val. As in 
human kidney membrane fractions, in uEVs NCC is present in a glycosylated and oligomeric 
structure.  
In both uEVs and human kidney membrane fractions NCC is present in oligomeric 
structures as demonstrated by the presence of NCC protein as complex bands of ~260 and 
~130 kDa (Fig. 2), representing the dimeric and monomeric forms, respectively. It was not 
possible to dissociate the dimeric NCC complex in a monomeric form by incubating the 
uEVs at 100 °C or exposing them to the reducing agents DTT and β-met. The NCC 
complexes of ~260 and ~130 kDa detected in the human uEVs are comparable to NCC 
expression in human kidney membrane fractions, indicative of detection of NCC derived 
from distal tubule epithelia, in line with our previously published studies (10, 43).  
Previously, it has been demonstrated that NCC is N-glycosylated in rat kidney and that 
N-glycosylation is essential for the cell surface expression of NCC, thiazide sensitivity and 
NCC activity (19). Our study demonstrates that in uEVs of healthy subjects and kidney 
membrane fractions of healthy donors both dimeric and monomeric NCC bands were 
sensitive to digestion with PNGase F, suggesting that NCC protein in uEVs, similarly to 
kidney membrane fractions, is glycosylated.  
Proteins that are sensitive to Endo H digestion are suggested to be retained in the 
endoplasmic reticulum and pre-Golgi complex without further processing (9, 14, 37). Our 
results demonstrate that in uEVs and human kidney membrane fractions both the dimeric 
and monomeric NCC bands were insensitive to Endo H digestion, indicating that NCC in 
uEVs is present as a matured protein with complex glycosylation. In an overexpression 
system, immunoblots of total membranes isolated from Xenopus oocytes injected with 
cRNAs coding for human NCC showed that the NCC immunoreactive band at ~130 kDa 
(monomer) is insensitive to Endo H treatment, while the NCC immunoreactive band at ~110 
kDa (monomer) is sensitive to Endo H digestion (9, 19), suggesting the presence of 
unprocessed NCC. The presence of an Endo H-insensitive NCC immunoreactive band at 
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~130 kDa (monomer) and the absence of an immunoreactive band of ~110 kDa (monomer) 
in uEVs, as in human kidney membrane fractions, suggests that NCC protein in uEVs 
represents a mature plasma membrane protein with complex glycosylation. Therefore, in 
humans, uEVs can be used as a non-invasive tool to study the regulation of NCC in the 
kidney. 
It has previously been shown that prolonged HCT treatment increases NCC abundance 
in the rodent kidney, in agreement with our results (29, 30). Additionally, the binding density 
of [3H] metolazone, an indirect measure of NCC abundance, is augmented by chronic HCT 
treatment in rat kidney membrane fractions (6). The increased abundance of NCC in the 
DCT, which is reflected by an increase abundance of NCC in uEVs, upon chronic HCT 
treatment, may be a compensatory effect to counteract reduced NCC activity as a result of 
thiazide-mediated inhibition of NCC (11). This compensatory response could, therefore, 
partly contribute to diuretic resistance (12). The upstream stimulator pathways of NCC, such 
as that of angiotensin II, are still intact upon HCT treatment (38), thus Val treatment blocks 
the angiotensin II dependent stimulation of NCC (47), which might explain why there is no 
enhancement of NCC abundance in uEVs after Val treatment. 
Sodium reabsorption along the distal nephron plays an important role in potassium 
homeostasis (42). Due to the inhibitory effect of HCT on NCC activity, sodium delivery to the 
collecting duct will increase, and these latter segments will therefore reabsorb more sodium. 
As a consequence more potassium is excreted, ultimately resulting in decreased plasma 
potassium levels (41). Conversely, Terker et al. demonstrated that a modest decrease in 
plasma potassium levels, within the narrow physiological range of 3.5–5.0 mmol/L, increases 
NCC abundance and activity (41). The reduced plasma potassium levels observed in this 
study may help to explain the increase in abundance of NCC1/2, NCC1-3, and pNCC1-3-
T55/T60 in uEVs of hypertensive patients following HCT treatment (Figs. 3C, 4 and 5, A and 
D). Additionally, Val treatment, in contrast to HCT, did not enhance the abundance of 
NCC1/2, NCC1-3, and pNCC1-3-T55/T60 in uEVs derived from essential hypertensive patients. 
The lack of NCC response to Val treatment may indicate NCC activation to be partly 
dependent on angiotensin II stimulation (5), whereas thiazides block NCC directly by 
interfering with chloride binding to NCC (20). Indeed, angiotensin II is also known to increase 
the abundance and activity of NCC through the WNK pathways (38). The upstream 
regulatory pathways of NCC stimulation (such as RAAS) are still intact during HCT treatment 
and may stimulate NCC abundance and phosphorylation, while its function is still blocked by 
HCT. When the dataset is separated into responders and non-responders, it becomes 
observable that in responders HCT or Val treatment reduces blood pressure of the 
hypertensive patients to a similar degree (Fig. 5B). Previously, it has been shown that high 
dietary sodium ingestion contributes to diuretic resistance (34). Patients with resistant 
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hypertension who were on a reduced sodium diet compared to those on an increased 
sodium diet showed significantly increased plasma renin levels (34). In this study, higher 
dietary sodium intake may have been a contributory factor to non-responsiveness to the 
HCT treatment (diuretic resistance).  
Here, we show that blood pressure correlates with the differential NCC abundance and 
plasma potassium levels of essential hypertensive patients treated with HCT, but not with 
Val (Fig. 6). NCC abundance was increased in the group of patients that responded to HCT 
treatment, as defined by a significant reduction in blood pressure, however, there was no 
difference in NCC abundance of non-responders.  
Loffing et al. have previously demonstrated in rats that 3 days HCT administration of 40 
mg/kg/day reduces NCC expression in the DCT and induces apoptosis of DCT cells (25). In 
contrast, 7 days HCT administration in mice increased NCC abundance in the kidney, 
measured by immunoblot and immunostaining (29), in agreement with our findings using 
human uEVs. Moreover, in mice HCT administration of 25 mg/kg/day for 6 days did not 
induce apoptosis of DCT cells or a decrease in NCC expression (30), while hypocalciuria, 
renal Mg2+ wasting and hypomagnesemia were observed (a phenotype resembling the 
effects of chronic thiazide administration and Gitelman syndrome) (8, 13, 15, 23). 
Subsequent experiments by Loffing et al. failed to reproduce the observed DCT cell 
apoptotic changes in mice, when using several mouse strains, both sexes of mice, and 
different thiazide-type diuretics and application protocols (30). Indeed, they found chronic 
HCT treatment in mice to increase NCC abundance in the kidney (30). Different doses of 
HCT administration, inter-species variation in transporter expression (2, 31) and the length 
of treatment regimen of the study may help to answer this discrepancy.  
Our study demonstrates that chronic HCT treatment, in contrast to Val, enhances the 
abundance of NCC1/2, NCC1-3, and pNCC1-3-T55/T60 in uEVs derived from essential 
hypertensive patients, indicative of such changes in the DCT (43, 44). NCC in uEVs is 
present in a glycosylated and oligomeric structure, as found in human kidney membrane 
fractions.  
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Abstract  
The NaCl cotransporter, NCC, is essential for electrolyte homeostasis and blood pressure 
control. The human SLC12A3 gene, encoding NCC, gives rise to three isoforms, of which 
only the shortest isoform (NCC3) has been studied extensively. All NCC isoforms share key 
phosphorylation sites at threonine 55 (T55) and 60 (T60) that are essential mediators of 
NCC function. Recently, a novel phosphorylation site at serine 811 (S811) was identified in 
isoforms 1 and 2 (NCCSV), only present in humans and higher primates. The aim of this 
study is, therefore, to investigate the role of S811 phosphorylation in the regulation of NCC 
by a combination of biochemical and fluorescent microscopy analyses. We show that the 
phosphorylation-deficient S811A mutant hinders phosphorylation at T55 and T60 in NCCSV, 
as well as in NCC3. NCCSV S811A impairs NCC3 activity in a dominant negative fashion, 
while it does not affect plasma membrane abundance. This effect may be explained by 
heterodimerization of NCCSV with NCC3. Taken together, our study highlights a dominant 
negative effect of NCCSV on T55 and T60 phosphorylation and NCC activity. Hereby, we 
reveal a new function of NCCSV in humans that broadens the understanding on NCC 
regulation in blood pressure control. 
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Introduction 
Hypertension (high blood pressure) affects over 1.3 billion people worldwide, and can lead to 
severe cardiovascular complications, including cerebrovascular disease, heart failure, 
ischemic heart disease and renal failure (6, 9, 19, 35, 39, 41). This makes hypertension the 
greatest contributing risk factor to morbidity and mortality worldwide. The cause of 
hypertension is identified in only ~10% of the cases (secondary hypertension) (10, 34). It is 
of critical importance to increase our understanding of the pathophysiology of hypertension. 
The kidneys play a key role in blood pressure control by regulating sodium (Na+) excretion 
(5, 7, 12, 13, 38). Fine-tuning (5-10%) of Na+ excretion primarily takes place in the distal 
convoluted tubule (DCT) by Na+ reabsorption through the NaCl cotransporter (NCC) (16, 17, 
59).  
Since the cloning of NCC, three splice isoforms of NCC have been identified, which are 
the result of alternative splicing of the SLC12A3 gene (59). So far, most research has 
focused on the shortest NCC isoform (NCC3), as the other two isoforms are not present in 
rodents (20). NCC isoforms 1 and 2 that result from alternative splicing of exon 20 are nine 
amino acids longer than NCC3 (20, 55). Subsequent studies confirmed the presence of both 
long and short forms of the exon 20 (20a and 20b respectively), which possibly indicates a 
splicing donor site (33). Compared to NCC isoform 1, isoform 2 lacks one amino acid at 
glutamine residue 95 within amino (N)-terminal domain. Therefore, NCC isoform 1 and 2 are 
practically indistinguishable and are, in this study, collectively referred to as NCC splice 
variant (NCCSV). Interestingly, NCCSV is only present in humans and higher primates. In the 
human kidney, NCCSV mRNA comprises ~44% of the total NCC content (59).  
The importance of NCC in blood pressure regulation is illustrated by diseases such as 
Gitelman Syndrome (OMIM #263800) (60-62) and Familial Hyperkalemic Hypertension 
(FHHt; OMIM #145260) (28, 50, 66, 68). Gitelman Syndrome is caused by loss of function 
mutations in the SLC12A3 gene, encoding NCC (60-62), resulting in renal Na+ wasting and 
hypotension (23, 55). In contrast, FHHt is a form of hypertension that results from gain of 
function of NCC, as a consequence of mutations in genes encoding for key signaling 
molecules (8, 66). In FHHt, mutations have been identified in WNK1 and WNK4 encoding 
the with no lysine (WNK) kinases (66), or in KLHL3 and CUL3, coding for Kelch-like 3 and 
Cullin 3, respectively (8). WNK kinases phosphorylate and activate Ste20-related proline-
alanine-rich kinase (SPAK) and oxidative stress response 1 (OSR1), which in turn 
phosphorylate threonine residues 55 and 60 (T55 and T60) in NCC (1, 43, 59). 
Phosphorylation of these sites is essential for NCC activity (16, 43, 57, 71) and plasma 
membrane abundance (27, 69).  
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Interestingly, Gonzales et al. described a novel phosphorylation site on serine residue 
811 (S811), which is only present in NCCSV (20). Our group has previously shown that 
NCCSV plays a role in physiological (59) and pathophysiological (45) processes. However, 
the importance of NCCSV S811 phosphorylation in NCCSV and NCC3 function remains 
unknown. Therefore, the present study aims to investigate the role of NCCSV S811 in the 
phosphorylation and activity of NCCSV as well as NCC3. A combinational approach of 
immunoblotting with phospho-specific antibodies, cell surface biotinylation, and fluorescence 
microscopy was used to examine the influence of S811 on the phosphorylation, membrane 
abundance and activity of NCC. In addition, the interaction of NCCSV with NCC3 was 
assessed by fluorescence lifetime imaging microscopy (FLIM). 
 
Materials and Methods 
Mutagenesis and constructs.  
NCC isoform 1 (accession no. NP_000330.2) was used in all experiments to represent 
NCCSV. For co-immunoprecipitation, enhanced green fluorescent protein (eGFP) carboxy 
(C)-terminal-coupled human NCC3-eGFP, NCCSV-eGFP, and the phospho-mutants of 
NCCSV-eGFP (constitutively phosphorylated S811D and non-phosphorylated S811A) in 
pCMV-SPORT6 were generated as previously described (16, 59). In addition, human NCC3, 
NCCSV, and NCCSV phospho-mutants were cloned into the HA pCINeo-IRES-mCherry vector 
using standard PCR and restriction cloning. For the FLIM and co-immunoprecipitation 
experiments, NCCSV and NCC3 were cloned into the pCINeo vector and human codon 
optimized mCitrine and mCherry tags were fused to the C-terminal end separated by a 15 
residues long linker region (3x GGGGS) using PCR and uracil excision based cloning (42). 
For the fluorescence microscopy measurements, NCC3, NCCSV, NCCSV phospho-mutants 
(S811D and S811A) and NCC3 phospho-mutant (T55A/T60A) were cloned into the pCINeo-
IRES-eCFP vector using restriction cloning. The vector carrying halide-sensitive yellow 
fluorescent protein (YFP) and mKate gene was described previously (64) and was kindly 
provided by Dr. Jeffrey M. Beekman (University Medical Center Utrecht, the Netherlands). 
 
Cell culture and transfection.  
Cell culture and transfection was performed as described previously (59). In brief, human 
embryonic kidney (HEK293) cells were grown in DMEM medium supplemented with 10% v/v 
fetal bovine serum, non-essential amino acids and 2 mM L-glutamine. The cells were 
transiently transfected using polyethylenimine (Polysciences, Warrington, PA, USA) in 
DNA:polyethylenimine ratio of 1:6. Cells transfected with empty vectors were used as control 
(mock). For co-transfection, cells were transfected in a DNA ratio of 1:1. 
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Buffers.  
The following buffers were used: isotonic control buffer contained (in mM) 135 NaCl, 5 KCl, 
0.5 CaCl2, 0.5 MgCl2, 0.5 Na2HPO4, 0.5 Na2SO4, 15 HEPES/Tris pH 7.4; hypotonic low Cl- 
buffer contained (in mM) 67.5 Na-Gluconate, 2.5 K-gluconate, 0.25 CaCl2, 0.25 MgCl2, 0.5 
Na2HPO4, 0.5 Na2SO4, 7.5 HEPES/Tris pH 7.4; dissection buffer contained (in mM) 300 
sucrose, 25 imidazole, 1 EDTA, HCl pH 7.2 and freshly added protease inhibitors (in µM) 50 
phenylmethylsulfonyl, 20 aproptinin, 20 leupeptin, 10 pepstatin A; PBS-CM, PBS 
supplemented with (in mM) 1 MgCl2, 0.5 CaCl2, NaOH pH 8.0; Lysis buffer contained (in 
mM) 50 Tris/HCl pH 7.5, 1 EGTA, 1 EDTA, 10 Na+ β-glycerophosphate, 1 Na-
orthovanadate, 50 Na-fluoride, 10 Na-pyrophosphate, 270 sucrose, 150 NaCl, 1% v/v Triton 
X-100 and freshly added protease inhibitors (in µM) 50 phenylmethylsulfonyl, 20 aproptinin, 
20 leupeptin, 10 pepstatin A; 1x Laemmli sample buffer contained (in mM) 40 DTT, 12 
Tris/HCl pH 6.8, 0.4% w/v SDS, 2% v/v glycerol, 0.002% w/v bromophenol blue; TBS-T 
contained (in mM) 140 NaCl, 20 Tris/HCl pH 7.5, 0.1% v/v Tween-20. NaI solution contained 
(in mM) 140 NaI, 4.2 KCl, 1.4 CaCl2, 1 MgCl2, 5.5 D-glucose, 10 HEPES/Tris pH 7.4, 300 
mosmol/kg H2O. 
 
Cell treatment.  
At 48 h post-transfection, the HEK293 cells were washed once with PBS. Next, cells were 
incubated for 30 min at 37ºC with isotonic control buffer or hypotonic low Cl- buffer. 
Subsequently, the cells were used for isolation of total cell membrane fractions, cell surface 
biotinylation, or co-immunoprecipitation. 
 
Isolation of total cell membrane fractions.  
HEK293 cells were lysed with ice-cold dissection buffer. Lysed cells were centrifuged at 
4,000 g for 8 min at 4ºC, after which the supernatant was centrifuged at 16,000 g for 40 min 
at 4ºC. The pellet was resuspended in ice-cold dissection buffer and protein concentration 
was determined using the Bradford method (Sigma-Aldrich, St. Louis, MO, USA). Proteins 
were eluted in 1x Laemmli sample buffer. Samples were incubated for 15 min at 65ºC prior 
to immunoblotting. 
 
Cell surface biotinylation.  
Cells surface biotinylation was performed as described previously (14). Subsequently, 
HEK293 cells were lysed in ice-cold lysis buffer and centrifuged at 16,000 g at 4°C. Protein 
concentrations were determined using the Bradford method (Sigma-Aldrich, St. Louis, MO, 
USA). Equal amounts of protein were incubated with neutravidin beads (Pierce 
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Biotechnology, Rockfort, IL, USA) for 2 h at 4°C. The beads were washed three times with 
lysis buffer and eluted in 1x Laemmli sample buffer. Samples were incubated for 15 min at 
65ºC prior to immunoblotting. 
 
Fluorescence lifetime imaging microscopy.  
FLIM images were generated from HEK293 cells 16 h after transfection with NCC3 and 
NCCSV containing mCitrine and/or mCherry C-terminal fusion plasmids. Total amount of 
DNA per transfection was 2 µg (1:1 donor acceptor ratio) in WillCo-dish (diameter 35 mm, 
WillCo Wells B.V. Amsterdam, Noord-Holland, NL) with 1.2 X 106 cell density. Imaging and 
measurements were performed as previously described (63). In brief, samples were washed 
and imaged in Live Cell imaging solution (HEPES buffered saline solution; Thermo 
Scientific, Rockford, IL, USA). Photon traces in Picoquant Photon Trace version (PT3) 
format were used to construct FLIM images in Image Cytometry Standard (ICS). Conversion 
of PT3 files to ICS was performed using PT32ICS conversion software (63). For FLIM 
statistics of single cells, photons were pooled for each individual cell and fitted with 
exponential decay functions de-convoluted with the instrument response function (IRF) using 
OriginPro2016 (Originlab, Northampton, MA, USA). Single pixel-fitted FLIM images were 
generated for individual cells (with at least 1,000,000 photons per cell) using the TRI2 
software (version 2.8.6.2; Gray institute, Oxford, OXF, UK) (3, 4). Settings used for TRI2 
were: 7 x 7 pixel circular binning and thresholding 15%-100% intensity. Lifetime imaging 
pictures were generated using FIJI ImageJ (52). 
 
Co-immunoprecipitation.  
Transfected HEK293 cells were lysed in ice-cold lysis buffer for 1 h at 4ºC. Subsequently, 
cell lysate was collected and centrifuged at 16,000 g at 4ºC. Protein concentrations were 
determined using the Bradford method. The anti-green fluorescent protein (GFP) or anti-HA 
antibodies were coupled to protein A/G plus agarose beads (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) by gentle agitation for 2 h at 4ºC. Subsequently, equal amounts of 
protein were incubated with GFP- or HA-conjugated beads for 2 h at 4ºC. GFP-conjugated 
beads were used for co-immunoprecipation of mCitrine-tagged NCC to demonstrate binding 
to mCherry-tagged NCC. Co-immunoprecipation of HA-tagged NCC was performed with the 
HA-conjugated beads to detect interaction with eGFP-tagged NCC. Beads were washed 
three times with ice-cold lysis buffer and proteins were eluted in 1x Laemmli sample buffer. 
Samples were incubated for 15 min at 65ºC prior to immunoblotting. The co-
immunoprecipitation was analyzed by anti-GFP, anti-HA, anti-mCherry antibodies. 
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Immunoblotting.  
Samples in Laemmli buffer were loaded on an 8% w/v SDS-PAGE gel, transferred to 
polyvinylidene difluoride membranes (Immobilon-P, Millipore Corporation, Bedford, MA, 
USA) that were subsequently blocked for 30 min with TBS-T containing 5% w/v skimmed 
dried milk powder. Subsequently, membranes were incubated with primary antibodies 
dissolved in 5% w/v in non-fat dry milk (NFDM) in TBS-T overnight at 4ºC. Next, membranes 
were incubated with horseradish peroxidase (HRP) conjugated secondary antibodies diluted 
in 1% w/v NFDM in TBS-T for 1 h at room temperature and visualized with the imaging 
system (ChemiDoc XRS, Bio-Rad Laboratories, Hercules, CA, USA) using enhanced 
chemiluminescence (Thermo Fischer Scientific, Waltham, MA, USA). Immunoreactive bands 
were quantified with Image Studio Lite software (LI-COR biosciences, Lincoln, NE, USA). 
 
Antibodies.  
The following antibodies were used: anti-total NCC (Millipore, Billerica, MA, USA, #AB3553; 
1:2,000); anti-NCC pT55 and anti-NCC pT60 (equivalent mouse NCC pT53 and pT58; 
1:2,000) as previously described (46), anti-HA (Cell Signaling Technology, Beverly, MA, 
USA, #2367; 1:5,000), anti-GFP (generated in house, detects eGFP and mCitrine, 1:5,000), 
anti-mCherry (Abcam, Cambridge, UK, #ab167453; 1:1,000) and anti-β-actin (Sigma-Aldrich, 
St. Louis, MO, USA, #A5441; 1:20,000). Secondary antibodies were as follows: horseradish 
peroxidase-conjugated goat-anti-rabbit (Sigma-Aldrich, St. Louis, MO, USA, #A4914; 
1:10,000) and goat-anti-mouse (Jackson Immunoresearch laboratories, West Grove, PA, 
USA, #515-035-003; 1:10,000). 
 
NCC activity measurements using YFP-mKate. 
NCC activity was performed as described previously (61). In brief, HEK293 cells were co-
transfected with the halide-sensitive YFP-mKate construct (64) and the appropriate human 
NCC pCINeo-IRES-eCFP construct or pCINeo-IRES-eCFP mock. Total amount of DNA per 
transfection was 2 µg (0.2 µg YFP-mKate + 1.8 µg NCC) in WillCo-dish with 1.2 X 106 cell 
density. 19 h after transfection and prior to the measurements, cells were incubated with 
hypotonic low Cl- buffer for 10 min at 37°C. Next, cells were placed in an incubation chamber 
containing hypotonic low Cl- buffer (500 µL) and attached to the stage of an inverted 
microscope (Axiovert 200M, Carl Zeiss, Jena, Germany). NCC-expressing HEK293 cells 
were identified by detecting eCFP fluorescence using a monochromator at 430-nm 
excitation, and subsequently the emitted light was directed by a 480AF30 dichroic mirror. 
After 30 s, an equal volume of NaI solution was added to the incubation chamber (final 
concentration of Na+ 105 mM and I- 70 mM). Changes in intracellular halide concentrations 
were monitored by simultaneous measurements of halide-sensitive YFP fluorescence and 
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the halide-insensitive fluorescence of mKate (64). Halide-sensitive YFP was excited at 488 
nm using a monochromator. The fluorescence-emitted light was directed by a 505DRLPXR 
dichroic mirror (Omega Optical, Brattleboro, VT) through a 535af26 emission filter. mKate 
was excited at 543 nm, and fluorescence-emitted light was directed by a 560DRLP dichroic 
mirror (Omega Optical) through a 565ALP emission filter onto a Cool-SNAP HQ 
monochrome CCD camera. The integration time of the CCD camera was set at 200 ms for 
both YFP and mKate, with a sampling interval of 3 s. All measurements were performed at 
37°C. Quantitative image analysis was performed with Metamorph 6.0 (Molecular Devices, 
Sunnyvale, CA). For each wavelength, the mean fluorescence intensity was monitored in an 
intracellular region and, for purpose of background correction, an extracellular region of 
identical size. After background correction, the fluorescence emission ratio of the green and 
red fluorescence of YFP and mKate, respectively, was used to determine changes in 
intracellular halide content as a measure for NCC activity. NCC is able to transport NaI as 
NaCl in a hydrochlorothiazide (HCTZ)-sensitive manner (61). Signal specificity was 
assessed by addition of 100 µM HCTZ or an equivalent amount of its solvent DMSO 
together to the hypotonic low Cl- buffer incubation for 10 min at 37°C. The thiazide-sensitive 
uptake was determined by the difference of the measurements with and without HCTZ. 
 
Statistics. 
The immunoblot data were analyzed by comparing integrated optical densities of bands by 
one-way ANOVA with Tukey’s multiple comparisons post hoc test if multiple groups were 
compared. In the FLIM and NCC activity measurements, all depicted data are averages of at 
least 3 independent experiments, and all statistical analyses were performed using a one-
way ANOVA with Dunnett’s multiple comparison post hoc test comparing the control 
condition versus all other conditions. Depicted values are means ± SEM of at least three 
independent experiments, and P<0.05 was considered statistically significant. All data were 
analyzed using Prism 6 software (Graph- Pad Software, La Jolla, CA). 
 
Results 
Effect of S811 on NCCSV phosphorylation at T55 and T60. 
To examine the role of phosphorylation at S811 in NCCSV, the NCCSV S811D and S811A 
plasmids were generated that represent the constitutively phosphorylated and non-
phosphorylated form of S811, respectively. HEK293 cells transfected with the respective 
plasmids were subjected to hypotonic low Cl- buffer, which is a known stimulus of NCC 
phosphorylation at T55 and T60 (Fig. 1A) (43, 48). Interestingly, NCCSV S811A did not show 
a significant stimulation of T55 and T60 phosphorylation upon hypotonic low Cl- buffer, 
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compared to the isotonic control buffer (Fig. 1). Moreover, T55 and T60 phosphorylation of 
NCCSV S811A was significantly lower compared to NCC3, NCCSV or NCCSV S811D under 
hypotonic low Cl- condition (Fig. 1, white bars). NCC3, NCCSV and NCCSV S811D 
demonstrated significantly higher phosphorylation at T55 and T60 upon hypotonic low Cl- 
buffer treatment, compared to the isotonic control buffer (Fig. 1). No difference in T55 and 
T60 phosphorylation was observed between NCCSV and NCC3 after treatment with 
hypotonic low Cl- buffer. Isotonic control buffer did not result in T55 and T60 phosphorylation 
in any of the conditions tested. Immunoreactive bands were not observed in cells transfected 
with the empty vector (mock) (Fig. 1A). 
 
Effect of S811 phosphorylation on phosphorylation of NCC3 at T55 and T60. 
As NCCSV and NCC3 are co-expressed at the apical membrane of epithelial cells lining the 
DCT (59), we hypothesized that S811 phosphorylation could affect the phosphorylation at 
T55 and T60 of NCC3. Co-expression of NCCSV S811A and NCC3 resulted in significantly 
less phosphorylation at T55 and T60 compared to co-expression of NCCSV and NCC3, when 
treated with hypotonic low Cl- buffer. Interestingly, this decrease was more than 50% for 
both T55 and T60 (Fig. 2B, C, white bars). Co-expression of NCC3 with NCCSV or NCCSV 
S811D showed significantly higher phosphorylation at T55 and T60 when treated with 
hypotonic low Cl- buffer, compared to isotonic control buffer (Fig. 2). Similar to Fig. 1, NCCSV 
S811A alone did not show significant difference in T55 and T60 phosphorylation between 
the isotonic control and hypotonic low Cl- buffer treatment (Fig. 2). In isotonic control buffer, 
there was no difference in T55 and T60 phosphorylation levels in any of the conditions 
tested (Fig. 2B and C, black bars). Cells transfected with the mock vector did not show 
immunoreactive bands (Fig. 2A). 
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Figure 1 | S811A mutant of NCCSV, but not S811D, prevents the phosphorylation at T55 and 
T60.  
(A) Representative immunoblot of total cell membrane fractions isolated from HEK293 cells 
transfected with mock, indicated NCC isoforms and NCCSV mutants, treated with isotonic control (Co) 
or hypotonic low Cl- (Hy) buffer. Immunoblots were probed with anti-total NCC (tNCC), anti-
phosphorylated T55 (pT55) and T60 (pT60) NCC antibodies, depicting the immunoreactive band of 
~130 kDa. β-actin was used as a sample loading control. (B and C) Densitometry analysis of 
immunoreactive bands of pT55 and pT60 to tNCC ratio. The abundance of tNCC and pT55 and pT60 
upon the treatment with hypotonic low Cl- buffer relative to the treatment with isotonic control buffer 
was determined. Subsequently, this relative abundance in hypotonic low Cl- condition of NCCSV, 
NCCSV S811D, and NCCSV S811A was compared to the relative abundance of NCC3. Values are 
expressed as mean ± SEM of at least 3 independent experiments. *indicates the significance of 
hypotonic low Cl- buffer compared to its own control. #indicates significance compared to NCCSV. 
*#P<0.05 was considered statistically significant. 
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Figure 2 | NCCSV S811A inhibits the phosphorylation at T55 and T60 of NCC3.  
(A) Representative immunoblot of total cell membrane fractions isolated from HEK293 cells co-
transfected with NCC3 and NCCSV or NCCSV mutants in a 1:1 ratio, treated with isotonic control (Co) 
or hypotonic low Cl- (Hy) buffer. Immunoblots were probed with anti-total NCC (tNCC), anti-
phosphorylated T55 (pT55) and T60 (pT60) NCC antibodies, depicting the immunoreactive band of 
~130 kDa. β-actin was used as a sample loading control. (B and C) Densitometry analysis of 
immunoreactive bands of pT55 and pT60 divided by immunoreactive bands of tNCC. The abundance 
of tNCC and pT55 and T60 upon the treatment with hypotonic low Cl- buffer relative to the treatment 
with isotonic control buffer was determined. This relative abundance in hypotonic low Cl- condition of 
each combination was compared with the relative abundance of NCC3 co-transfected with NCCSV. 
Values are expressed as mean ± SEM of at least 3 independent experiments. *indicates the 
significance of hypotonic low Cl- buffer compared to its own control. #indicates significant compared to 
NCC3 + NCCSV. *#P<0.05 was considered statistically significant. 
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NCCSV and NCC3 form hetero- and homo-dimers. 
To assess whether the effect of NCCSV S811 phosphorylation on NCC3 T55 and T60 
phosphorylation could be exerted via dimerization of NCCSV with NCC3, a Förster resonance 
energy transfer (FRET) based microscopy approach was used with C-terminal mCitrine and 
mCherry fusions of NCCSV and NCC3, respectively. FRET was measured using FLIM 
microscopy, which has the advantage that the lifetime (τ) is not dependent on excitation 
power and probe concentration, thereby being technically less challenging than ratiometric 
FRET analysis (65). The amount of FRET, which represents the interaction between the 
donor and acceptor pair, is measured as lifetime of the mCitrine fluorescent signal. This 
signal shortens due to the energy transfer to the mCherry probe in case of protein 
dimerization (26, 63). Co-expression of NCCSV-mCitrine with either NCCSV-mCherry or 
NCC3-mCherry in HEK293 cells resulted in a significant decrease in lifetime as shown by the 
phasor plots (Fig. 3B) and single-cell analysis (Fig. 3A), indicating the formation of both 
hetero- and homo-dimers of NCCSV with NCCSV and NCC3, respectively. The dimerization of 
NCCSV and NCC3 was further tested by a competition experiment, where NCCSV-mCitrine 
was co-expressed with unlabeled NCC3 as competitor together with NCC3-mCherry. 
Competition with unlabeled NCC3 resulted in an increase of the donor lifetime, compared to 
HEK293 cells co-expressing NCCSV-mCitrine and NCCSV-mCherry (Fig. 3B). In addition, 
SLC41A1 is used as a negative control. This is a Mg2+ transporter that localizes to the apical 
membrane of the DCT (21, 25), but does not interact with NCCSV. Therefore, NCCSV-
mCitrine and SLC41A1-mCherry were co-expressed in HEK293 cells, which did not co-
localize (Fig. 4A) and showed no significant lifetime decrease in line with two proteins that 
do not interact (Fig. 4A and B). The dimerization, as observed by FRET/FLIM, was further 
established by co-immunoprecipitation experiments, where NCCSV-mCitrine was co-
expressed with NCCSV-mCherry and NCC3-mCherry in HEK293 cells. As the GFP antibody 
binds to mCitrine, our results demonstrated that NCCSV-mCitrine (bound to GFP-coupled 
beads) interacted with both NCCSV- and NCC3-mCherry (Fig. 3C). As a negative control, 
NCCSV-mCitrine and mock were co-expressed in HEK293 cells and did not show interaction 
between mCitrine and mCherry (Fig. 3C). In addition, a co-immunoprecipitation was 
performed with HA- and eGFP-tagged plasmids to confirm the dimerization of NCCSV 
mutants and NCC3. eGFP-tagged NCC3 plasmid was co-expressed with HA-tagged NCC3, 
NCCSV, NCCSV S811D, or NCCSV S811A in HEK293 cells. NCC3 showed an interaction 
between NCC3 and NCCSV, NCCSV S811D, or NCCSV S811A (Fig. 4C). No immunoreactive 
bands were observed in any of the samples of HEK293 cells co-transfected with mock-eGFP 
or mock-HA (Fig. 4C). Input samples demonstrated equal expression under all conditions 
(Figs. 3C and 4C). Immunoblots with β-actin were used as a sample loading control.  
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Effect of S811 phosphorylation on the NCC function. 
Since NCC activity is regulated by its phosphorylation (43), a functional assay was used to 
study the effect of S811 phosphorylation on the transport activity of NCCSV and NCC3. The 
respective plasmids were co-transfected in HEK293 cells with halide-sensitive YFP coupled 
to halide-insensitive fluorescent red protein mKate. Prior to the measurements, transfected 
HEK293 cells were incubated in hypotonic low Cl- buffer to maximally increase NCC 
phosphorylation and activity (61). After 30 s, NaI was added to the medium, which induced a 
significant reduction in YFP/mKate ratio in NCC3-expressing cells, indicative of NCC 
transport activity (Fig. 5A and B). Pretreatment with HCTZ (40 min, 100 µM), a well-known 
inhibitor of NCC, completely abrogated this response (Fig. 5B). As described previously (61), 
NCC activity is measured as the difference in the YFP/mKate ratio (Δ YFP/mKate ratio) 
between t=0 and t=180 s after NaI addition. This is plotted as the HCTZ-specific NCC 
activity: Δ YFP/mKate ratio without HCTZ minus Δ YFP/mKate ratio with HCTZ (Fig. 5C). 
Cells expressing NCCSV S811A alone or in combination with NCC3 displayed significantly 
reduced NCC activity compared to NCC3 (Fig. 5C). The NCC3 phospho-deficient T55A/T60A 
mutant (NCC3 T55A/T60A) was included as negative control and displayed significantly 
reduced NCC activity compared to wild-type NCC3 (Fig. 5C). Of note, the basal YFP/mKate 
ratio at t=0 s was not significantly different between the various conditions tested (Fig. 5B). 
 
The effect of S811 on the abundance of NCC at the plasma membrane. 
To determine the effect of S811 phosphorylation on the localization of NCC at the plasma 
membrane, HEK293 cells transfected with mock, NCC3, NCCSV, NCCSV S811D or S811A 
mutants, were subjected to cell surface protein biotinylation. NCC protein was demonstrated 
in the total cell lysate (input) and the biotinylated fraction upon both isotonic control and 
hypotonic low Cl- conditions (Fig. 5D). The optical density of biotinylated fraction was 
corrected for input fraction to assess NCC protein abundance at the plasma membrane. No 
significant difference was observed between the conditions tested, indicating equal amount 
of NCC protein abundance at the plasma membrane (Fig. 5E). Cells transfected with the 
mock vector did not show immunoreactive bands of NCC in biotinylated fractions or the input 
(Fig. 5D). 
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Figure 3 | NCCSV and NCC3 form hetero- and homo-dimers.  
(A) NCCSV-mCitrine was transiently co-transfected with NCC3-mCherry or NCCSV-mCherry in HEK293 
cells. Förster resonance energy transfer between the labels was monitored by fluorescence lifetime 
imaging. Representative confocal microscopy (left) and convoluted FLIM (right) images of 
NCCSV-mCitrine (green) with NCC3-mCherry (red) or NCCSV-mCherry (red) with scale bars of 10 µm. 
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Figure 3 | Continued.  
(B) Whole cell apparent fluorescence lifetimes demonstrating hetero- and homo-dimerization of 
NCCSV and NCC3 proteins in live cells. Significant difference between NCCSV-mCitrine + mock and 
other conditions is denoted by * and their difference from NCCSV-mCitrine + NCC3-mCherry + NCC3 is 
denoted by #. N≥3; n>20/condition. #*P<0.05 was considered statistically significant. (C) Co-
immunoprecipitation with mCitrine-labelled NCCSV and mCherry-labelled mock, NCCSV and NCC3. 
GFP-coupled beads represent the immunoprecipitated NCCSV-mCitrine fraction and the immublots 
were probed with anti-mCherry and anti-GFP antibodies, depicting the immunoreactive NCC band of 
~130 kDa. The total cell lysate (input) was probed with anti-mCherry, anti-GFP or anti-β-actin 
antibodies. β-actin was used as a sample loading control. 
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Figure 4 | NCCSV and NCC3 form hetero- and homo-dimers. 
(A) As control for a specific background FRET/FLIM, NCCSV-mCitrine (green) and SLC41A1-mCherry 
(red) were transiently co-transfected in human embryonic kidney (HEK)293 cells. Förster resonance 
energy transfer between the labels was monitored by fluorescence lifetime imaging. Representative 
confocal microscopy (left) and convoluted FLIM (right) images of NCCSV-mCitrine (green) with 
SLC41A1-mCherry (red). Scale bars are 10 µm. (B) Whole cell apparent fluorescence lifetimes 
demonstrated for NCCSV-mCitrine plus mock or SLC41A1-mCherry. (C) Representative immunoblots 
of co-immunoprecipitation with NCC isoforms and NCCSV phospho-mutants. Co-immunoprecipitation 
with eGFP-tagged NCC3 and HA-tagged mock, NCC3, NCCSV, NCCSV S811D and NCCSV S811A. The 
HA-coupled beads fraction represents the immunoprecipitated fraction and probed with anti-GFP and 
anti-HA antibodies, depicting the immunoreactive NCC band of ~130 kDa. The total cell lysate (input) 
was probed with anti-HA and anti-β-actin antibodies. β-actin was used as a sample loading control. 
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Figure 5 | S811A exhibits significantly impaired NCC activity.  
(A) Model of NCC activity assay in HEK293 cells depicting the co-expression of an NCC isoform with 
a halide-sensitive yellow fluorescent protein (YFP) that is coupled to the red fluorescent protein 
mKate. The latter is insensitive to changes in intracellular halide concentrations. Pre-incubation of 
these cells in hypotonic low Cl- solution containing 70 mM Na-Gluconate (NaGluc) for 40 min and 
subsequent addition of NaI (final Na+ and I- concentration 105 and 70 mM, respectively) resulted in a 
change in YFP fluorescence, which is corrected for the red fluorescent iodide-insensitive (mKate) 
signal. This allows the determination of changes in intracellular iodide concentrations using the 
YFP/mKate ratio as a measure of NCC activity. (B) NaI was added 30 s after the start (t=0) and the 
YFP/mKate ratio was plotted over time for mock and NCC3 expressing HEK293 cells treated with or 
without thiazide (HCTZ, 100 µM); [N=3, mock (DMSO, ), N=3; NCC3 HCTZ ( ), N=3; NCC3 DMSO (
)]. (C) Activity of NCC3, NCCSV, NCCSV S811D, NCCSV S811A and NCC3 T55A/T60A is expressed 
as the difference in the YFP/mKate ratio (Δ YFP/mKate ratio, t=0 s minus t=180 s). The thiazide-
specific NCC activity was determined by the ratio difference of the measurements with and without 
HCTZ. Significant difference in activity between NCC3 and all other constructs is denoted by *. N=3; 
n>65/condition. *P<0.05 was considered statistically significant.  
Chapter 4                                                                                                 Dominant role of S811 in NCC function | 
 
 
100 
 
Figure 5 | Continued.  
(D) Representative immunoblot of total lysate (input) and biotinylated fractions of HEK293 cells 
transfected with NCC3, NCCSV or the indicated mutants, probed with anti-HA and β-actin antibodies. 
β-actin was used as a sample loading control. (E) Densitometry analysis of cell surface biotinylation. 
The optical densities of the beads fractions were divided by corresponding optical densities of the 
input samples. N=3. Values are expressed as mean ± SEM. *P<0.05 was considered statistically 
significant.  
 
Discussion  
This study shows that S811 acts as a dominant regulatory site for phosphorylation of T55 
and T60 in NCCSV as well as in NCC3. Moreover, our findings demonstrate that the 
phosphorylation-deficient S811A mutant decreases the transport activity of both NCCSV and 
NCC3. The effect of S811 phosphorylation on NCC3 activity likely occurs through the 
formation of heterodimers. Together, this provides strong evidence that S811, present only 
in NCCSV, is a crucial new residue involved in NCC regulation.  
 Our findings demonstrate that S811 has a dominant-negative effect on T55 and T60 
phosphorylation. Richardson et al. previously showed that mutation of T60 to alanine in 
NCC3 markedly inhibits phosphorylation of neighboring residues, such as T55, induced by 
hypotonic low Cl- treatment (48). Additionally, the T60A mutant strongly inhibited NCC 
activity, while this was less prominent for the T55A mutant (48). This implies that T60 can 
exert a dominant-negative role over other phosphorylation sites in NCC3 (48). Several other 
studies have shown that T60 is a key phosphorylation site for NCC activity (43, 48, 69). This 
is highlighted by a loss of function mutation at T60 in NCC that is linked to Gitelman 
Syndrome (29, 69). Previously, it has also been shown that defective T60 phosphorylation 
corrects the phenotype of FHHt in mice (69). Our study adds a new important site solely 
present in NCCSV at S811. Importantly, this site could have a regulatory role on NCC, as the 
S811A mutant prevented the T55 and T60 phosphorylation and inhibited the activity in both 
NCCSV and NCC3 (Fig. 6). The inhibitory effect of S811A on NCC function is in line with our 
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previous data showing that Xenopus laevis oocytes expressing NCCSV S811A exhibited 
decreased 22Na+-uptake compared to oocytes expressing wild-type NCCSV (59). 
Furthermore, it was shown that WNK4 inhibits both NCC3 and NCCSV function independent 
of S811, since the NCCSV S811D mutant was not protected from the inhibitory effects of 
WNK4 (59). While it is known that T55 and T60 are phosphorylated via activation of WNK-
SPAK signaling pathway (1, 43), the kinase involved in S811 phosphorylation remains to be 
elucidated. Notably, prediction software suggested that the S811 phosphorylation site shows 
high similarity to a protein kinase A (PKA) consensus site. Therefore, hormones regulating 
the PKA pathway could potentially be involved in regulating NCCSV-mediated Na+ transport 
in DCT. There is a growing body of evidence demonstrating that NCC abundance and 
phosphorylation is affected by protein kinase C or PKA downstream of angiotensin II or 
vasopressin signaling, respectively (11, 40, 46, 51). 
 It has previously been shown that NCC mRNA in the human kidney comprises 55% of 
NCC3 and 45% of NCCSV (59). To mimic the physiological distribution, a co-transfection 
experiment was performed with NCCSV S811A and NCC3, demonstrating significantly less 
phosphorylation at T55 and T60 compared to cells co-transfected with NCCSV and NCC3. We 
show that NCC3 and NCCSV can dimerize resulting in a mixture of hetero- and homo-dimers 
of the two variants. Interestingly, the observed decrease in phosphorylation levels was more 
than 50% for both T55 and T60, which suggests that NCCSV S811A not only affected NCCSV 
but also blocked T55 and T60 phosphorylation in NCC3 (Fig. 6). Furthermore, cells co-
expressing NCCSV S811A and NCC3 showed significantly impaired NCC activity, confirming 
the dominant-negative effect of NCCSV S811 on NCC3 function. The observations that 
NCCSV is significantly expressed in the kidney (59) together with the fact that S811 can 
affect T55 and T60 phosphorylation and function in NCCSV and NCC3, implicates a potential 
key role of S811 in NCC-mediated renal salt handling. 
Although the NCCSV to NCC3 mRNA ratio in the human kidney is 45% on average , this 
ratio of NCCSV to NCC3 expression varied from 19% to 63% in 7 human kidneys (59). This 
large difference in NCCSV to NCC3 ratio suggests that splicing of NCC is highly regulated in 
humans (33). In humans, it has been shown that ~95% of genes are alternatively spliced 
(44). The production of alternatively spliced mRNAs is diversely regulated by a variety of 
external stimuli or/and genetic make-up. Between human individuals, altered splicing can 
lead to differences in alternative spliced mRNAs that can consequently impact abundance or 
function of a protein (31, 47).  Mechanisms of alternative splicing machinery are highly 
variable and not well understood (31). In several well-documented examples, such natural 
variation of alternative splicing has indeed been shown to contribute to the development of 
various diseases, such as cancer and diabetes (2, 24, 56, 58, 70). Moreover, altered splicing 
of genes are suggested to influence drug response (22). Therefore, unravelling the 
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mechanism behind the splicing ratio of NCCSV to NCC3 in the kidney might revise our 
understanding of salt transport and response to diuretics in the distal part of the nephron. 
 
 
Figure 6 | Schematic model for NCCSV S811 regulation.  
The NCCSV S811A mutant not only abolishes the hypotonic low Cl--induced phosphorylation at T55 
and T60 in NCCSV, but also prevents the phosphorylation at T55 and T60 in NCC3. With no lysine 
(WNK) kinases are auto-phosphorylated (activated) when the intracellular Cl- concentration 
decreases. WNKs can phosphorylate and activate Ste20-related proline-alanine-rich kinase (SPAK) 
and oxidative stress response 1 (OSR1), which in turn phosphorylate threonine residues 55 and 60 
(T55 and T60) in NCC (top panel). The dominant-negative effect of NCCSV S811A on the 
phosphorylation of T55 and T60 in NCCSV and NCC3 may occur through the formation of 
heterodimers between NCCSV and NCC3 (bottom panel). 
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To explore the molecular mechanism by which NCCSV S811 exerts a dominant-negative 
effect on NCC3, FLIM and co-immunoprecipitation experiments were conducted. Here, we 
showed that both the constitutively phosphorylated and non-phosphorylated NCCSV S811 
mutants form heterodimers with NCC3, indicating that the effect of S811 on phosphorylation 
of NCC3 can occur through interaction between the two isoforms. The phosphorylation status 
of S811 did not affect the interaction between NCCSV and NCC3. Importantly, our findings 
show for the first time that NCCSV and NCC3 form hetero- and homo-dimers in living cells 
and that NCCSV competes with NCC3 on the functional level. Homodimerization of two NCC3 
has been proposed in previous studies using immunoblotting (15, 18, 49, 61), and it was 
also found that NCC is present at the plasma membrane in a dimerized form (15, 18). While 
it has been shown for other proteins that dimerization occurs at the surface of plasma 
membrane (30), our data now suggests that the dimerization of NCC already occurs in the 
cytosol as decreased lifetime of NCC3 was observed in organellar membranes. Dimerization 
of transmembrane proteins is a common mechanism that precedes advanced functional 
regulation of a protein. For example, in the tyrosine kinase pathway, Erb2/Erb3 cross-
phosphorylate each other after dimerization (32, 53). From its dimeric nature, NCC 
resembles NaKCl cotransporter (NKCC2) (18, 37), suggesting that other members of the 
family of electroneutral cation-chloride cotransporters form similar oligomeric structures. 
Interestingly, it has recently been shown that NCC can interact with the epithelial Na+ 
channel (ENaC) (54). Moreover, inhibition of NCC also affected the function of ENaC, 
probably through direct interaction of both proteins (36). As NCC and ENaC are co-
expressed along the later part of the DCT, it has been suggested that this interaction can 
regulate Na+ reabsorption in the DCT (36, 67). The heterodimerization of NCCSV with NCC3 
suggests that NCCSV phosphorylation adds an additional regulatory mechanism by affecting 
the phosphorylation of the N-terminal T55 and T60 of NCC3 via dimerization. 
 NCC abundance at the plasma membrane is a powerful mechanism to modulate Na+ 
reabsorption in the kidney. In our study, cell surface biotinylation of NCC-transfected cells 
revealed that a change in S811 phosphorylation of NCCSV does not affect the abundance of 
NCCSV at the plasma membrane, where NCC is functionally active. Moreover, there is no 
change in plasma membrane abundance of NCC in any of the NCC isoforms or mutants 
when cells are exposed to hypotonic low Cl- stress. Our findings indicate that, upon 
hypotonic low Cl- stress, translocation of NCC to the plasma membrane is not affected. 
Rather, intrinsic T55 and T60 phosphorylation of NCC at the plasma membrane is 
increased. Our findings are in correspondence with previous studies demonstrating that 
NCC surface expression is not affected by the phosphorylation status of T60 or S811 in 
Xenopus laevis oocytes (43, 59). Similarly, the triple mutation of T55, T60 and serine 73 to 
alanine did not significantly change the NCC abundance at the plasma membrane (27). 
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Previously, the relation between the T60 phosphorylation and membrane stability of NCC 
has been suggested (69). Although, several studies demonstrated a decreased abundance 
of NCC3 T60A in both the biotinylated fractions and input fraction, suggesting unaltered 
abundance at the plasma membrane (27, 69).  
Taking together, our results show that S811 of NCCSV plays a crucial role in NCC 
function, and could therefore be a key factor in renal salt handling. Further experiments are 
needed to find the kinases that regulate S811 phosphorylation, which can provide more 
insight in the influence of S811 on NCC activity and might be crucial in elucidating the 
pathogenesis of essential hypertension.  
 
Acknowledgements 
The authors thank Marco A. Valdez-Flores, Sjoerd Verkaart, Geert v.d. Bogaart, Danielle 
R.J. Verboogen for technical assistance and advice.  
 
Grants 
This study was financially supported by the Netherlands Organization for Scientific Research 
(VENI 863.13.010 and VICI 016.130.668) and the Dutch Kidney Foundation (PHD12.14 and 
16OI04). The authors declare no conflicts of interest. 
 
Disclosures  
The authors declare that they have no conflicts of interest with the contents of this article. 
 
Author contribution  
O.A.T., F.B., R.J.M.B., J.G.J.H., and J.W. conceived and designed the research; O.A.T., 
F.B., D.A.S., and J.W. performed the research; O.A.T., F.B., and D.A.S. analyzed the data. 
O.A.T., F.B., D.A.S., and J.W. drafted the manuscript; all authors read and approved the 
final manuscript. 
 
Chapter 4                                                                                                 Dominant role of S811 in NCC function | 
 
 
105 
References 
1. Alessi DR, Zhang J, Khanna A, Hochdörfer T, Shang Y, Kahle KT. The WNK-SPAK/OSR1 
pathway: master regulator of cation-chloride cotransporters. Science signaling 7: re3–re3, 
2014. 
2. Allagnat F, Christulia F, Ortis F, Pirot P, Lortz S, Lenzen S, Eizirik DL, Cardozo AK. Sustained 
production of spliced X-box binding protein 1 (XBP1) induces pancreatic beta cell dysfunction 
and apoptosis. Diabetologia 53: 1120–1130, 2010. 
3. Barber PR, Ameer-Beg SM, Gilbey J, Carlin LM, Keppler M, Ng TC, Vojnovic B. Multiphoton 
time-domain fluorescence lifetime imaging microscopy: practical application to protein–protein 
interactions using global analysis. Journal of The Royal Society Interface 6: S93–S105, 2009. 
4. Barber PR, Ameer-Beg SM, Gilbey JD, Edens RJ. Global and pixel kinetic data analysis for 
FRET detection by multi-photon time-domain FLIM. Proc SPIE. 
5. Bianchi G, Fox U, Di Francesco GF, Bardi U, Radice M. The hypertensive role of the kidney in 
spontaneously hypertensive rats. Clin Sci Mol Med Suppl 45 Suppl 1: 135s–9, 1973. 
6. Bloch MJ. Worldwide prevalence of hypertension exceeds 1.3 billion. J Am Soc Hypertens 10: 
753–754, 2016. 
7. Boudoulas KD, Triposkiadis F, Parissis J, Butler J, Boudoulas H. The Cardio-Renal 
Interrelationship. Prog Cardiovasc Dis 59: 636–648, 2016. 
8. Boyden LM, Choi M, Choate KA, Nelson-Williams CJ, Farhi A, Toka HR, Tikhonova IR, 
Bjornson R, Mane SM, Colussi G, Lebel M, Gordon RD, Semmekrot BA, Poujol A, Välimäki 
MJ, De Ferrari ME, Sanjad SA, Gutkin M, Karet FE, Tucci JR, Stockigt JR, Keppler-Noreuil 
KM, Porter CC, Anand SK, Whiteford ML, Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, 
Belsha CW, Hunley TE, Nelson RD, Trachtman H, Cole TRP, Pinsk M, Bockenhauer D, 
Shenoy M, Vaidyanathan P, Foreman JW, Rasoulpour M, Thameem F, Al-Shahrouri HZ, 
Radhakrishnan J, Gharavi AG, Goilav B, Lifton RP. Mutations in kelch-like 3 and cullin 3 cause 
hypertension and electrolyte abnormalities. Nature 482: 98–102, 2012. 
9. Cameron AC, Lang NN, Touyz RM. Drug Treatment of Hypertension: Focus on Vascular 
Health. Drugs 76: 1529–1550, 2016. 
10. Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation 101: 
329–335, 2000. 
11. Castañeda-Bueno M, Arroyo JP, Zhang J, Puthumana J, Yarborough O III, Shibata S, Rojas-
Vega L, Gamba G, Rinehart J, Lifton RP. Phosphorylation by PKC and PKA regulate the 
kinase activity and downstream signaling of WNK4. Proc Natl Acad Sci 114: E879–E886, 
2017. 
12. Coffman TM, Crowley SD. Kidney in hypertension: guyton redux. Hypertension 51: 811–816, 
2008. 
13. Dahl LK, Heine M. Primary role of renal homografts in setting chronic blood pressure levels in 
rats. Circ Res 36: 692–696, 1975. 
14. de Groot T, Lee K, Langeslag M, Xi Q, Jalink K, Bindels RJM, Hoenderop JGJ. Parathyroid 
Hormone Activates TRPV5 via PKA-Dependent Phosphorylation. J Am Soc Nephrol 20: 1693–
1704, 2009. 
15. de Jong JC, Willems PHGM, Mooren FJM, van den Heuvel LPWJ, Knoers NVAM, Bindels 
RJM. The structural unit of the thiazide-sensitive NaCl cotransporter is a homodimer. J Biol 
Chem 278: 24302–24307, 2003. 
16. Dimke H, San-Cristobal P, de Graaf M, Lenders JW, Deinum J, Hoenderop JGJ, Bindels RJM. 
γ-Adducin stimulates the thiazide-sensitive NaCl cotransporter. J Am Soc Nephrol 22: 508–
517, 2011. 
17. Ellison DH, Velazquez H, Wright FS. Thiazide-sensitive sodium chloride cotransport in early 
distal tubule. Am J Physiol 253: F546–54, 1987. 
18. Frindt G, Palmer LG. Surface expression of sodium channels and transporters in rat kidney: 
effects of dietary sodium. Am J Physiol Renal Physiol 297: F1249–55, 2009. 
19. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, 
Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, 
Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, 
Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Neumar 
Chapter 4                                                                                                 Dominant role of S811 in NCC function | 
 
 
106 
RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, 
Virani SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics Committee 
and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2014 update: a report 
from the American Heart Association. Circulation 129: e28–e292, 2014. 
20. Gonzales PA, Pisitkun T, Hoffert JD, Tchapyjnikov D, Star RA, Kleta R, Wang NS, Knepper 
MA. Large-scale proteomics and phosphoproteomics of urinary exosomes. J Am Soc Nephrol 
20: 363–379, 2009. 
21. Goytain A, Quamme GA. Functional characterization of human SLC41A1, a Mg2+ transporter 
with similarity to prokaryotic MgtE Mg2+ transporters. Physiol Genomics 21: 337–342, 2005. 
22. Heinzen EL, Yoon W, Tate SK, Sen A, Wood NW, Sisodiya SM, Goldstein DB. Nova2 
interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice 
variants of SCN1A. Am J Hum Genet 80: 876–883, 2007. 
23. HJ G, JB G, LG W. A new familial disorder characterized by hypokalemia and 
hypomagnesemia. Trans Assoc Am Physicians 79: 221–235, 1965. 
24. Hull J, Campino S, Rowlands K, Chan M-S, Copley RR, Taylor MS, Rockett K, Elvidge G, 
Keating B, Knight J, Kwiatkowski D. Identification of common genetic variation that modulates 
alternative splicing. PLoS Genet 3: e99, 2007. 
25. Hurd TW, Otto EA, Mishima E, Gee HY, Inoue H, Inazu M, Yamada H, Halbritter J, Seki G, 
Konishi M, Zhou W, Yamane T, Murakami S, Caridi G, Ghiggeri G, Abe T, Hildebrandt F. 
Mutation of the Mg2+ transporter SLC41A1 results in a nephronophthisis-like phenotype. 
Journal of the American Society of Nephrology 24: 967–977, 2013. 
26. Jares-Erijman EA, Jovin TM. FRET imaging. Nat Biotechnol 21: 1387–1395, 2003. 
27. Khan MZH, Sohara E, Ohta A, Chiga M, Inoue Y, Isobe K, Wakabayashi M, Oi K, Rai T, 
Sasaki S, Uchida S. Phosphorylation of Na-Cl cotransporter by OSR1 and SPAK kinases 
regulates its ubiquitination. Biochem Biophys Res Commun 425: 456–461, 2012. 
28. Lalioti MD, Zhang J, Volkman HM, Kahle KT, Hoffmann KE, Toka HR, Nelson-Williams C, 
Ellison DH, Flavell R, Booth CJ, Lu Y, Geller DS, Lifton RP. Wnk4 controls blood pressure and 
potassium homeostasis via regulation of mass and activity of the distal convoluted tubule. Nat 
Genet 38: 1124–1132, 2006. 
29. Lin S-H, Shiang J-C, Huang C-C, Yang S-S, Hsu Y-J, Cheng C-J. Phenotype and genotype 
analysis in Chinese patients with Gitelman's syndrome. J Clin Endocrinol Metab 90: 2500–
2507, 2005. 
30. Lin W-C, Iversen L, Tu H-L, Rhodes C, Christensen SM, Iwig JS, Hansen SD, Huang WYC, 
Groves JT. H-Ras forms dimers on membrane surfaces via a protein-protein interface. Proc 
Natl Acad Sci 111: 2996–3001, 2014. 
31. Lu Z-X, Jiang P, Xing Y. Genetic variation of pre-mRNA alternative splicing in human 
populations. Wiley Interdiscip Rev RNA 3: 581–592, 2012. 
32. Maruyama IN. Mechanisms of activation of receptor tyrosine kinases: monomers or dimers. 
Cells 3: 304–330, 2014. 
33. Mastroianni N, Bettinelli A, Bianchetti M, Colussi G, De Fusco M, Sereni F, Ballabio A, Casari 
G. Novel molecular variants of the Na-Cl cotransporter gene are responsible for Gitelman 
syndrome. Am J Hum Genet 59: 1019–1026, 1996. 
34. Messerli FH, Williams B, Ritz E. Essential hypertension. The Lancet 370: 591–603, 2007. 
35. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global 
Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-
Based Studies From 90 Countries. Circulation 134: 441–450, 2016. 
36. Mistry AC, Wynne BM, Yu L, Tomilin V, Yue Q, Zhou Y, Al-Khalili O, Mallick R, Cai H, Alli AA, 
Ko B, Mattheyses A, Bao H-F, Pochynyuk O, Theilig F, Eaton DC, Hoover RS. The sodium 
chloride cotransporter (NCC) and epithelial sodium channel (ENaC) associate. Biochem J 473: 
3237–3252, 2016. 
37. Moore-Hoon ML, Turner RJ. The structural unit of the secretory Na+-K+-2Cl- cotransporter 
(NKCC1) is a homodimer. Biochemistry 39: 3718–3724, 2000. 
38. Mullins LJ, Bailey MA, Mullins JJ. Hypertension, kidney, and transgenics: a fresh perspective. 
Physiological Reviews 86: 709–746, 2006. 
39. Murray CJL, Lopez AD. Measuring the Global Burden of Disease. N Engl J Med 369: 448–
457, 2013. 
40. Mutig K, Saritas T, Uchida S, Kahl T, Borowski T, Paliege A, Bohlick A, Bleich M, Shan Q, 
Chapter 4                                                                                                 Dominant role of S811 in NCC function | 
 
 
107 
Bachmann S. Short-term stimulation of the thiazide-sensitive Na+-Cl- cotransporter by 
vasopressin involves phosphorylation and membrane translocation. Am J Physiol Renal 
Physiol 298: F502–9, 2010. 
41. Narayan KMV, Ali MK, Koplan JP. Global noncommunicable diseases – where worlds meet. N 
Engl J Med 363: 1196–1198, 2010. 
42. Nørholm MHH. A mutant Pfu DNA polymerase designed for advanced uracil-excision DNA 
engineering. BMC Biotechnol 10: 21, 2010. 
43. Pacheco-Alvarez D, Cristobal PS, Meade P, Moreno E, Vazquez N, Munoz E, Diaz A, Juarez 
ME, Gimenez I, Gamba G. The Na+:Cl- cotransporter is activated and phosphorylated at the 
amino-terminal domain upon intracellular chloride depletion. J Biol Chem 281: 28755–28763, 
2006. 
44. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing 
complexity in the human transcriptome by high-throughput sequencing. Nat Genet 40: 1413–
1415, 2008. 
45. Pathare G, Tutakhel OAZ, V D Wel MC, Shelton LM, Deinum J, Lenders JW, Hoenderop JGJ, 
Bindels RJM. Hydrochlorothiazide treatment increases the abundance of the NaCl 
cotransporter in urinary extracellular vesicles of essential hypertensive patients. Am J Physiol 
Renal Physiol 312: F1063–F1072, 2017. 
46. Pedersen NB, Hofmeister MV, Rosenbaek LL, Nielsen J, Fenton RA. Vasopressin induces 
phosphorylation of the thiazide-sensitive sodium chloride cotransporter in the distal convoluted 
tubule. Kidney Int 78: 160–169, 2010. 
47. Pickrell JK, Marioni JC, Pai AA, Degner JF, Engelhardt BE, Nkadori E, Veyrieras J-B, 
Stephens M, Gilad Y, Pritchard JK. Understanding mechanisms underlying human gene 
expression variation with RNA sequencing. Nature 464: 768–772, 2010. 
48. Richardson C, Richardson C, Rafiqi FH, Rafiqi FH, Karlsson HKR, Karlsson HKR, Moleleki N, 
Moleleki N, Vandewalle A, Vandewalle A, Campbell DG, Campbell DG, Morrice NA, Morrice 
NA, Alessi DR, Alessi DR. Activation of the thiazide-sensitive Na+-Cl- cotransporter by the 
WNK-regulated kinases SPAK and OSR1. J Cell Sci 121: 675–684, 2008. 
49. Rieg T, Tang T, Uchida S, Hammond HK, Fenton RA, Vallon V. Adenylyl Cyclase 6 Enhances 
NKCC2 Expressionand Mediates Vasopressin-Induced Phosphorylation of NKCC2 and NCC. 
The American Journal of Pathology 182: 96–106, 2013. 
50. Rozansky DJ, Cornwall T, Subramanya AR, Rogers S, Yang Y-F, David LL, Zhu X, Yang C-L, 
Ellison DH. Aldosterone mediates activation of the thiazide-sensitive Na-Cl cotransporter 
through an SGK1 and WNK4 signaling pathway. J Clin Invest 119: 2601–2612, 2009. 
51. Saritas T, Borschewski A, McCormick JA, Paliege A, Dathe C, Uchida S, Terker A, Himmerkus 
N, Bleich M, Demaretz S, Laghmani K, Delpire E, Ellison DH, Bachmann S, Mutig K. SPAK 
differentially mediates vasopressin effects on sodium cotransporters. Journal of the American 
Society of Nephrology 24: 407–418, 2013. 
52. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, 
Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri K, Tomancak 
P, Cardona A. Fiji: an open-source platform for biological-image analysis. Nat Methods 9: 
676–682, 2012. 
53. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF 
receptors. Science 306: 1506–1507, 2004. 
54. Schmitt R, Ellison DH, Farman N, Rossier BC, Reilly RF, Reeves WB, Oberbäumer I, Tapp R, 
Bachmann S. Developmental expression of sodium entry pathways in rat nephron. Am J 
Physiol 276: F367–81, 1999. 
55. Simon DB, Nelson-Williams C, Johnson Bia M, Ellison D, Karet FE, Molina AM, Vaara I, Iwata 
F, Cushner HM, Koolen M, Gainza FJ, Gitelman HJ, Lifton RP. Gitelman“s variant of Barter”s 
syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive 
Na–Cl cotransporter. Nat Genet 12: 24–30, 1996. 
56. Skotheim RI, Nees M. Alternative splicing in cancer: noise, functional, or systematic? Int J 
Biochem Cell Biol 39: 1432–1449, 2007. 
57. Subramanya AR, Liu J, Ellison DH, Wade JB, Welling PA. WNK4 diverts the thiazide-sensitive 
NaCl cotransporter to the lysosome and stimulates AP-3 interaction. J Biol Chem 284: 18471–
18480, 2009. 
58. Sveen A, Kilpinen S, Ruusulehto A, Lothe RA, Skotheim RI. Aberrant RNA splicing in cancer; 
Chapter 4                                                                                                 Dominant role of S811 in NCC function | 
 
 
108 
expression changes and driver mutations of splicing factor genes. Oncogene 35: 2413–2427, 
2016. 
59. Tutakhel OAZ, Jeleń S, Valdez-Flores M, Dimke H, Piersma SR, Jimenez CR, Deinum J, 
Lenders JW, Hoenderop JGJ, Bindels RJM. Alternative splice variant of the thiazide-sensitive 
NaCl cotransporter: a novel player in renal salt handling. Am J Physiol Renal Physiol 310: 
F204–F216, 2016. 
60. Urbanová M, Reiterová J, Stěkrová J, Lněnička P, Ryšavá R. DNA analysis of renal electrolyte 
transporter genes among patients suffering from Bartter and Gitelman syndromes: summary of 
mutation screening. Folia Biol (Praha) 57: 65–73, 2011. 
61. Valdez-Flores MA, Vargas-Poussou R, Verkaart S, Tutakhel OAZ, Valdez-Ortiz A, Blanchard 
A, Treard C, Hoenderop JGJ, Bindels RJM, Jeleń S. Functionomics of NCC mutations in 
Gitelman syndrome using a novel mammalian cell-based activity assay. Am J Physiol Renal 
Physiol 311: F1159–F1167, 2016. 
62. Vargas-Poussou R, Dahan K, Kahila D, Venisse A, Riveira-Munoz E, Debaix H, Grisart B, 
Bridoux F, Unwin R, Moulin B, Haymann J-P, Vantyghem M-C, Rigothier C, Dussol B, Godin 
M, Nivet H, Dubourg L, Tack I, Gimenez-Roqueplo A-P, Houillier P, Blanchard A, Devuyst O, 
Jeunemaitre X. Spectrum of mutations in Gitelman syndrome. Journal of the American Society 
of Nephrology 22: 693–703, 2011. 
63. Verboogen DRJ, González Mancha N, Beest Ter M, van den Bogaart G. Fluorescence 
Lifetime Imaging Microscopy reveals rerouting of SNARE trafficking driving dendritic cell 
activation. Elife 6: 3289, 2017. 
64. Vijftigschild LAW, van der Ent CK, Beekman JM. A novel fluorescent sensor for measurement 
of CFTR function by flow cytometry. Cytometry A 83: 576–584, 2013. 
65. Wallrabe H, Periasamy A. Imaging protein molecules using FRET and FLIM microscopy. Curr 
Opin Biotechnol 16: 19–27, 2005. 
66. Wilson FH, Disse-Nicodème S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, Gunel 
M, Milford DV, Lipkin GW, Achard J-M, Feely MP, Dussol B, Berland Y, Unwin RJ, Mayan H, 
Simon DB, Farfel Z, Jeunemaitre X, Lifton RP. Human hypertension caused by mutations in 
WNK kinases. Science 293: 1107–1112, 2001. 
67. Wynne BM, Mistry AC, Al-Khalili O, Mallick R, Theilig F, Eaton DC, Hoover RS. Aldosterone 
Modulates the Association between NCC and ENaC. Sci Rep 7: 4149, 2017. 
68. Yang C-L, Zhu X, Ellison DH. The thiazide-sensitive Na-Cl cotransporter is regulated by a 
WNK kinase signaling complex. J Clin Invest 117: 3403–3411, 2007. 
69. Yang S-S, Fang Y-W, Tseng M-H, Chu P-Y, Yu I-S, Wu H-C, Lin S-W, Chau T, Uchida S, 
Sasaki S, Lin Y-F, Sytwu H-K, Lin S-H. Phosphorylation Regulates NCC Stability and 
Transporter Activity In Vivo. J Am Soc Nephrol 24: 1587–1597, 2013. 
70. Zhang W, Duan S, Bleibel WK, Wisel SA, Huang RS, Wu X, He L, Clark TA, Chen TX, 
Schweitzer AC, Blume JE, Dolan ME, Cox NJ. Identification of common genetic variants that 
account for transcript isoform variation between human populations. Hum Genet 125: 81–93, 
2009. 
71. Zhou B, Zhuang J, Gu D, Wang H, Cebotaru L, Guggino WB, Cai H. WNK4 enhances the 
degradation of NCC through a sortilin-mediated lysosomal pathway. J Am Soc Nephrol 21: 
82–92, 2010. 
 
 
 
5
Calcineurin inhibitors increase 
the NaCl cotransporter in 
urinary vesicles and predicts 
thiazide sensitivity
Omar A.Z. Tutakhel1*, Arthur D. Moes3*, Marco A. Valdez-Flores1,5, 
Marleen L. A. Kortenoeven4, Mathijs v. d. Vrie2, Sabina Jele1, Robert A. Fenton4, 
Robert Zietse3, Joost G.J. Hoenderop1, Ewout J. Hoorn3, Luuk Hilbrands2, 
and René J.M. Bindels1
1Department of Physiology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, 
Nijmegen, The Netherlands; 2Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud 
university medical center, Nijmegen, The Netherlands; 3Department of Internal Medicine, Nephrology and 
 Transplantation, Erasmus Medical Center, Rotterdam, The Netherlands; 4Department of Biomedicine, Center for 
Interaction of Proteins in Epithelial Transport, Aarhus University, Aarhus, Denmark; 5Programa Regional en 
Doctorado en Biotecnología, Universidad Autónoma de Sinaloa, Sinaloa, Mexico.
* Authors contributed equally
PLOS ONE, 12: e0176220, 2017
Chapter 5                                                                  Effect of calcineurin inhibitors on NaCl cotransporter |  
	 	
112 
Abstract 
Animal studies have shown that the calcineurin inhibitors (CNIs) cyclosporine and tacrolimus 
can activate the thiazide-sensitive NaCl cotransporter (NCC). A common side effect of CNIs 
is hypertension. Renal salt transporters such as NCC are excreted in urinary extracellular 
vesicles (uEVs) after internalization into multivesicular bodies. Human studies indicate that 
CNIs also increase NCC abundance in uEVs, but results are conflicting and no relationship 
with NCC function has been shown. Therefore, we investigated the effects of CsA and Tac 
on the abundance of both total NCC (tNCC) and phosphorylated NCC at Thr60 
phosphorylation site (pNCC) in uEVs, and assessed whether NCC abundance in uEVs 
predicts the blood pressure response to thiazide diuretics. Our results show that in kidney 
transplant recipients treated with cyclosporine (n=9) or tacrolimus (n=23), the abundance of 
both tNCC and pNCC in uEVs is 4-5 fold higher than in CNI-free kidney transplant recipients 
(n=13) or healthy volunteers (n=6). In hypertensive kidney transplant recipients, higher 
abundances of tNCC and pNCC prior to treatment with thiazides predicted the blood 
pressure response to thiazides. During thiazide treatment, the abundance of pNCC in uEVs 
increased in responders (n=10), but markedly decreased in non-responders (n=8). Thus, our 
results show that CNIs increase the abundance of both tNCC and pNCC in uEVs, and these 
increases correlate with the blood pressure response to thiazides. This implies that 
assessment of NCC in uEVs could represent an alternate method to guide anti-hypertensive 
therapy in kidney transplant recipients. 
 
Keywords: Hypertension / Calcineurin inhibitors / NaCl cotransporter / Thiazide diuretics / 
Urinary extracellular vesicles 
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Introduction 
The calcineurin inhibitors (CNIs) cyclosporine A (CsA) and tacrolimus (Tac) are widely used 
to prevent rejection of transplanted organs. CNIs inhibit the calcineurin-mediated immune 
response in T-cells (13). Although both CsA and Tac exert their principal 
immunosuppressive effects through inhibition of the same target protein, calcineurin, they 
differ in cytoplasmic-binding proteins, namely cyclophilins and FKBP12 for CsA and Tac, 
respectively. CsA and Tac also vary with respect to their immunosuppressive potency (40, 
58) and side effects (14, 25, 29). A common side effect of CNIs is hypertension, although 
CsA appears more hypertensinogenic than Tac (4, 5, 29). CNI-induced hypertension may be 
accompanied by hyperkalemia and metabolic acidosis (17, 21). The clinical characteristics of 
CNI-treated patients sometimes resemble that of familial hyperkalemic hypertension (FHHt) 
(2, 37), also known as Gordon syndrome (12) or pseudohypoaldosteronism type II (50) 
(OMIM 145260). FHHt results from mutations in WNK [with no lysine (K)] kinases WNK1 and 
WNK4 (59), KLHL3 (26), or Cullin3 (3), which all lead to a gain-of-function in the thiazide-
sensitive NaCl cotransporter (NCC) resulting in salt retention in the distal part of the nephron 
(23, 47, 59, 61). Several studies have shown that CNIs increase NCC activity possibly 
contributing to hypertension (16, 24). Melnikov et al. demonstrated that rats treated with CsA 
develop a phenotype similar to that of FHHt, which they attributed to an increase in WNK4 
abundance in the kidney (31). This phenomenon is supported by in vitro studies showing 
that the abundance of WNK4 and ultimately of total NCC (tNCC) and phosphorylated, or 
active, NCC (pNCC), is increased in immortalized mouse distal convoluted tubule (mDCT) 
cells treated with CsA (31). Hoorn et al. revealed that Tac-induced hypertension in mice is 
predominantly mediated by an increase in pNCC abundance, possibly through an effect of 
the NCC-regulating kinases WNK3, WNK4, and STE20/SPS1-related proline/alanine-rich 
kinase (SPAK) (16). Recent evidence suggests that in mice, Tac prevents the high 
potassium stimulated NCC dephosphorylation (53). Additionally, it has been demonstrated 
that Tac acts directly on kidney tubule cells expressing NCC to cause hypertension, and that 
inhibition of calcineurin is required for this effect (24).  
In humans, urinary extracellular vesicles (uEVs), including exosomes, have been 
extensively characterized and studied as non-invasive biomarkers for renal tubular disorders 
(7, 11, 15, 49). uEVs are nanosized membranous vesicles released from all cells lining the 
nephron. Alterations in the expression of different proteins present in the epithelial cells of 
the distal convoluted tubule (DCT), including NCC, are reflected in the composition of uEVs 
(18, 55, 56). Patients with FHHt have an increased NCC abundance in uEVs (18, 30, 56), 
while patients with Gitelman syndrome exhibit a decreased NCC abundance in uEVs (7, 20). 
In humans, mineralocorticoid administration rapidly increased the abundance of tNCC and 
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pNCC in uEVs, possibly via the WNK pathway (60). This suggests that NCC abundance in 
uEVs reflects the actual state of NCC expression in the epithelial cells of the DCT. 
Accordingly, we previously showed that in patients with primary aldosteronism, pNCC 
increased similarly in kidney and uEVs (56).  
Although protein abundance and characterization in uEVs can potentially be used as 
biomarkers for some diseases (7, 18, 20, 30, 56), only a few studies have been conducted to 
investigate the role of NCC in CNI-induced hypertension in humans. Esteva-Font et al. found 
a positive correlation between plasma CsA levels and NCC abundance in uEVs of CsA-
treated kidney transplant recipients (9). Rojas-Vega et al. showed an increased abundance 
of NCC in uEVs of Tac-treated hypertensive kidney transplant recipients (45). Although 
these studies showed the stimulatory effect of CNIs on NCC abundance in uEVs of kidney 
transplant recipients, they did not explore the relationship between NCC abundance and 
blood pressure in kidney transplant recipients. Therefore, in the present study, we performed 
a large-scale study to investigate the effect of CsA and Tac on the abundance of both tNCC 
and pNCC in uEVs, and assessed whether NCC abundance in uEVs predicts the blood 
pressure response to thiazide diuretics. Finally, in order to confirm the effect of CNIs on 
NCC in the kidney, an ex vivo study was conducted in mice cortical tubules exposed to CsA.  
 
Materials and Methods 
Study Design and Population 
Two groups of kidney transplant recipients using CNIs were studied. Group 1 was recruited 
at the Radboud university medical center, in Nijmegen, The Netherlands, and consisted of a 
randomly selected cohort of 45 kidney transplant recipients and 6 healthy volunteers of 
whom uEVs were isolated and analyzed. The kidney transplant recipients used CsA (n=9), 
Tac (n=23) or a CNI-free immunosuppressive regimen (n=13) for at least 6 months and were 
matched for age and gender. Kidney transplant recipients who had been using thiazide 
diuretics or aldosterone antagonists after transplantation were excluded. Group 2 consisted 
of Tac-treated hypertensive kidney transplant recipients (median of 2.4 years after kidney 
transplantation), recruited from a clinical trial studying the anti-hypertensive effect of 
thiazide-type diuretic chlorthalidone at the Erasmus Medical Center, in Rotterdam, The 
Netherlands (32). Patients with an office blood pressure >140/90 mmHg were invited for 
ambulatory blood pressure measurement. In this group, 18 patients with an average daytime 
systolic blood pressure >140 mmHg were enrolled and followed for 8 weeks chlorthalidone 
(12-25 mg once daily) treatment. Patients who responded to chlorthalidone (‘responders’, 
decrease of ≥10 mmHg in average daytime systolic blood pressure, n=10) were compared 
with patients who did not respond to chlorthalidone (‘non-responders’, no change or an 
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increase in average daytime systolic blood pressure, n=8). All participants gave written 
informed consent and both cohorts were approved by Medical Ethics Committee 
(CMO09/073 for Radboud university medical center and MEC-2012-417 for Erasmus 
Medical Center) and this study was conducted according to the principles expressed in the 
Declaration of Helsinki. 
 
Urine collection and isolation of extracellular vesicles 
In Group 1, second-morning mid-stream urine sample was collected. In Group 2, second-
morning mid-stream urine was collected just before starting and after 8 weeks of 
chlorthalidone treatment. In both groups, immediately after urine collection, the protease 
inhibitors (50 µmol/L phenylmethylsulfonyl fluoride, 20 µmol/L aprotinin, 10 µmol/L pepstatin 
A, and 20 µmol/L leupeptin) were added to the urine to reduce protein degradation. All 
samples were directly stored at -80°C. uEVs were isolated as reported previously (41, 55, 
56). In brief, 10 to 40 mL of the collected urine samples were centrifuged at 17,000 × g for 
15 minutes at 24°C in an ultracentrifuge (Sorvall™ WX Floor Ultra Centrifuges, Thermo 
Scientific, Asheville, NC, USA) with a 70.1Ti rotor. The supernatant was stored at room 
temperature for 25 minutes. The pellet was resuspended in 50 μL of 3.24 mol/L dithiothreitol 
and 200 μL isolation solution (10 mmol/L triethanolamine, 250 mmol/L sucrose, HCl pH 7.6) 
and centrifuged at 17,000 × g for 15 minutes at 24°C. Next, the supernatant was collected 
and combined with the supernatant obtained from the previous centrifugation, and the 
combined supernatants were centrifuged at 170,000 × g for 2.5 hours at 24°C. Pellets 
containing uEVs were solubilized in Laemmli sample buffer (0.6% w/v SDS, 3% v/v glycerol, 
18 mmol/L Tris-HCl pH 6.8 and 0.003% w/v bromophenol blue). All the samples were 
preheated for 15 minutes at 65°C before immunoblotting. Urinary creatinine was measured 
according to Jaffe’s method with the use of a colorimetric assay (Labor und Technik, Berlin, 
Germany). 
 
Mouse cortical tubule suspension 
Animal protocols were approved by the board of the Institute of Biomedicine, University of 
Aarhus. The animal protocols comply with the European Community guidelines for the use 
of experimental animals, were approved and performed under a license issued for the use of 
experimental animals by the Danish Ministry of Justice (Dyreforsøgstilsynet). For this study 
mice were anesthetized using isoflurane inhalation, followed by cervical dislocation. Both 
kidneys from a male wildtype C57BL/6J mouse were removed and dissected into 
approximately 1 mm pieces and placed into 4 mL of enzyme solution containing 1.5 mg/mL 
collagenase type B (Worthington Labs, Lakewood, NJ, USA) in basic buffer (125 mmol/L 
NaCl, 30 mmol/L glucose, 0.4 mmol/L KH2PO4, 1.6 mmol/L K2HPO4, 1 mmol/L MgSO4, 10 
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mmol/L Na-acetate, 1 mmol/L α-ketoglutarate, 1.3 mmol/L Ca-gluconate, 5 mmol/L glycine, 
48 μg/mL trypsin inhibitor, and 50 μg/mL DNase, Tris-HCl pH 7.4). Samples were mixed 
continuously at 37°C using a benchtop orbital mixer. Samples were incubated for 15 minutes 
at 22°C to let the large fragments sink down to the bottom of the tube. Next, 2 mL of the 
enzyme solution was removed and replaced with 2 mL of basic buffer. After 10 minutes’ 
incubation at 4°C, an additional 2 mL of basic buffer was added, and samples were 
incubated for an additional 10 minutes at 22°C. Large fragments were allowed to settle, the 
supernatant was removed and centrifuged at 200 × g for 2 minutes. The pellet was 
resuspended in 5 mL of basic buffer (buffer B) (120 mmol/L NaCl, 30 mmol/L glucose, 1 
mmol/L CaCl2, 1 mmol/L MgCl2, 1 mmol/L Na2HPO4, 1 mmol/L Na2SO4, 15 mmol/L Na-
HEPES, Tris-HCl pH 7.4) and centrifuged at 200 × g for 2 minutes. The tubular suspensions 
were resuspended in buffer B and 500 µL was transferred into individual tubes containing 
either DMSO (negative control) or different concentrations of CsA (final concentrations of 5, 
10, or 20 μmol/L). Hypotonic low chloride (buffer H), which stimulates NCC (36, 44), was 
used as a positive control. Suspensions were incubated with continuous mixing for 30 and 
90 minutes at 37°C. Tubules were centrifuged for 10 minutes at 3,000 × g at 4°C and pellets 
were resuspended in 300 µL Laemmli sample buffer containing dithiothreitol (50 mg/mL). 
Finally, the samples were heated for 15 minutes at 60°C before immunoblotting. 
 
Immunoblotting 
uEV-samples were loaded on a gradient SDS-PAGE gel (4-15% v/v Criterion™ TGX™ 
Precast Gel, Bio-Rad, The Netherlands). The volume of uEV-suspension per lane was 
adjusted according to the urinary creatinine concentration to account for concentration 
differences between the uEV-samples (49). Loading was not dependent on the fraction of 
the total protein in uEV-samples. The volume of uEV-suspension was lowest in the sample 
with the lowest urinary creatinine concentration, and the samples with a higher urinary 
creatinine concentration were diluted according to the ratio compared to that of the lowest 
urinary creatinine concentration. Subsequently, immunoblotting was performed on 
polyvinylidene difluoride membranes (Immobilon-P, Millipore Corporation, Bedford, MA, 
USA), which were blocked and probed with antigen-specific primary antibodies. Blots were 
incubated with species-specific fluorescent secondary antibodies and visualized using 
enhanced chemiluminescence (Thermo Fischer Scientific, Waltham, MA, USA) and gel 
imaging system (ChemiDoc XRS, Bio-Rad Laboratories, Hercules, CA, USA). Finally, both 
the dimeric and monomeric forms of the NCC bands on the blots were quantified together 
with Image Studio Lite software (LI-COR Biosciences, NE, USA) or ImageQuant TL (GE 
Healthcare Life Sciences, PA, USA). To analyze whether normalization by urinary creatinine 
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resulted in a similar number of uEVs loaded on a gel, the abundance of the uEV-marker 
CD9 was measured (1, 49, 55).  
 
Antibodies 
The following antibodies were used: anti-total NCC (Millipore, Billerica, MA, USA, #AB3553; 
1:2,000); anti-human phosphorylated NCC at Thr60 or (anti-mouse phosphorylated NCC at 
Thr58; 1:2,000) as previously described (38) and anti-uEV marker CD9 of human origin (C4, 
Santa Cruz Biotechnology, Inc., CA, USA; 1:500). Secondary antibodies used were 
peroxidase-conjugated goat anti-rabbit (Sigma-Aldrich, St. Louis, MO, USA; 1:10,000), and 
anti-mouse (Sigma-Aldrich, St. Louis, MO, USA; 1:10,000). 
 
Statistical analysis 
Values are expressed as mean ± SEM. In Group 1 the immunoblot data were analyzed by 
comparing integrated optical densities of bands by one-way ANOVA with Dunnett multiple 
comparisons post hoc test. In Group 2 the immunoblot data were analyzed using a non-
parametric Student's t-test (comparing responders to non-responders). Two-way ANOVA 
was used to assess changes in uEV protein abundance before and after the chlorthalidone 
treatment. In the mouse study the immunoblot data were analyzed by comparing integrated 
optical densities of bands after 30 and 90 minutes exposure to CsA separately compared to 
its negative control (basic buffer without CsA) by one-way ANOVA with Dunnett multiple 
comparisons post hoc test. In this study, fold-change of 1 means no change. P<0.05 was 
considered statistically significant. All data were analyzed using Prism 5 software (GraphPad 
Software Inc, La Jolla, CA, USA). 
 
Results 
CNIs increase NCC in uEVs of kidney transplant recipients 
Table 1 shows the clinical and laboratory characteristics of 9 CsA, 23 Tac and 13 CNI-free 
immunosuppressive regimens treated kidney transplant recipients (Group 1). The effect of 
CNI on NCC abundance in uEVs was assessed using immunoblot analysis. Two 
immunoreactive bands of ~260 and ~130 kDa representing the dimeric and monomeric 
forms of the NCC protein were detected in uEVs (Fig. 1). Both forms were included in the 
analysis to determine the effect of CNI treatment on NCC abundance in uEVs. The 
abundances of tNCC and pNCC in uEVs of both CsA and Tac-treated kidney transplant 
recipients were significantly increased compared to uEVs isolated from kidney transplant 
recipients treated with CNI-free immunosuppressive regimens or healthy volunteers (Fig. 2, 
A and C). No significant difference in tNCC and pNCC abundance was detected between 
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CsA and Tac-treated kidney transplant recipients. The ratio of pNCC to tNCC did not differ 
between kidney transplant recipients treated with CsA, Tac, CNI-free immunosuppressive 
regimens, and healthy volunteers (Fig. 2E). Females may express more NCC (46), but in our 
study a gender difference in the abundance of NCC in the uEVs was not demonstrated 
(supplemental Fig. S3 available online). No significant differences in CD9 abundance were 
observed between the four experimental groups, suggesting comparable uEV numbers (Fig. 
2, B and D). Additional normalization by CD9 abundance showed that both tNCC and pNCC 
abundance in both CsA- and Tac-treated kidney transplant recipients was significantly 
increased in comparison to kidney transplant recipients treated with CNI-free 
immunosuppressive regimens, but not healthy volunteers (supplemental Fig. S4, A and B 
available online).  
 
NCC abundance in uEVs predicts the anti-hypertensive response to thiazides 
Subsequently, we investigated whether the blood pressure response to thiazide diuretics in 
hypertensive kidney transplant recipients treated with Tac correlates with NCC abundance in 
uEVs. To this end, we compared tNCC and pNCC abundances in uEVs of patients with a 
blood pressure response to a thiazide in comparison to those who did not respond. Table 2 
shows the clinical and laboratory characteristics of these patients (Group 2). Pre-treatment 
abundances of both tNCC and pNCC in uEVs were significantly higher in chlorthalidone 
responders compared to non-responders (Fig. 3). Furthermore, both pNCC and tNCC 
abundance in uEVs correlated with the blood pressure response (R2=0.27 and 0.30 using 
log-tranformed densitometry data because of non-normal distribution, P<0.05 for both, Fig. 
3). Subsequently, the change in NCC abundance before and after treatment with 
chlorthalidone in uEVs of both responders and non-responders was compared (Fig. 4 and 
supplemental Figs. S5 and S6 available online, show original immunoblots). The increase of 
tNCC in uEVs was larger in non-responders than in responders (P<0.05). While pNCC in 
uEVs also increased in most responders, there was a decrease in pNCC in the majority of 
non-responders (P<0.05). As a result, the pNCC to tNCC ratio remained constant in the 
responders, but markedly decreased in non-responders (P<0.05). This suggests that 
phospho-occupancy at the measured site was lower in non-responders. No gender 
differences were found (supplemental Fig. S9 available online). Again, no significant 
differences were found in the abundances of CD9 between groups, suggesting comparable 
uEV-numbers (Fig. 3 and supplemental Fig. S7 available online). Additional normalization by 
CD9 abundance led to similar results (supplemental Fig. S8 available online).  
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Table 1 | Clinical and laboratory characteristics of the patients in study Group 1. 
SEM = standard error of the mean; ESRD = end stage renal disease; data are presented as mean ± 
SEM. a = P-value for difference between CsA and CNI-free; b = P-value for difference between Tac 
and CNI-free, 95% CI, 95% confidence interval. 
Characteristic  
(mean ± SEM) 
CNI-free group  
(n=13)  
CsA group  
(n=9) 
Tac group  
(n=23) 
P-value 
Age  53 ± 3 51 ± 2 52 ± 3 0.90a, 0.96b 
Male (n (%)) 7 (54) 5 (56) 12 (52)  
Body mass index, Kg/m2  25 ± 1 27 ± 2 27 ± 1 0.53a, 0.38b 
Cause of ESRD (n)     
Polycystic kidney disease 3 1 5  
Diabetes 0 2 2  
Glomerular disease 2 0 0  
Hypertension/Vascular 0 0 2  
Other 8 6 14  
Plasma Na, mmol/L  140 ± 1 138 ± 1 139 ± 1 0.44a, 0.72b 
Plasma K, mmol/L  4.0 ± 0.1 4.1 ± 0.1 4.1 ± 0.1 0.80a, 0.72b 
Plasma Cl, mmol/L  106 ± 1 105 ± 1 108 ± 1 0.80a, 0.29b 
Plasma creatinine, mg/dL  1.6 ± 0.1 1.5 ± 0.1 1.7 ± 0.1 0.80a, 0.72b 
eGFR, mL/min/1.73 m2 46 ± 2 42 ± 3 45 ± 4 0.76a, 0.97b 
Systolic blood pressure, mmHg  135 ± 3 137 ± 4 142 ± 3 0.91a, 0.22b 
Diastolic blood pressure, mmHg  80 ± 2 84 ± 4 82 ± 2 0.52a, 0.77b 
CsA pre-dose level, μg/L   127 ± 14   
Tac pre-dose level, μg/L    6.7 ± 0.4  
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Figure 1 | Representative immunoblots of tNCC and pNCC abundance in uEVs of kidney 
transplant recipients treated with CsA, Tac or CNI-free immunosuppressive regimens and 
healthy volunteers.  
Panels A and B show the immunoreactive bands in uEVs of patients treated with CsA (n=4), Tac 
(n=5), CNI-free immunosuppressive regimens (n=3), and healthy volunteers (n=5). tNCC (A) and 
pNCC (B) immunoreactive bands in uEVs of both CsA- and Tac-treated kidney transplant recipients 
were stronger compared to kidney transplant recipients treated with CNI-free immunosuppressive 
regimens and healthy volunteers. 
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Figure 2 | Densitometry of tNCC and pNCC immunoreactive bands in uEVs of all kidney 
transplant recipients treated with CsA (n=9), Tac (n=23) or CNI-free immunosuppressive 
regimens (n=13) and healthy volunteers (n=6).  
Both tNCC (A) and pNCC (C) abundance in both CsA- and Tac-treated kidney transplant recipients 
was significantly increased in comparison to kidney transplant recipients treated with CNI-free 
immunosuppressive regimens and healthy volunteers. Densitometry analysis of CD9 expression of 
the immunoblots for tNCC (B) and pNCC (D) showed no significant differences between the four 
groups. The ratio of pNCC to tNCC abundance in uEVs of CsA- and Tac-treated group was not 
significantly increased in comparison to kidney transplant recipients treated with CNI-free 
immunosuppressive regimens and healthy volunteers (E). The original immunoblots are shown in Fig. 
1 and supplemental Figs. S1 and S2 available online. Values are mean ± SEM normalized to kidney 
transplant recipients treated with CNI-free immunosuppressive regimens (one-way ANOVA, *P<0.05, 
n=51).  
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Table 2 | Clinical and laboratory characteristics of the patients in study Group 2. 
SEM = standard error of the mean; ESRD = end stage renal disease; data are presented as mean ± 
SEM. P-value for difference between responders and non-responders, 95% CI, 95% confidence 
interval. 
 
Increased pNCC in mouse cortical tubule suspensions exposed to CsA 
To study the acute effect of CsA on NCC abundance in kidney, mouse cortical tubules were 
isolated and exposed to CsA. All mouse cortical tubule suspensions were incubated in basic 
buffer for 30 or 90 minutes in the absence or presence of CsA (at final concentrations of 5, 
10, and 20 μmol/L). No significant changes were observed in tNCC, while the pNCC 
abundance and the ratio of pNCC to tNCC were significantly increased after 30 minutes of 
exposure to 10 or 20 μmol/L of CsA, and after 90 minutes of exposure to 5, 10, or 20 μmol/L 
of CsA (Fig. 5). Hypotonic low chloride, which decreases the intracellular chloride 
concentration thereby activating the WNK-SPAK and OSR1 pathways (36, 44), was used as 
a positive control. pNCC and the ratio of pNCC to tNCC were significantly increased in 
hypotonic low chloride buffer, whereas tNCC remained unchanged (Fig. 5).  
Characteristic 
(mean ± SEM) 
Responders 
(n=10) 
Non-responders 
(n=8) 
P-value 
Age 61 ± 2 57 ± 3 0.15 
Males (n (%)) 6 (60) 6 (75) 0.27 
Body mass index, Kg/m2 27 ± 2 30 ± 2 0.14 
Cause of ESRD (n)    
Polycystic kidney disease 1 0  
Diabetes 2 3  
Glomerular disease 0 3  
Hypertension/vascular 6 1  
Other 1 1  
Plasma Na, mmol/L 140 ± 1 140 ± 1 0.40 
Plasma K, mmol/L 4.5 ± 0.1 5.1 ± 0.2* <0.01 
Plasma Cl, mmol/L 103 ± 1 105 ± 1 0.07 
Plasma creatinine, mg/dL 1.2 ± 0.1 1.7 ± 0.2* 0.01 
eGFR, mL/min/1.73 m2 55 ± 5 43 ± 6 0.06 
Urine K/creatinine, mmol/mmol 5.2 ± 2.1 4.6 ± 1.9 0.28 
Systolic blood pressure, mmHg  158 ± 4 151 ± 5 0.15 
Diastolic blood pressure, mmHg  86 ± 2 80 ± 3 0.07 
Tac pre-dose level, μg/L 5.5 ± 0.4 5.8 ± 0.5 0.30 
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Figure 3 | Pre-treatment tNCC and pNCC abundances in uEVs isolated from hypertensive 
kidney transplant recipients who did or did not respond to chlorthalidone.  
Shown are immunoblots of tNCC (panel A) and pNCC (panel B) together with CD9 in uEVs of 
hypertensive kidney transplant recipients using Tac. ‘Responders’ (n=10) refer to patients who 
subsequently had a significant anti-hypertensive response (≥10 mmHg reduction in systolic blood 
pressure) to 8-week treatment with chlorthalidone. Non-responders (n=8) did not have an anti-
hypertensive response to chlorthalidone (no change or increase in systolic blood pressure). uEVs 
were isolated before the treatment with chlorthalidone. Both tNCC and pNCC abundance were 
significantly higher in responders compared to non-responders (non-parametric t-test, *P<0.05, n=18). 
Both pNCC and tNCC abundance in uEVs correlated with the blood pressure response (panel C, 
R2=0.27 and panel D, R2=0.30 using log-tranformed densitometry data because of non-normal 
distribution, P<0.05 for both). Abbreviations: SBP, ambulatory systolic blood pressure. 
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Figure 4 | pNCC and tNCC abundances in uEVs before and after treatment with chlorthalidone.  
Panel A shows pNCC and tNCC abundances in uEVs before (B) and after (A) the 8-week treatment 
period with chlorthalidone in both responders (n=10) and non-responders (n=8). The fold-changes in 
the before-after abundances of pNCC and tNCC in uEVs (as measured by densitometry) of both 
responders and non-responders are shown in panel B (Fold-change of 1 means no change, *P<0.05). 
The scatter plots represent the fold change in tNCC, pNCC or their ratio after treatment with 
chlorthalidone (densitometry values before treatment with chlorthalidone were set to 1). 
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Figure 5 | tNCC and pNCC abundance in mouse cortical tubule suspension exposed to CsA.  
Panel A shows representative immunoblots of tNCC and pNCC abundance in mouse cortical tubule 
suspension exposed to CsA. Immunoblots of protein homogenates of mouse cortical tubule 
suspensions were incubated in basic (B) buffer for 30 and 90 minutes, in the absence (-) or presence 
of CsA at final concentrations of 5, 10, or 20 μmol/L (A). tNCC remained at baseline levels (B), while 
pNCC (C) and ratio of pNCC to tNCC (D) were significantly increased in the mouse cortical tubule 
suspension after 30 minutes of exposure to 10 and 20 μmol/L of CsA and 90 minutes of exposure to 
5, 10, and 20 μmol/L of CsA. Similarly, pNCC and the ratio of pNCC to tNCC were significantly 
increased in hypotonic low chloride (H) buffer (C and D). The original immunoblots for 30 and 90 
minutes, in the absence (-) or presence of CsA at final concentrations of 5, 10, or 20 μmol/L are 
shown in Fig. 5 and supplemental Fig. S10 available online. Values are mean ± SEM normalized to 
basic (B) condition (one-way ANOVA, *P<0.05, 30 minutes exposure n=3, 90 minutes exposure n=4). 
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Discussion 
Our study demonstrates that chronic treatment with CNIs increases both tNCC and pNCC 
abundance in uEVs of kidney transplant recipients, suggesting increased Na reabsorption in 
the distal part of the nephron. Additionally, we show that the increase in pNCC abundance in 
uEVs of kidney transplant recipients correlates with the blood pressure response to NCC-
inhibiting thiazide diuretics. Lastly, we corroborate that CNIs affect the NCC level in the 
kidney by showing that short-term exposure to cyclosporine increases pNCC but not tNCC 
abundance in mouse cortical tubules suspensions. Collectively, these observations indicate 
that the CNI-induced increase in NCC abundance and activity are involved in the 
pathogenesis of hypertension in kidney transplant recipients, and suggest that pNCC 
abundance in uEVs could be used as a biomarker to predict the blood pressure response to 
thiazide diuretics. 
Since the introduction of CNIs in the 1980s, there has been a steep increase in the 
prevalence of hypertension after kidney transplantation (10, 28). In a study using a kidney 
specific 12 kDa FK506-binding protein, FKBP12, knockout mice, Tac caused hypertension 
by inhibiting calcineurin directly in DCT cells expressing NCC (24). Moreover, NCC knockout 
mice were protected from tacrolimus-induced hypertension (16), confirming the role of NCC 
in CNI-induced hypertension. Although both CsA and Tac inhibit calcineurin, they differ in 
structure and cytoplasmic binding protein, which might explain why hypertension is less 
common and less severe in patients using Tac than in those using CsA (4, 5, 17, 29, 39, 58). 
However, it is still not known whether the higher incidence of hypertension in CsA-treated 
kidney transplant recipients is due to a stronger tNCC and pNCC upregulation in CsA- 
compared to Tac-treated kidney transplant recipients. Our study demonstrates that CsA 
does not increase tNCC and pNCC abundances in uEVs of kidney transplant recipients 
more than Tac (Fig. 2). This suggests that factors other than NCC might contribute to the 
discrepancy in the increased blood pressure between patient groups using CsA and Tac. It 
is known that CNIs affect tissues other than the kidney, which are also involved in the 
development of hypertension (24). CsA and Tac might differ in their ability to cause 
vasoconstriction (33, 51), activate the renin-angiotensin-aldosterone system (RAAS) (16, 
33), or the sympathetic nervous system (27), all of which can contribute to the development 
of hypertension. 
Several guidelines recommend thiazide-type diuretics as first-line treatment for the 
management of hypertension in adults (19, 42). Thiazide-type diuretics act by blocking NCC, 
thus increasing Na excretion by the kidney (8). Given the role of NCC in CNI-induced 
hypertension, thiazide diuretics might be especially effective drugs for hypertensive 
transplant recipients using CNIs and NCC abundance in their uEVs might predict the blood 
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pressure response to thiazide diuretics. Indeed, uEV analysis in patients selected from our 
crossover study demonstrates that pre-treatment abundances of tNCC and pNCC in uEVs 
predict the blood pressure response to thiazide diuretics (Fig. 3). This implies that the 
abundance of pNCC in uEVs of hypertensive kidney transplant recipients using CNIs could 
be used to predict thiazide sensitivity. Although it may be more pragmatic to simply test the 
response to a trial of thiazide diuretics, urinary biomarkers may help individualize anti-
hypertensive treatment, especially with the development of high-throughput assays (48). 
However, acute regulators of NCC activity such as the RAAS and potassium status should 
also be taken into account when interpreting the obtained results (see below). A relevant 
question is what explains the higher pNCC and tNCC in uEVs of responders prior to 
treatment, and the decrease in ratio of pNCC to tNCC in non-responders after thiazide 
treatment. One could argue that CNI-induced NCC activation was greater in responders. An 
alternative possibility is that the potassium balance determined thiazide sensitivity. A high 
potassium diet and hyperkalemia have recently been shown to inhibit NCC (43, 54). Indeed, 
serum potassium concentrations were higher in non-responders compared to responders. 
Here, we show that NCC abundance was increased in the majority of “responders” after 
thiazide treatment (Fig. 4), which is consistent with data obtained in animal models (34, 35). 
Na et al. showed with immunoblot analysis and immunostaining that chronic 
hydrochlorothiazide treatment in rats increased the abundance of NCC (34). Moreover, 
chronic hydrochlorothiazide infusion in mice increased the binding density of [3H] 
metolazone, an indirect measure of NCC activity, which confirms the increase of NCC after 
hydrochlorothiazide (6). Similarly, chronic administration of the diuretics furosemide and 
amiloride (which blocks the Na-K-Cl cotransporter and the epithelial Na channel, 
respectively), increased the abundance of these proteins in rodent kidney (22, 34). These 
effects might be the result of compensatory mechanisms, potentially mediated by the RAAS 
or/and potassium balance, which counteract reduced NCC function by the thiazide treatment 
(52). Of interest, non-responders had a completely different pattern during thiazide treatment 
with a decrease in pNCC and ratio of pNCC to tNCC (Fig. 4). The explanation for this 
difference is unclear, but one might speculate that a blood pressure response to thiazides is 
accompanied by RAAS activation resulting in different NCC excretion patterns in uEVs. 
Alternatively, differences in potassium balance may explain these results, because a recent 
study showed that pNCC stimulation by angiotensin II occurs as a compensatory response 
to renal potassium loss (57).     
To further confirm the effect of CNIs on NCC in the kidney, we performed an ex vivo 
study using mice cortical tubules. This experiment demonstrated that short-term exposure to 
CsA increases pNCC abundance, while tNCC remained stable (Fig. 5). This phenomenon 
was previously reported by Hoorn et al. (16) in mice and human embryonic kidney 293 cells 
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treated with Tac, and by Melnikov et al. (31) in mDCT cells treated with CsA. Recently, it 
was demonstrated in mice that treatment with Tac prevents the acute high potassium 
induced NCC dephosphorylation, while tNCC remained unaffected (53). In contrast to 
previous studies, this acute regulatory system mediated by calcineurin is shown to be 
independent of the WNK-SPAK signaling cascade (53). Our study demonstrated that chronic 
administration of CNIs increases the abundance of both tNCC and pNCC in uEVs of kidney 
transplant recipients. This suggests that the difference in tNCC increase between mice 
cortical tubules and uEVs might be dependent on the time of stimulation or another signaling 
molecule involved in the in vivo situation.  
A number of limitations of our study should be mentioned. First, several other factors, in 
addition to CNIs, may regulate NCC, which may also explain differences in expression of 
NCC and in thiazide sensitivity. Second, an unresolved question in the uEV-field remains 
whether the abundance of protein per uEV varies, or that the number of uEVs is regulated. 
Although we included the uEV-marker CD9, techniques that allow uEV counting will be 
necessary to address this point more conclusively.  
Our findings demonstrate that CNI treatment increases both tNCC and pNCC 
abundance in uEVs isolated from kidney transplant recipients. We also show that the blood 
pressure response to chlorthalidone in Tac-treated hypertensive kidney transplant recipients 
was related to the pNCC abundance in uEVs. This implies that pNCC in uEVs of kidney 
transplant recipients treated with a CNI might be used to predict blood pressure response to 
thiazide diuretics. In addition, uEV analysis may have clinical utility as a non-invasive 
biomarker for a variety of physiological and pathological conditions. 
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Abstract 
The distal convoluted tubule (DCT) of the kidney plays an important role in blood pressure 
regulation by modulating Na+ reabsorption via the Na+-Cl- cotransporter (NCC). A diet 
containing high salt (NaCl) and low K+ activates NCC, thereby causing Na+ retention and a 
rise in blood pressure. Since high blood pressure, hypertension, is associated with changes 
in serum calcium (Ca2+) and magnesium (Mg2+) levels, we hypothesized that dietary Na+ and 
K+ intake affects Ca2+ and Mg2+ transport in the DCT. Therefore, the present study aimed to 
investigate the effect of a high Na+/low K+ diet on renal Ca2+ and Mg2+ handling. Mice were 
divided in 4 groups and fed a normal Na+/normal K+, normal Na+/low K+, high Na+/normal K+, 
or high Na+/low K+ diet for 4 days. Serum and urine were collected for electrolyte and 
hormone analysis. Gene and protein expression of electrolyte transporters were assessed in 
kidney and intestine by qPCR and immunoblotting. While Mg2+ homeostasis was not 
affected, the mice had elevated urinary Ca2+ and phosphate (Pi) excretion upon high Na+ 
intake, as well as significantly lower serum Ca2+ levels in the high Na+/low K+ group. 
Alterations in the gene and protein expression of players involved in Ca2+ and Pi transport 
indicate that reabsorption in the proximal tubular and TAL is affected, while inducing a 
compensatory response in the DCT. These effects may contribute to the negative health 
impact of a high salt diet, including kidney stone formation, chronic kidney disease, and loss 
of bone mineral density.    
 
Keywords: Potassium / Salt / Kidney / Calcium / Phosphate 
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Introduction 
The majority of people worldwide consume a diet containing high salt (NaCl) and low 
potassium (K+) levels, which is associated with increased blood pressure (hypertension) (44). 
Hypertension is one of the most important public health issues due to its increased risk of 
cardiovascular-renal disease, resulting in an overall elevated mortality (24). While 
mechanisms for salt-dependent hypertension have been mainly related to the consumption 
of Na+, it has recently been shown that K+ intake plays an essential role in blood pressure 
regulation. Dietary K+ intake is inversely correlated to the risk of hypertension and 
cardiovascular-related mortality (31, 34). A K+-rich diet is expected to have a protective 
effect and can reduce blood pressure in hypertensive patients (1). 
The kidney is the central organ for maintaining the body’s Na+ balance by controlling 
Na+ reabsorption along different nephron segments. Specifically, the aldosterone-sensitive 
distal part of the nephron, consisting of the distal convoluted (DCT), connecting tubule (CNT), 
and collecting duct (CD), is essential for Na+ reabsorption (50). The DCT can be further 
subdivided into the early and late DCT, DCT1 and DCT2 respectively. Na+ reabsorption is 
mediated by the Na+-Cl--cotransporter (NCC) in DCT1 and DCT2, as well as by the epithelial 
Na+ channel (ENaC) in DCT2, CNT and CD. Here, Na+ reabsorption through ENaC is 
coupled to K+ secretion via the renal outer medullary K+ channel (ROMK). In short, Na+ 
reabsorption in the DCT1 determines the amount of Na+ delivery to the downstream 
segments and thereby has an indirect role in K+ secretion. This is highlighted by the 
molecular mechanisms underlying Gitelman syndrome and pseudohypoaldosteronism type 2 
(familial hyperkalemic hypertension, FHHt). Gitelman syndrome results from inactivating 
mutations in the NCC gene (48), which leads to reduced NCC function. Patients suffer from 
hypokalemia that can partly be explained by enhanced Na+ delivery to ENaC and 
subsequent K+ secretion by ROMK due to disturbed NCC-mediated Na+ reabsorption in the 
DCT. On the contrary, FHHt patients suffer from hyperkalemia as a result of mutations in the 
genes encoding for proteins regulating NCC, including Cullin3, KLHL3, and the with-no-
lysine kinases WNK1 and WNK4 (7, 60). Activation of the WNK kinases leads to 
phosphorylation and thereby activation of two related proteins, SPAK (STE20/SPS1-related 
proline/alanine-rich kinase) and OSR1 (oxidative stress–responsive kinase 1) (58). Activated 
SPAK and OSR1 kinases then phosphorylate key residues in the amino-terminal region of 
NCC, resulting in enhanced Na+ reabsorption by either increased transport activity or 
enriched NCC abundance at the apical membrane (35). Hence, Na+ reabsorption and 
subsequent K+ secretion are diminished in downstream segments, which can explain the 
hyperkalemia in FHHt. In addition, WNK kinases have also been shown to directly alter 
ENaC and ROMK function (23).   
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Interestingly, a recent study by Terker et al. postulated an additional relationship 
between K+ and Na+ in which dietary K+ can regulate renal Na+ handling through plasma K+ 
levels (53). They suggested that lower plasma K+ induces a Cl- efflux from the DCT cell, 
thereby releasing the Cl--dependent inhibition of WNK1. Subsequently, this results in WNK1 
autophosphorylation and activation (38), which in turn phosphorylates and activates NCC 
through the SPAK/OSR1 kinases (53). Conversely, increasing dietary K+ intake was shown 
to reduce NCC phosphorylation (and activity) in a linear range (40, 49, 56). 
In addition to regulating renal Na+ and K+ handling, the distal part of the nephron also 
determines the final urinary Ca2+ and Mg2+ excretion since no Ca2+ or Mg2+ reabsorption 
takes place beyond the DCT/CNT. Interestingly, hypertension is associated with altered 
serum Ca2+ and Mg2+ levels (41, 42). However, the underlying molecular mechanisms are 
not well understood. Since renal Na+ and K+ handling plays a key role in the pathogenesis of 
hypertension, we hypothesized that the disturbances in the Ca2+ and Mg2+ balance can be 
explained by Na+ and/or K+-induced changes in Ca2+ and Mg2+ reabsorption in the distal part 
of the nephron. The present study aimed to identify the molecular players involved in the 
effect of dietary Na+ and K+ intake on renal Ca2+ and Mg2+ handling in wild-type mice fed a 
high Na+ diet combined with normal or low K+. Furthermore, we examined renal phosphate 
(Pi) handling. 
 
Materials and Methods  
Antibodies 
The following primary antibodies were used: NCC (Millipore, Billerica, MA, USA; #AB3553; 
immunoblotting (IB) 1:2,000; immunohistochemistry (IHC) 1:200), pNCC-T58 (kindly 
provided by Dr. Robert Fenton (36); IB 1:2,000), β-actin (Sigma-Aldrich, St. Louis, MO, USA; 
#A5441; IB 1:10,000), CaBP28k (Sigma; #C9848; IB 1:5,000), NaPi-2a (kind gift of Dr. Jürg 
Biber (15); IB 1:2,000), NaPi-2c (Lifespan BioSciences Inc., Seattle, WA, USA; #LS-
C101349; IB 1:2,000) and TRPV5 ((25), IHC 1:2,000). Secondary antibodies were as 
follows: peroxidase conjugated goat anti-rabbit (Sigma-Aldrich; #A4914; IB 1:10,000); 
peroxidase conjugated sheep anti-mouse (Jackson ImmunoResearch Laboratories Inc., 
West Grove, PA, USA; #515-035-003; IB 1:10,000); Anti-guinea pig Biotin-SP-conjugated 
secondary antibody (Jackson ImmunoResearch Laboratories Inc.; #106-065-003; IHC 
1:2,000); anti-rabbit Alexa Fluor® 594 conjugated secondary antibody (Invitrogen; #A11012; 
IHC 1:300). 
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Buffers  
Lysis buffer: 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (v/v) 
Triton X-100, 1 mM sodium-orthovanadate, 10 mM sodium-glycerophosphate, 50 mM 
sodium fluoride, 10 mM sodium pyrophosphate, 0.27 M sucrose, containing freshly added 
tablet of complete protease inhibitor cocktail (Roche, Basel, Switzerland) and 0.1% (v/v) β-
mercaptoethanol. TBS-T (Tris-buffered saline, 0.1% Tween 20): Tris-HCL (200 mM, pH 7.5), 
0.15 M NaCl, and 0.2% v/v Tween-20. SDS-PAGE sample buffer: 5x 10% w/v SDS, 10 mM 
β-mercaptoethanol, 50% v/v glycerol, 0.3 M Tris-HCl (pH 7.5), 0.05% w/v bromophenol blue. 
 
Animals 
Studies were approved by the Central Animal Laboratory Nijmegen and the animal ethics 
board of the Radboud University Nijmegen (CCD #AVD103002016382). All mice were 10-12 
weeks old males, 20–25 g, and had a C57Bl/6 background. Prior to dietary intervention, they 
were housed in standard cages in a temperature- and light-controlled room, with control 
synthetic pellet chow and drinking water available ad libitum for 4 days. Following, the mice 
were randomly divided in 4 groups of 10 mice and fed their respective diet for 4 days. At the 
last day, they were housed in metabolic cages for 24 hours to collect urine and feces. After 
anesthetizing with 4% (v/v) isoflurane, the mice were sacrificed and blood, kidneys, and 
intestines were collected and snap frozen in liquid nitrogen. 
 
Animal diets 
All diets were prepared by SSNIFF Spezialdiäten GmbH, Soest, Germany. High Na+ was 
obtained by adding NaCl to make a 6% (w/w) NaCl diet. Low K+ diets (<0.05% (w/w) K+) had 
no additional K+ added, and normal K+ was obtained by adding KCl to make a 1% (w/w) K+ 
diet. This resulted in the following diets: normal Na+/normal K+ (NN/NK), normal Na+/low K+ 
(NN/LK), high Na+/normal K+ (HN/NK), and high Na+/low K+ (HN/LK). 
 
Electrolyte and renin measurements 
Serum and urinary total Mg2+ concentrations were determined using a colorimetric xylidyl-II 
blue assay kit according to the manufacturer’s protocol (Roche/Hitachi), on a Bio-Rad plate 
reader at 600 nm. Serum and urinary total Ca2+ were colorimetrically determined with a 
chromogenic/buffer dual-component kit (Sigma Aldrich), on a Bio-Rad plate reader at 570 
nm. The obtained values were calibrated using a Precinorm standard solution (Precinorm U, 
Roche). Serum and urinary Na+, K+, and Cl- determinations were performed at the university 
hospital central clinical lab on an automated system according to the manufacturer’s protocol 
(Abbott Diagnostics, Hoofddorp, The Netherlands). Total urine volume was used to calculate 
24 hours excretion. Active plasma renin concentration (APRC) was measured with a 
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radioimmunoassay that detects the amount of angiotensin I (ang I) produced per hour in the 
presence of excess angiotensinogen (nanograms of ang I produced per milliliter of plasma 
per hour) (9). 
 
Immunoassays 
Enzyme-linked immunosorbent assays (ELISA) was used to determine circulating levels of 
fibroblast growth factor (FGF)23 (C-terminal FGF23 ELISA) and PTH 1–84 in the plasma of 
the mice (both Immutopics International, San Clemente, CA, USA). 
 
Immunohistochemistry 
Immunohistochemistry was performed as previously described (25). In brief, co-staining of 
TRPV5 with NCC were performed on 5-µm sections of poly-L-lysine paraformaldehyde 
(PLP) fixed frozen mouse kidney samples. Sections were incubated for 16 hours at 4°C with 
guinea pig anti-TRPV5 primary antibody. TRPV5 staining was enhanced using TSA 
fluorescence System according to manufacturer protocol (Perkin Elmer, Groningen, The 
Netherlands). Subsequently, sections were incubated for 2 hours at room temperature with 
rabbit anti-NCC primary antibody. The NCC proteins were visualized with anti-rabbit Alexa 
Fluor® 594 conjugated secondary antibody. Fluorescence microscopy was performed using 
10x and 40x objectives on a Leica DMI6000 confocal microscope, and images were 
processed using LAS AF software. 
 
Quantitative real-time PCR 
Total kidney RNA was isolated using TRIzol agent (Invitrogen, Breda, The Netherlands) 
according to the manufacturer’s protocol, and subsequently treated with DNase (Promega, 
Fitchburg, MA, USA) to remove genomic DNA. Reverse transcription of the mRNA was 
performed by M-MLV reverse transcriptase (Invitrogen) for 1 hour at 37°C. Gene expression 
levels were determined by SYBR Green (Bio-Rad, Veenendaal, The Netherlands) real time 
PCR on a Bio-Rad (Hercules) analyzer and normalized for glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh) expression levels. Relative expression was calculated according to 
the Livak method (2 –ΔΔCt, ΔCt (cycle threshold)=Ct gene of interest – Ct housekeeping gene) 
and presented as fold change of expression compared to control diet (NN/NK). Primer 
sequences are indicated in Table 1. 
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Table 1 | Primer sequences. 
 
Protein isolation 
Cortex and medulla sections were macroscopically isolated from kidney tissue and 
homogenized in ice cold lysis buffer. The kidney lysates were clarified by centrifugation at 
4 °C for 15 minutes at 16,000 g and supernatants were snap frozen in aliquots and stored at 
-80 °C. Protein concentrations were determined using the Bradford method according to the 
manufacturer’s protocol (Bio-Rad). 
 
Immunoblotting 
Lysates (50 μg) in SDS sample buffer were subjected to electrophoresis on Criterion TGX 
precast gels (Bio-Rad) and then transferred to PVDF membranes. The membranes were 
blocked in TBS-T containing 5% (w/v) nonfat dry milk (NFDM) for 30 minutes at room 
temperature. Subsequently, they were immunoblotted overnight at 4°C with primary antibody 
(in TBS-T containing 5% (w/v) NFDM). Next day, the blots were washed with TBS-T to 
remove unbound primary antibody and incubated with horseradish peroxidase (HRP) 
conjugated secondary antibodies for 1 hour at room temperature. After subsequent washes, 
the protein was visualized with chemiluminescent reagent (SuperSignal West femto/pico; 
Thermo Scientific, Waltham, MA, USA) and processed with the Bio-Rad ChemiDoc XRS. 
The NCC bands on the immunoblots were quantified with Image J software (NIH). 
 
Gene Forward primer 5'-3' Reverse primer 5'-3' 
Gapdh TAACATCAATGAGGGTGAGG GGTTCACACCCTACACAAAC 
Trpm6 AAAGCCATGCGAGTTATCAGC CTTCACAATGAAAACCTGCCC 
Trpm7 GGTTCCTCCTGTGGTGCCIT CCCCATGTCGTCTCTGTCGT 
Trpv5 CTGGAGCTGTGGTTTCCTC TCCACTTCAGGCTCACC 
Trpv6 GGCCTCACAACCTCATTTAC CTCAATGAGCAGTCTAACAATC 
Cyp24a1 GGAGTCCATGAGGCTACCC GGTAGCGTGTTACTACCCAGA 
Cyp27b1 GTGITGAGATTGTACTCGCTGG TGGGGAATTACATATGCITCTACAC 
CaBP28k GACGGAAGTGTGTACCTGG AITTCCGGTGATAGCTCC 
Renin GCACCGCTACCTTTGAA GCTGTGAATCCCACAAGC 
NaPi2a TCAGGAAGAGGAGCAAAAGC AAAGGAAAGCCAGCATCAGA 
NaPi2c GTGGTCAGCAGCTTTCTCAA ACAGCACCACATTGTCCTTG 
Cldn 19 GGTTCCTTTCTCTGCTGCAC CGGGCAACTTAACAACAGG 
Cldn 14 GTCCAGCTCCTAGGCTTCCT CATCCACAGTCCCTTCAGGT 
Cldn 16 CCATCATTGAATCGCTCTCC GAGGAGCGTTCGACGTAAAC 
Cldn 2 CCAGGGCAATCGTACCAACT ACTCTTGGCTTTGGGCTGTT 
Slc8a1 CTCCCTTGTGCTTGAGGAAC CAGTGGCTGCTTGTCATCAT 
Slc12a1 GGCTTGATCTTTGCTTTTGC CCATCATTGAATCGCTCTCC 
SLC9a3 TCACCTTCAAATGGCACCAC TGGGACAGGTGAAAGACGATT 
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Statistical analysis 
All data are shown as mean standard error of the mean (SEM). Statistical significance 
(p<0.05) was determined by analysis of variance and a Bonferroni post-hoc test. All data 
were analyzed using GraphPad Prism 7.0 (GraphPad Software Inc). 
 
Results 
Effect of dietary intervention on electrolyte handling 
To investigate the role of dietary Na+ and K+ intake on renal electrolyte handling, the mice 
were fed 4 different diets (NN/NK (control), NN/LK, HN/NK, and HN/LK) and blood, and 24-
hour urine were collected using metabolic cages. No differences in body weight or food 
intake were observed between the groups (Table 2). Importantly, water intake and urine 
production were significantly elevated in the high Na+ groups (HN/NK and HN/LK) compared 
to the control group. Moreover, the HN/LK group has a slightly higher water intake and urine 
output compared to high Na+ alone (HN/NK) (p=0.13). The effect of the diets was also 
evident from changes in electrolyte handling (Table 3). First, the HN/LK group had 
significantly elevated serum Na+ levels compared to all other groups. Second, serum K+ 
levels were significantly lower in the groups fed a low K+ diet compared to the normal K+ 
groups. Of note, high Na+ intake did not affect serum K+. Third, serum Cl- levels decreased 
significantly in the NN/LK group, while the other groups showed no differences. Next, urinary 
excretion of Na+, K+, and Cl- were determined in 24-hour urine. Urinary K+ excretion 
corresponded to the serum K+ levels and was for instance drastically reduced in the low K+ 
groups. The urinary Na+ and Cl- excretion was significantly enhanced in groups fed a high 
Na+ diet. To confirm the dietary effect on NCC phosphorylation as previously described (53), 
kidney cortex samples were subjected to immunoblotting demonstrating enhanced 
phosphorylation of NCC in both low K+ groups (Fig. 1A). 
Interestingly, the low K+ diet resulted in a reduced renal expression of Na+-K+-Cl-
cotransporter (NKCC2), the family member of NCC that transports Na+, K+, and Cl- in the 
thick ascending limb of Henle’s loop (TAL) (Fig. 1B). Furthermore, we analyzed the 
expression of the proximal tubular Na+/H+ exchanger NHE3 by qPCR. The HN/LK group 
showed a significant downregulation of Slc9a3, the gene encoding NHE3 (Fig. 1C), 
compared to groups fed a normal K+ (NN/NK and HN/NK). 
After establishing that the dietary intervention resulted in electrolyte changes, serum 
levels and 24-hour urine excretion of Ca2+ and Mg2+ were analyzed. There were no 
differences in serum Mg2+ levels or urinary Mg2+ excretion between the groups (Fig. 2, A and 
B). Interestingly, Ca2+ excretion was elevated upon high Na+ intake and an additional rise 
was demonstrated in the HN/LK group compared to HN/NK (Fig. 2C). Serum Ca2+ levels 
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were also significantly decreased in the HN/LK group, while no changes were observed for 
the mice fed a HN/NK diet (Fig. 2D). In addition, phosphate (Pi) levels in urine and serum 
were examined. Urinary Pi excretion was significantly higher in mice fed a high Na+ diet, 
independent of dietary K+. Serum Pi was not different between the groups (Fig. 2, E and F).  
 
Table 2. Metabolic parameters. 
Mice were fed the indicated diets for 4 days and were kept in individual metabolic cages for the last 
24 hours. Values are depicted as mean +/- SEM (n=10). Significant differences are indicated as: a = 
p<0.05 compared to NN/NK, b = p<0.05 compared to NN/LK, and c = p<0.05 compared to HN/NK. 
 
Table 3. Electrolyte levels in serum and urine. 
Data were collected after housing the mice in metabolic cages for the last 24 hours. Urinary excretion 
(24h) and serum levels of Na+, K+, and Cl- from mice kept on the indicated diets are shown as mean 
+/- SEM (n=10), and significance is indicated as: a = p<0.05 compared to NN/NK, b = p<0.05 
compared to NN/LK, and c = p<0.05 compared to HN/NK. 
 
Expression of renal electrolyte transporters 
The expression of genes encoding for proteins involved in Mg2+ (re)absorption in kidney and 
intestine was analyzed in the different groups using RT-qPCR (Fig. 3). Renal transcript 
levels of Trpm6, encoding the apical Mg2+ channel TRPM6, were significantly higher in the 
high Na+ groups, while no significant differences were observed for Trpm6 expression levels 
in colon (Fig. 3, A and C). Of note, the renal expression of Trpm7, encoding the ubiquitous 
Mg2+ channel, was significantly lower in the HN/LK group (Fig. 3B).  
Next, the expression of several calciotropic genes in kidney and intestine was examined. 
There was no difference between the groups in the expression levels of renal Trpv5 or 
intestinal Trpv6, coding for luminal epithelial Ca2+ channels in the kidney and duodenum, 
 NN/NK NN/LK HN/NK HN/LK 
Body weight (g) 24.0 +/- 0.3 23.7 +/- 0.3 23.4 +/- 0.3 23.1 +/- 0.3 
Food intake (g) 3.4 +/- 0.2 3.8 +/- 0.5 3.0 +/- 0.2 3.4 +/- 0.2 
Water intake (ml) 3.2 +/- 0.6 3.9 +/- 0.5 6.6 +/- 0.6a 9.4 +/- 1.4a,b 
Urine volume (ml) 1.4 +/-0.1 1.7 +/- 0.3 4.4 +/- 0.4a,b 5.9 +/- 0.7a,b 
 NN/NK NN/LK HN/NK HN/LK 
Serum electrolytes (mM)    
Na+ 157 +/- 1 157 +/- 1 159 +/- 1 163 +/- 1a,b.c 
Cl- 113 +/- 1 107 +/- 1a 112 +/- 1b 115 +/- 1b 
K+ 5.2 +/- 0.1 4.3 +/- 0.2a 5.3 +/- 0.1b 3.9 +/- 0.1a,c 
Urine  electrolytes (µmol/24h)    
Na+ 230 +/- 19 131 +/- 10 1939 +/- 146a,b 1847 +/- 155a,b 
Cl- 530 +/- 44 155 +/- 14a 2444 +/- 195a,b 2023 +/- 155a,b 
K+ 502 +/- 40 12.3 +/- 1.7a 549 +/- 32b 26.8 +/- 2.5a,c 
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respectively (Fig. 4, A and B). Immunohistochemical analysis of mouse kidney sections also 
showed that there are no differences in TRPV5 protein abundance between the groups (Fig. 
5, A and B). The sections were co-stained with NCC to confirm localization of TRPV5 in the 
DCT2, and demonstrate that NCC protein expression was not altered (Fig. 5, A and B). 
Interestingly, the expression levels of the genes coding for the basolateral Ca2+ transporter 
NCX1 (Slc8a1) and for Ca2+-binding protein calbindin-D28k (CaBP28k) were significantly 
downregulated upon a low dietary K+ intake (Fig. 4, C and D). This restored to control levels 
by addition of high Na+, as the HN/LK group had significantly higher expression levels than 
NN/LK and did not significantly differ from NN/NK (Fig. 4, C and D). In addition, the high Na+ 
diet (both HN/NK and HN/LK) was shown to increase CaBP28k protein levels in the kidney 
cortex (Fig. 4E). 
The expression of several members of the paracellular pathway was also investigated. 
Claudin-16, -19 play an important role in transport of Ca2+ and Mg2+ in the TAL (26). While 
renal expression of Cldn19 was not different, the Cldn16 expression significantly decreased 
in mice fed a low K+ diet (Fig. 3D). In addition, claudin-14 expression was examined as it is 
thought to be involved in claudin-16/19 function (22). There were no differences in Cldn14 
expression (Fig. 3E). Furthermore, expression of claudin-2, which participates in paracellular 
Ca2+ transport in the proximal tubule (33), is unaltered by the diet (Fig. 4F). 
In order to assess the differences in urinary Pi excretion, expression of phosphate 
transporters was examined. The major part of filtered Pi is reabsorbed in the proximal tubule 
by the Na+-dependent Pi cotransporters NaPi-2a and NaPi-2c (45). Genes encoding these 
transporters, Napi2a and Napi2c, respectively, were significantly downregulated in mice fed 
a HN/LK diet compared to control (NN/NK) (Fig. 6, A and B). Of note, Napi2c was also 
expressed significantly lower in the NN/LK group compared to NN/NK and HN/NK groups. 
Immunoblotting confirmed the mRNA expression data of Napi2a demonstrating a lower renal 
NaPi-2a protein expression in the HN/LK group compared to control (Fig. 6, C and D). In 
addition, NaPi-2c protein levels were significantly lower in the mice fed the high salt/low K+ 
diet compared to other groups (Fig. 6, C and D). 
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Figure 1 | Immunoblot analysis of NCC and pNCC (pT58) in kidney cortex from mice fed the 
indicated diet (left panel).  
(A) Immunoblot analysis of NCC and pNCC (pT58) in kidney cortex from mice fed the indicated diet 
(left panel). Bar graph of the densitometry shows relative pNCC/NCC protein expression (right panel). 
(B) Immunoblot analysis of NKCC2 in kidney cortex from mice fed the indicated diet (left panel). 
Arrows indicate monomeric and dimeric form of NKCC2. Bar graph of the densitometry shows NKCC2 
protein expression (right panel, corrected for b-actin). Data is shown as mean +/- SEM (n=5). 
Significance is indicated as: a = p<0.05 compared to NN/NK and c = p<0.05 compared to HN/NK. 
 
Chapter 6                                               High Na+/low K+ affects calcium and phosphate homeostasis | 
 
146 
 
Figure 2 | Effect of dietary Na+ and K+ intake on urine and serum Mg2+, Ca2+, and Pi levels. 
(A and B) Urine Mg2+ excretion (24h) and serum Mg2+ from mice kept on the indicated diets. (C and 
D) Urine Ca2+ excretion (24h) and serum Ca2+ from mice kept on the indicated diets. (E and F) Urine 
Pi excretion (24h) and serum Pi from mice kept on the indicated diets. Significant differences are 
indicated as: a = p<0.05 compared to NN/NK, b = p<0.05 compared to NN/LK, and c = p<0.05 
compared to HN/NK. 
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Figure 3 | The mRNA expression levels of the Mg2+ channels coding genes Trpm6 and Trpm7 
in colon and kidney.  
(A-C) Relative mRNA expression levels (corrected for GAPDH) are shown for Trpm6 (A) and Trpm7 
(B) in the kidney, as well as for Trpm6 in the distal colon (C). Data are shown as mean +/- SEM 
(n=10), a = p<0.05 compared to NN/NK, b = p<0.05 compared to NN/LK. D-F) Relative mRNA 
expression levels (corrected for GAPDH) are shown for Cldn16 (D), Cldn19 (E), and Cldn14 (F) in the 
kidney. 
Chapter 6                                               High Na+/low K+ affects calcium and phosphate homeostasis | 
 
148 
 
  
 
Figure 4 | The expression levels of calciotropic genes in kidney and duodenum.  
(A-D) Relative mRNA expression levels (corrected for GAPDH) are shown for Trpv5 (A), Ncx1 (C), 
and CaBP28k (D) in the kidney, as well as for Trpv6 (B) in the proximal duodenum. Data are shown as 
mean +/- SEM (n=10). (E) Immunoblot analysis of CaBP28k in kidney cortex from mice fed the 
indicated diet (right panel). Bar graph of the densitometry shows relative CaBP28k protein expression 
(left panel) as mean +/- SEM (n=5). Significance is indicated as: a = p<0.05 compared to NN/NK, b = 
p<0.05 compared to NN/LK, and c = p<0.05 compared to HN/NK. (F) Relative mRNA expression 
levels (corrected for GAPDH) for Cldn2 in the kidney. 
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Figure 5 | Protein expression of TRPV5 in kidney.  
(A) Representative microphotographs are shown for TRPV5 (green) and NCC (red) protein 
expression in mouse kidney tissue, with a 10x (upper) and 40x (lower) magnification. Groups are 
indicated above the images. (B) Protein expression of TRPV5 and NCC was quantified by 
fluorescence microscopy (Leica DMI6000B). Bar graph of the analysis shows arbitrary units for 
TRPV5 and NCC protein expression as mean +/- SEM (n=10). 
 
Hormonal regulation upon dietary intervention 
To assess the effect of the dietary regimes on hormonal regulation, the expression of renin 
in the kidney as well as APRC was examined. Both renin mRNA expression and APRC were 
significantly lower in the high Na+ conditions (HN/NK and HN/LK), but there was no 
difference upon K+ restriction in a high Na+ diet (Fig. 7, A and B). Of note, K+ restriction 
alone (NN/LK) led to higher APRC compared to all other groups (Fig. 7B). 
Next, the expression of Cyp27b1 and Cyp24a1, encoding for proteins that are 
responsible for the production and degradation of active vitamin D, respectively, was 
examined. While renal Cyp24a1 expression levels did not differ between the groups, the 
Chapter 6                                               High Na+/low K+ affects calcium and phosphate homeostasis | 
 
150 
expression of Cyp27b1 was lower in the groups fed either a low K+ (NN/LK), high Na+ 
(HN/NK) or a combined (HN/LK) diet compared to control (Fig. 7, C and D). Moreover, the 
expression was lowest in the HN/LK group, which was significant compared to HN/NK (Fig. 
7C). 
In order to understand whether hormones involved in the maintenance of the Ca2+ 
balance were altered, plasma PTH (PTH 1-84) and FGF23 (FGF23 C-term.) levels were 
analyzed. There were no differences in these hormone levels between the groups (Fig. 7, E 
and F). 
 
Figure 6 | Effect of dietary Na+ and K+ intake on renal Pi transporters.  
(A and B) Relative mRNA expression levels (corrected for GAPDH) are shown for Napi2a (A) and 
Napi2c (B) in the kidney. Data are shown as mean +/- SEM (n=10). (C) Immunoblot of NaPi-2a and 
Napi-2c in kidney cortex from mice fed the indicated diet (right panel). (D) Bargraph of the 
densitometry shows relative NaPi-2a (left panel) and NaPi-2c (right panel) protein expression as 
mean +/- SEM (n=5).  a = p<0.05 compared to NN/NK, b = p<0.05 compared to NN/LK. 
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Figure 7 | Hormonal regulation upon changes in dietary Na+ and K+ intake.  
Relative mRNA expression levels (corrected for GAPDH) are shown for renin (A), Cyp27b1 (C), and 
Cyp24a1 (D) in the kidney. Data are shown as mean +/- SEM (n=10). (B) Active plasma renin 
concentration (APRC) is measured as the amount of angiotensin I (Ang I) generated per volume per 
time in the presence of excess angiotensinogen. Data are shown as mean +/- SEM (n=10). 
Significance is indicated as: a = p<0.05 compared to NN/NK, b = p<0.05 compared to NN/LK, and c = 
p<0.05 compared to HN/NK. (E-F) Plasma PTH (E) and FGF23 (F) levels were measured in the 
different groups of mice. Data represents single values and depicts mean +/- SEM (n=3-5). 
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Discussion 
The present study demonstrates that a diet containing high Na+ with low K+ can have 
significant effects on renal Ca2+ handling, while not affecting the Mg2+ balance. Serum and 
urine Mg2+ levels were not changed upon 4 days of diet. In contrast, the urinary Ca2+ 
excretion was significantly enhanced by high Na+ intake, which was aggravated upon 
lowering dietary K+ in combination with high Na+. The latter also resulted in decreased serum 
Ca2+ levels. In addition, there was a significant increase in urinary Pi excretion upon high Na+ 
intake. This study provides more insight into the effects of an altered Na+ and K+ intake on 
renal Ca2+, Mg2+, and Pi handling and offers further insight into the observed molecular 
changes in the kidney.  
There is a growing body of evidence demonstrating that dietary K+ intake associates 
inversely with blood pressure, often as strong as the positive correlation with dietary salt (1, 
2, 17, 21, 31, 34). Importantly, it has recently been postulated that low blood K+ levels are a 
key regulator of renal Na+ reabsorption through stimulation of NCC-mediated Na+ transport 
in the DCT (53). Our study demonstrated that low dietary K+ intake enhances pNCC 
abundance in both NN/LK and HN/LK conditions, in line with a previous study by Terker et al. 
(53). In order to preserve extracellular fluid (ECF) volume, hence blood pressure, NCC is 
phosphorylated and activated via the renin-angiotensin-aldosterone system (RAAS) during 
dietary salt restriction (53). We showed an enhanced NCC phosphorylation despite low 
RAAS activation at HN/LK condition. Suppressed activation of RAAS was validated by 
decreased APRC in both HN/NK and HN/LK conditions. Together, this indicates that the 
effect of K+ deficiency is more powerful than ECF volume by controlling Na+ reabsorption in 
the DCT. High dietary K+ was shown to suppress NCC phosphorylation during low Na+ 
conditions likely to preserve kaliuresis (57).  
Next to regulating Na+ reabsorption, the DCT is also the main segment of active Mg2+ 
transport. The Mg2+ permeable channel TRPM6 is considered the gatekeeper of the Mg2+ 
balance as it determines the final urinary Mg2+ excretion (59). Importantly, our study showed 
that high Na+ and/or K+ deficiency does not affect Mg2+ transport in the DCT in a similar way 
as Na+ transport, suggesting that the signaling pathway affecting NCC function is not linked 
to TRPM6-mediated transport. In contrast, a previous study demonstrated increased urinary 
Mg2+ excretion in rats fed a high Na+ diet (29). This discrepancy could be due to the period 
of the diets (7 days versus 4 days), suggesting a time-dependent effect. A high Na+ diet 
likely reduces paracellular Mg2+ transport in the proximal tubule and the TAL, resulting in an 
increased distal delivery of Mg2+ that is subsequently responsible for the observed 
upregulation of TRPM6. This could be the first defense mechanism to maintain blood Mg2+ 
levels constant. 
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While the various diets had no major effect on renal Mg2+ handling, there were 
prominent outcomes on urinary Ca2+ excretion and serum Ca2+ levels. Ca2+ homeostasis is 
maintained through the interplay between the intestines, bone, and kidney. Dietary Ca2+ is 
absorbed via the intestine into the blood, subsequently filtered by the glomerulus and 
reabsorbed along the nephron or stored in bone. The amount of filtered Ca2+ that is not 
reabsorbed along the nephrons will be excreted in the urine, demonstrating the important 
role of the kidney in the Ca2+ balance. An inappropriately high amount of urinary Ca2+ 
excretion, also known as hypercalciuria, contributes to the development of osteoporosis and 
kidney stone formation (4, 13). It has been established that a high salt diet induces 
hypercalciuria (12, 16), and that restricted salt intake is often used for prevention of kidney 
stones recurrence, particularly in cases of Ca2+-containing stones (14, 30, 43, 47). Together, 
there is a clinical association between salt intake, hypertension, hypercalciuria and 
increased risk of kidney stones (10, 55). Interestingly, our study reveals a rapid renal 
response to dietary changes as inappropriate loss of urinary Ca2+ was observed in the 
HN/LK diet group after 4 days. Furthermore, urinary Pi excretion follows the same trend and 
is also significantly elevated in the HN/LK-fed mice. This is particularly interesting given the 
fact that ~10% of all kidney stones are calcium-phosphate stones (61). Our findings 
demonstrated that short-term dietary changes can already result in hypercalciuria and 
phosphaturia, which are important risk factors for stone formation. There is an increasing 
interest in dietary intervention for kidney stone prevention and a diet high in K+ was recently 
associated with a lower risk of kidney stones (18). Future studies should aim at 
understanding the underlying molecular effects of low salt and high K+ diet on progression of 
age-related bone loss and development of kidney stones.   
The effect on urinary Ca2+ and Pi excretion suggests that the high Na+/low K+ diet 
initially affects proximal tubular reabsorption. It is widely assumed that the degree of 
hypercalciuria increases proportionately with the amount of Na+ excreted in the urine and 
that dietary Na+ restriction can decrease urinary Ca2+ excretion in both stone formers and 
healthy individuals (28, 37, 47, 52, 54). Earlier micropuncture studies have also 
demonstrated that Ca2+ reabsorption correlates with Na+ reabsorption along the proximal 
tubule (39). Our study now demonstrated a reduced NHE3 expression, which indicates that 
Na+ reabsorption in the proximal tubule could be reduced. Though, there was no increased 
urinary Na+ excretion in the HN/LK group compared to high Na+ diet alone, while urinary 
Ca2+ was significantly enhanced upon dietary K+ depletion in combination with high Na+ 
(HN/LK). This suggests an additional effect of low plasma K+ levels on renal Ca2+ handling, 
next to the proposed Na+-dependent Ca2+ reabsorption in the proximal tubule (51). We 
propose that the TAL-mediated reabsorption could be altered as a result of low K+ diet. Both 
groups of mice, either NN/LK or HN/LK, have lower NKCC2 and claudin-16 expression. 
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Therefore, we propose that the high Na+ diet alone mainly affects proximal tubular 
reabsorption via extracellular fluid expansion, resulting in increased urinary Ca2+ and Pi 
excretion. But the aggravated hypercalciuria in HN/LK animals might be due to a combined 
effect on the proximal tubule and TAL, which could not be completely compensated by the 
DCT. Furthermore, Terker et al. showed that NCC activation plays an essential role in the 
Ca2+ excretion under low K+ condition. NCC knockout mice exhibited a diminished urinary 
Ca2+ excretion upon receiving a HN/LK diet (53). Our study demonstrated that CaBP28k 
protein levels were significantly enhanced in the high Na+ groups, suggesting a 
compensatory mechanism for increased Ca2+ transport in the DCT. However, there was no 
change in expression of the apical Ca2+ channel TRPV5. Though, it should be noted that 
expression changes do not necessarily reflect alterations in protein function and transport 
capacity.  
The body usually compensates for urinary Ca2+ loss by increased intestinal absorption 
of Ca2+. Importantly, TRPV6 expression was not changed in duodenum, the main site for 
active (regulated) Ca2+ absorption. However, we demonstrated downregulation of renal 
Cyp27b1, encoding for 25-hydroxyvitamin D3 1-alpha-hydroxylase (1α-hydroxylase), in the 
groups receiving either a low K+ diet (NN/LK) or high Na+ diet (HN/NK), or a combination diet 
(HN/LK). The 1α-hydroxylase is responsible for the generation of active vitamin D, which in 
turn acts towards increasing serum Ca2+ levels. Vitamin D can act towards increasing serum 
Ca2+ levels by stimulating intestinal Ca2+ absorption, renal Ca2+ reabsorption, and Ca2+ 
release from bone (19). Lower levels of this enzyme could partly explain the unchanged 
TRPV5 and TRPV6 mRNA expression despite extreme hypercalciuria. The Cyp27b1 
expression in the HN/LK group was even significantly lower than high Na+ alone (HN/NK), in 
line with an aggravated hypercalciuria.  
Interestingly, the trend of Cyp27b1 expression coincided with that of Napi2c in the 
different dietary groups, as well as Napi2a downregulation in the HN/LK group. NaPi-2a and 
NaPi-2c protein levels were also significantly reduced in this group, which is in line with the 
phosphaturic response upon a HN/LK diet. Of note, it is proposed that the abundance of 
NaPi-2a protein reflects the capacity of the kidney to reabsorb Pi (5, 32). In contrast to our 
results, previous studies reported a significant decrease in NaPi-2c protein abundance upon 
longer (14 days) dietary K+-deficiency in rats and mice, while the abundance of NaPi-2a 
increased (8, 62). This discrepancy could be due to the different dietary time frames (4 vs. 
14 days) as we did not observe hyperphosphaturia or hypophosphatemia upon diet-induced 
hypokalemia by the low K+ diet alone. The lack of changes in urinary or plasma Pi levels 
could also be explained by the significantly elevated APRC in the NN/LK group, which 
induces high angiontensin II levels that in turn stimulate proximal tubular reabsorption of Na+ 
and other electrolytes. 
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In addition, it would be interesting to examine the effect of the diets on serum FGF23 
and PTH levels. There is a clear interrelationship between hormonal control of Ca2+ and Pi 
handling, which involves the PTH-FGF23-vitamin D axis (6). While vitamin D is known to 
regulate intestinal Pi absorption, it has not been established whether vitamin D is directly 
involved in the regulation of renal Pi reabsorption. There are vitamin D-responsive elements 
in human genes encoding NaPi-2a and NaPi-2c, but data regarding its effect on expression 
have remained controversial so far (11, 20, 27). Vitamin D is known to act in concert with 
FGF23 and PTH to control renal Pi and Ca2+ reabsorption. For example, FGF23 can have 
instant effects on Pi homeostasis through reduction of renal NaPi-2a and Cyp27b1 levels 
(46). Interestingly, it was recently shown in mice deficient in Fgf23 that FGF23 can regulate 
renal Na+ reabsorption via altering NCC expression and function (3). We have examined the 
effect of the diets on serum FGF23 and PTH levels, but did not find changes in response to 
the diets. Future studies should increase our understanding of the role of PTH-FGF23-
vitamin D axis in high Na+ and/or low K+ diet-induced changes in electrolyte handling. 
In conclusion, during short-term modification of Na+ and K+ intake, the kidney rapidly 
develops adaptation with corresponding changes in urinary electrolyte excretion. Our results 
suggest that instant dietary modifications have primary effects on proximal tubular 
reabsorption with a compensatory response in the DCT. As the majority of Ca2+ and Pi is 
reabsorbed in the proximal tubule, the distal part of the nephron is unable to recover for the 
excessive loss, while the mechanism is sufficient to maintain Mg2+ homeostasis.   
 
Acknowledgements 
The authors thank Anique ter Braake, Iza Peilouw, and Elco Eidhof for their assistance with 
the animal experiments.  
 
Grants 
This study was financially supported by the Netherlands Organization for Scientific Research 
(VENI 863.13.010 and VICI 016.130.668) and the Dutch Kidney Foundation (PHD12.14, 
CP16.01). 
 
Disclosures  
No conflicts of interest, financial or otherwise, are declared by the authors. 
 
 
Chapter 6                                               High Na+/low K+ affects calcium and phosphate homeostasis | 
 
156 
Author contribution  
J.W., O.A.T., J.G.J.H., and R.J.M.B. conceived and designed the research; J.W., O.A.T., 
and C.B. performed the experiments; J.W. and O.A.T. analyzed the data and drafted the 
manuscript; A.H.J.D. performed the APRC analysis. E.J.H., J.G.J.H., and R.J.M.B. edited, 
revised and approved the manuscript. Funding acquisition is done by J.W., J.G.J.H., and 
R.J.M.B. 
 
Chapter 6                                               High Na+/low K+ affects calcium and phosphate homeostasis | 
 
157 
References 
1. Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FP. Effect of increased 
potassium intake on cardiovascular risk factors and disease: systematic review and meta-
analyses. BMJ 346: f1378–f1378, 2013. 
2. Adrogué HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N Engl J 
Med 356: 1966–1978, 2007. 
3. Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B, Pohl EE, Erben 
RG. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med 6: 744–759, 
2014. 
4. Asplin JR, Donahue S, Kinder J, Coe FL. Urine calcium excretion predicts bone loss in 
idiopathic hypercalciuria. Kidney Int 70: 1463–1467, 2006. 
5. Beck L, Karaplis AC, Amizuka N, Hewson AS, Ozawa H, Tenenhouse HS. Targeted 
inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and 
skeletal abnormalities. Proc Natl Acad Sci USA 95: 5372–5377, 1998. 
6. Blau JE, Collins MT. The PTH-Vitamin D-FGF23 axis. Rev Endocr Metab Disord 16: 165–174, 
2015. 
7. Boyden LM, Choi M, Choate KA, Nelson-Williams CJ, Farhi A, Toka HR, Tikhonova IR, 
Bjornson R, Mane SM, Colussi G, Lebel M, Gordon RD, Semmekrot BA, Poujol A, Välimäki 
MJ, De Ferrari ME, Sanjad SA, Gutkin M, Karet FE, Tucci JR, Stockigt JR, Keppler-Noreuil KM, 
Porter CC, Anand SK, Whiteford ML, Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha 
CW, Hunley TE, Nelson RD, Trachtman H, Cole TRP, Pinsk M, Bockenhauer D, Shenoy M, 
Vaidyanathan P, Foreman JW, Rasoulpour M, Thameem F, Al-Shahrouri HZ, Radhakrishnan J, 
Gharavi AG, Goilav B, Lifton RP. Mutations in kelch-like 3 and cullin 3 cause hypertension and 
electrolyte abnormalities. Nature 482: 98–102, 2012. 
8. Breusegem SY, Takahashi H, Giral-Arnal H, Wang X, Jiang T, Verlander JW, Wilson P, 
Miyazaki-Anzai S, Sutherland E, Caldas Y, Blaine JT, Segawa H, Miyamoto K-I, Barry NP, 
Levi M. Differential regulation of the renal sodium-phosphate cotransporters NaPi-IIa, NaPi-IIc, 
and PiT-2 in dietary potassium deficiency. Am J Physiol Renal Physiol 297: F350–61, 2009. 
9. Campbell DJ, Nussberger J, Stowasser M, Danser AHJ, Morganti A, Frandsen E, Ménard J. 
Activity assays and immunoassays for plasma Renin and prorenin: information provided and 
precautions necessary for accurate measurement. Clin Chem 55: 867–877, 2009. 
10. Cappuccio FP, Kalaitzidis R, Duneclift S, Eastwood JB. Unravelling the links between calcium 
excretion, salt intake, hypertension, kidney stones and bone metabolism. J Nephrol 13: 169–
177, 2000. 
11. Capuano P, Radanovic T, Wagner CA, Bacic D, Kato S, Uchiyama Y, St-Arnoud R, Murer H, 
Biber J. Intestinal and renal adaptation to a low-Pi diet of type II NaPi cotransporters in vitamin 
D receptor- and 1alphaOHase-deficient mice. Am J Physiol, Cell Physiol 288: C429–34, 2005. 
12. Cirillo M, Ciacci C, Laurénzi M, Mellone M, Mazzacca G, De Santo NG. Salt intake, urinary 
sodium, and hypercalciuria. Miner Electrolyte Metab 23: 265–268, 1997. 
13. Coe FL, Worcester EM, Evan AP. Idiopathic hypercalciuria and formation of calcium renal 
stones. Nature Reviews Nephrology 12: 519–533, 2016. 
14. Colussi G, Surian M, De Ferrari ME, Pontoriero G, Rombolà G, Brando B, Malberti F, Cosci P, 
Aroldi A, Castelnovo C. Relationship between sodium intake, proximal tubular function and 
calcium excretion in normal subjects and in idiopathic hypercalciuria. Proc Eur Dial Transplant 
Assoc 20: 455–459, 1983. 
15. Custer M, Lötscher M, Biber J, Murer H, Kaissling B. Expression of Na-P(i) cotransport in rat 
kidney: localization by RT-PCR and immunohistochemistry. Am J Physiol 266: F767–74, 1994. 
16. Damasio PCG, Amaro CRPR, Cunha NB, Pichutte AC, Goldberg J, Padovani CR, Amaro JL. 
The role of salt abuse on risk for hypercalciuria. Nutr J 10: 3, 2011. 
17. Ekmekcioglu C, Elmadfa I, Meyer AL, Moeslinger T. The role of dietary potassium in 
hypertension and diabetes. J Physiol Biochem 72: 93–106, 2016. 
18. Ferraro PM, Mandel EI, Curhan GC, Gambaro G, Taylor EN. Dietary Protein and Potassium, 
Diet-Dependent Net Acid Load, and Risk of Incident Kidney Stones. Clin J Am Soc Nephrol 
11: 1834–1844, 2016. 
19. Fleet JC. The role of vitamin D in the endocrinology controlling calcium homeostasis. Mol. Cell. 
Chapter 6                                               High Na+/low K+ affects calcium and phosphate homeostasis | 
 
158 
Endocrinol. (April 9, 2017). doi: 10.1016/j.mce.2017.04.008. 
20. Friedlaender MM, Wald H, Dranitzki-Elhalel M, Zajicek HK, Levi M, Popovtzer MM. Vitamin D 
reduces renal NaPi-2 in PTH-infused rats: complexity of vitamin D action on renal P(i) handling. 
Am J Physiol Renal Physiol 281: F428–33, 2001. 
21. Geleijnse JM, Kok FJ, Grobbee DE. Blood pressure response to changes in sodium and 
potassium intake: a metaregression analysis of randomised trials. J Hum Hypertens 17: 471–
480, 2003. 
22. Gong Y, Renigunta V, Himmerkus N, Zhang J, Renigunta A, Bleich M, Hou J. Claudin-14 
regulates renal Ca⁺⁺ transport in response to CaSR signalling via a novel microRNA pathway. 
EMBO J 31: 1999–2012, 2012. 
23. Hadchouel J, Ellison DH, Gamba G. Regulation of Renal Electrolyte Transport by WNK and 
SPAK-OSR1 Kinases. Annu Rev Physiol 78: 367–389, 2016. 
24. Havas S, Roccella EJ, Lenfant C. Reducing the public health burden from elevated blood 
pressure levels in the United States by lowering intake of dietary sodium. Am J Public Health 
94: 19–22, 2004. 
25. Hoenderop JG, Hartog A, Stuiver M, Doucet A, Willems PH, Bindels RJ. Localization of the 
epithelial Ca(2+) channel in rabbit kidney and intestine. J Am Soc Nephrol 11: 1171–1178, 
2000. 
26. Hou J, Goodenough DA. Claudin-16 and claudin-19 function in the thick ascending limb. Curr 
Opin Nephrol Hypertens 19: 483–488, 2010. 
27. Kido S, Kaneko I, Tatsumi S, Segawa H, Miyamoto K-I. Vitamin D and type II sodium-
dependent phosphate cotransporters. Contrib Nephrol 180: 86–97, 2013. 
28. KLEEMAN CR, BOHANNAN J, BERNSTEIN D, LING S, MAXWELL MH. EFFECT OF 
VARIATIONS IN SODIUM INTAKE ON CALCIUM EXCRETION IN NORMAL HUMANS. Proc 
Soc Exp Biol Med 115: 29–32, 1964. 
29. Lee C-T, Lien Y-HH, Lai L-W, Ng H-Y, Chiou TT-Y, Chen H-C. Variations of dietary salt and 
fluid modulate calcium and magnesium transport in the renal distal tubule. Nephron Physiol 
122: 19–27, 2012. 
30. Martini LA, Cuppari L, Colugnati FA, Sigulem DM, Szejnfeld VL, Schor N, Heilberg IP. High 
sodium chloride intake is associated with low bone density in calcium stone-forming patients. 
Clin Nephrol 54: 85–93, 2000. 
31. Mente A, O'Donnell MJ, Rangarajan S, McQueen MJ, Poirier P, Wielgosz A, Morrison H, Li W, 
Wang X, Di C, Mony P, Devanath A, Rosengren A, Oguz A, Zatonska K, Yusufali AH, Lopez-
Jaramillo P, Avezum A, Ismail N, Lanas F, Puoane T, Diaz R, Kelishadi R, Iqbal R, Yusuf R, 
Chifamba J, Khatib R, Teo K, Yusuf S, PURE Investigators. Association of urinary sodium and 
potassium excretion with blood pressure. N Engl J Med 371: 601–611, 2014. 
32. Murer H, Hernando N, Forster I, Biber J. Proximal tubular phosphate reabsorption: molecular 
mechanisms. Physiol Rev 80: 1373–1409, 2000. 
33. Muto S, Hata M, Taniguchi J, Tsuruoka S, Moriwaki K, Saitou M, Furuse K, Sasaki H, Fujimura 
A, Imai M, Kusano E, Tsukita S, Furuse M. Claudin-2-deficient mice are defective in the leaky 
and cation-selective paracellular permeability properties of renal proximal tubules. Proc Natl 
Acad Sci USA 107: 8011–8016, 2010. 
34. O'Donnell M, Mente A, Rangarajan S, McQueen MJ, Wang X, Liu L, Yan H, Lee SF, Mony P, 
Devanath A, Rosengren A, Lopez-Jaramillo P, Diaz R, Avezum A, Lanas F, Yusoff K, Iqbal R, 
Ilow R, Mohammadifard N, Gulec S, Yusufali AH, Kruger L, Yusuf R, Chifamba J, Kabali C, 
Dagenais G, Lear SA, Teo K, Yusuf S, PURE Investigators. Urinary sodium and potassium 
excretion, mortality, and cardiovascular events. N Engl J Med 371: 612–623, 2014. 
35. Pacheco-Alvarez D, Cristóbal PS, Meade P, Moreno E, Vázquez N, Muñoz E, Díaz A, Juárez 
ME, Giménez I, Gamba G. The Na+:Cl- cotransporter is activated and phosphorylated at the 
amino-terminal domain upon intracellular chloride depletion. J Biol Chem 281: 28755–28763, 
2006. 
36. Pedersen NB, Hofmeister MV, Rosenbaek LL, Nielsen J, Fenton RA. Vasopressin induces 
phosphorylation of the thiazide-sensitive sodium chloride cotransporter in the distal convoluted 
tubule. Kidney Int 78: 160–169, 2010. 
37. Phillips MJ, Cooke JN. Relation between urinary calcium and sodium in patients with idiopathic 
hypercalciuria. Lancet 1: 1354–1357, 1967. 
38. Piala AT, Moon TM, Akella R, He H, Cobb MH, Goldsmith EJ. Chloride sensing by WNK1 
Chapter 6                                               High Na+/low K+ affects calcium and phosphate homeostasis | 
 
159 
involves inhibition of autophosphorylation. Sci Signal 7: ra41–ra41, 2014. 
39. Poujeol P, Chabardes D, Roinel N, de Rouffignac C, Philippe P, Malorey P. Influence of 
extracellular fluid volume expansion on magnesium, calcium and phosphate handling along 
the rat nephron. Pflugers Arch 365: 203–211, 1976. 
40. Rengarajan S, Lee DH, Oh YT, Delpire E, Youn JH, McDonough AA. Increasing plasma [K+] 
by intravenous potassium infusion reduces NCC phosphorylation and drives kaliuresis and 
natriuresis. Am J Physiol Renal Physiol 306: F1059–68, 2014. 
41. Resnick LM, Bardicef O, Altura BT, Alderman MH, Altura BM. Serum ionized magnesium: 
relation to blood pressure and racial factors. Am J Hypertens 10: 1420–1424, 1997. 
42. Rinner MD, Spliet-van Laar L, Kromhout D. Serum sodium, potassium, calcium and 
magnesium and blood pressure in a Dutch population. J Hypertens 7: 977–981, 1989. 
43. Robertson WG. Dietary recommendations and treatment of patients with recurrent idiopathic 
calcium stone disease. Urolithiasis 44: 9–26, 2016. 
44. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, 
Miller ER, Simons-Morton DG, Karanja N, Lin PH, DASH-Sodium Collaborative Research 
Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to 
Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 
344: 3–10, 2001. 
45. Segawa H, Onitsuka A, Furutani J, Kaneko I, Aranami F, Matsumoto N, Tomoe Y, Kuwahata 
M, Ito M, Matsumoto M, Li M, Amizuka N, Miyamoto K-I. Npt2a and Npt2c in mice play distinct 
and synergistic roles in inorganic phosphate metabolism and skeletal development. Am J 
Physiol Renal Physiol 297: F671–8, 2009. 
46. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, 
Fukumoto S, Yamashita T. FGF-23 is a potent regulator of vitamin D metabolism and 
phosphate homeostasis. J Bone Miner Res 19: 429–435, 2004. 
47. Silver J, Rubinger D, Friedlaender MM, Popovtzer MM. Sodium-dependent idiopathic 
hypercalciuria in renal-stone formers. Lancet 2: 484–486, 1983. 
48. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, Vaara I, Iwata F, 
Cushner HM, Koolen M, Gainza FJ, Gitleman HJ, Lifton RP. Gitelman“s variant of Bartter”s 
syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive 
Na-Cl cotransporter. Nat Genet 12: 24–30, 1996. 
49. Sorensen MV, Grossmann S, Roesinger M, Gresko N, Todkar AP, Barmettler G, Ziegler U, 
Odermatt A, Loffing-Cueni D, Loffing J. Rapid dephosphorylation of the renal sodium chloride 
cotransporter in response to oral potassium intake in mice. Kidney Int 83: 811–824, 2013. 
50. Subramanya AR, Ellison DH. Distal convoluted tubule. Clin J Am Soc Nephrol 9: 2147–2163, 
2014. 
51. Sutton RA, Dirks JH. The renal excretion of calcium: a review of micropuncture data. Can J 
Physiol Pharmacol 53: 979–988, 1975. 
52. Sutton RA, Walker VR. Responses to hydrochlorothiazide and acetazolamide in patients with 
calcium stones. Evidence suggesting a defect in renal tubular function. N Engl J Med 302: 
709–713, 1980. 
53. Terker AS, Zhang C, McCormick JA, Lazelle RA, Zhang C, Meermeier NP, Siler DA, Park HJ, 
Fu Y, Cohen DM, Weinstein AM, Wang W-H, Yang C-L, Ellison DH. Potassium modulates 
electrolyte balance and blood pressure through effects on distal cell voltage and chloride. Cell 
Metab 21: 39–50, 2015. 
54. Ticinesi A, Nouvenne A, Maalouf NM, Borghi L, Meschi T. Salt and nephrolithiasis. Nephrol 
Dial Transplant 31: 39–45, 2016. 
55. Timio F, Kerry SM, Anson KM, Eastwood JB, Cappuccio FP. Calcium urolithiasis, blood 
pressure and salt intake. Blood Press 12: 122–127, 2003. 
56. Vallon V, Schroth J, Lang F, Kuhl D, Uchida S. Expression and phosphorylation of the Na+-Cl- 
cotransporter NCC in vivo is regulated by dietary salt, potassium, and SGK1. Am J Physiol 
Renal Physiol 297: F704–12, 2009. 
57. van der Lubbe N, Moes AD, Rosenbaek LL, Schoep S, Meima ME, Danser AHJ, Fenton RA, 
Zietse R, Hoorn EJ. K+-induced natriuresis is preserved during Na+ depletion and 
accompanied by inhibition of the Na+-Cl- cotransporter. Am J Physiol Renal Physiol 305: 
F1177–88, 2013. 
58. Vitari AC, Deak M, Morrice NA, Alessi DR. The WNK1 and WNK4 protein kinases that are 
Chapter 6                                               High Na+/low K+ affects calcium and phosphate homeostasis | 
 
160 
mutated in Gordon's hypertension syndrome phosphorylate and activate SPAK and OSR1 
protein kinases. Biochem J 391: 17–24, 2005. 
59. Voets T, Nilius B, Hoefs S, van der Kemp AWCM, Droogmans G, Bindels RJM, Hoenderop 
JGJ. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J 
Biol Chem 279: 19–25, 2004. 
60. Wilson FH, Disse-Nicodème S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, Gunel M, 
Milford DV, Lipkin GW, Achard JM, Feely MP, Dussol B, Berland Y, Unwin RJ, Mayan H, 
Simon DB, Farfel Z, Jeunemaitre X, Lifton RP. Human hypertension caused by mutations in 
WNK kinases. Science 293: 1107–1112, 2001. 
61. Worcester EM, Coe FL. Nephrolithiasis. Prim Care 35: 369–91– vii, 2008. 
62. Zajicek HK, Wang H, Puttaparthi K, Halaihel N, Markovich D, Shayman J, Béliveau R, Wilson 
P, Rogers T, Levi M. Glycosphingolipids modulate renal phosphate transport in potassium 
deficiency. Kidney Int 60: 694–704, 2001. 
 

7
General discussion 
and summary
Chapter 7                                                            Discussion and summary on the NaCl cotransporter |  
	 	
164 
Electrolyte handling in the distal convoluted tubule 
In the kidney, the distal part of the nephron that comprises the distal convoluted tubule 
(DCT), connecting tubule (CNT) and collecting duct (CD) plays a central role in maintaining 
the blood pressure by controlling the sodium (Na+) reabsorption and potassium (K+) 
secretion (Fig. 1) (5, 14, 16, 62). In the distal part of the nephron, Na+ reabsorption primarily 
occurs through thiazide-sensitive NaCl co-transporter (NCC) (27) and residual Na+ is 
reabsorbed by amiloride-sensitive epithelial Na+ channel (ENaC) (62). The Na+ reabsorption 
through ENaC is coupled to K+ secretion via the renal outer medullary K+ channel (ROMK) 
(59). NCC is expressed exclusively in the DCT with a robust expression in the early part of 
the DCT (DCT1) that decreases into the later part of the DCT (DCT2) (27, 49, 50, 67). The 
ENaC abundance increases gradually along the DCT2 and is highly expressed in the CNT 
and CD (6, 49, 92).  
Na+ reabsorption, through NCC, in the DCT1 determines the amount of Na+ delivery to 
the downstream segments where the secretion of K+ occurs (4). Therefore, NCC indirectly 
plays an important role in the regulation of K+ secretion. This interplay between renal Na+ 
and K+ secretion is tightly regulated by the renin-angiotensin-aldosterone system (RAAS). 
Physiologically, the RAAS operates in the kidney to increase renal Na+ retention in a 
hypovolemic condition (93). In short, renin is released from the kidney, which then cleaves 
angiotensinogen to produce angiotensin I that in turn is converted to angiotensin II (84). 
Subsequently, angiotensin II stimulates the secretion of aldosterone from the adrenal gland. 
During hypovolemia angiotensin II and aldosterone stimulate Na+ reabsorption through 
activation of NCC and ENaC (23, 52, 88, 106). Additionally, aldosterone is also released 
upon an increase in plasma K+ (hyperkalemia), favoring ROMK-mediated K+ secretion from 
DCT2 onwards (107). This release occurs independent of the volemic state. Interestingly, 
NCC is not activated during hyperkalemia, even in hypovolemic state when Na+ retention is 
desired (4, 84). Conversely, NCC is activated under hypokalemic conditions despite 
hypervolemia and decreased RAAS activation. NCC activation will reduce downstream 
tubular Na+ delivery, thereby diminishing ENaC-mediated Na+ transport and subsequently 
reduce K+ secretion via ROMK. This mechanism controls the K+ balance at the expense of 
Na+ retention and increased blood pressure. Taken together, aldosterone can have a 
different mode of action in the distal part of the nephron upon concurrent changes in plasma 
K+ and blood volume. This divergent function of aldosterone is referred to as the aldosterone 
paradox (4). Since angiotensin II is the hallmark of volume depletion and is not affected by 
plasma K+ concentration, it is suggested to play an important role in mediating the distinctive 
response during hypovolemia and hyperkalemia.  
The above-described key role of NCC in the regulation of Na+ and K+ is highlighted by 
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the molecular mechanisms underlying pseudohypoaldosteronism type 2 (familial 
hyperkalemic hypertension, FHHt), Gitelman syndrome and thiazide-type diuretics 
treatment. Patients with FHHt suffer from hypertension and hyperkalemia that results from 
gain-of-function of NCC (45, 85, 110, 113). This activation of NCC is a consequence of 
mutations in with no lysine (WNK) kinases, mainly WNK1 and WNK4, Kelch-like 3 (KLHL3), 
or Cullin 3 (CUL3) (7). Mutations in either of these genes results in phosphorylation of WNK 
kinases that leads to phosphorylation and thereby activation of two related proteins, SPAK 
(STE20/SPS1-related proline/alanine-rich kinase) and OSR1 (oxidative stress responsive 
protein type 1) (68, 85). Subsequently, SPAK and OSR1 kinases phosphorylate key 
residues in the amino (N)-terminal region of NCC, resulting in enhanced Na+ reabsorption by 
increased transport activity of NCC (68). This leads to decreased Na+ delivery to the 
downstream segments, thereby resulting in subsequent diminished K+ secretion, which can 
explain the hyperkalemia in FHHt. The hypertension as well as the hyperkalemia disorders 
in FHHt patients can be corrected by a low dose of thiazide-type diuretics (42, 58, 77). 
Moreover, several guidelines recommend thiazide-type diuretics as first-line treatment for 
the management of hypertension, including in patients with FHHt (42, 77). Thiazide-type 
diuretics act by blocking NCC, thus increasing Na+ delivery to the downstream segments of 
distal part of the nephron (27). Hence, more Na+ is reabsorbed through ENaC which 
coincides with an increased K+ secretion via ROMK, resulting in hypokalemia (Fig. 1) (59). 
Similarly, patients with Gitelman syndrome suffer from hypokalemia that can be explained by 
the loss-of-function mutations in the NCC gene (20, 34, 95) Recently, it has been shown that 
plasma K+ levels, independent of hormonal effects, directly modulates the WNK-
SPAK/OSR1-NCC cascade (102). The current molecular mechanism suggests that lower 
plasma K+ levels hyperpolarize the DCT cell membrane, thereby driving chloride (Cl-) efflux 
(101). Subsequently, a lower intracellular Cl- concentration results in auto-phosphorylation of 
WNKs (102) that subsequently leads to activation of the SPAK/OSR1-NCC phosphorylation 
cascade (63, 73). There is accumulating evidence that a typical diet, containing high Na+ 
and low K+, activates NCC (36, 102) despite high Na+ levels. Hence, the body attempts to 
maintain the K+ balance at the expense of an increase in blood pressure, which could partly 
be responsible for the hypertension pandemic that is currently the most critical and 
expensive public health problem worldwide (84). Therefore, not only Na+ restriction, but also 
K+ supplementation, could be useful in the treatment to control the blood pressure. 
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Figure 1 | Thiazide-induced Na+ delivery and K+ secretion in the distal part of the nephron. 
(A and B) NCC is apically localized in epithelial cells lining the early part of the DCT (DCT1, blue), but 
its expression gradually decreases along the later part of the DCT (DCT2, blue-green), where it co-
localizes with the epithelial Na+ channel (ENaC) and renal outer medullary K+ channel (ROMK). The 
ENaC expression increases gradually along the DCT2 and is robust in the connecting tubule (CNT, 
green) and collecting duct (CD, green). (B) Due to the inhibitory effect of thiazides on NCC activity, 
Na+ delivery towards the DCT2, CNT and CD will increase. These segments will, therefore, reabsorb 
more Na+ via ENaC. As a consequence, more K+ is secreted by ROMK, ultimately resulting in 
decreased plasma K+ levels. Thiazide-mediated NCC inhibition and subsequent decrease in plasma 
K+ concentrations raise plasma renin and angiotensin II levels. Angiotensin II stimulates the secretion 
of aldosterone from the adrenal gland. Mineralocorticoid receptor (MR) is activated by the 
aldosterone. In addition, thiazide treatment increases both the abundance and activity of NCC and 
ENaC. 
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NCC in health and disease 
The alternative splice variant of NCC (NCCSV) 
Since the molecular cloning of human NCC in 1996, it has been shown that there are three 
isoforms of NCC present in the human kidney (53, 57, 96). While many studies over the past 
decades have emphasized the importance of NCC in electrolyte homeostasis and blood 
pressure control, these reports have focused on the shortest NCC isoform (NCC3). The NCC 
isoform 1 and 2, collectively referred to as NCC splice variant (NCCSV), remained 
unexplored. The NCCSV is present in humans and higher primates, but it is not present in 
rodents (mouse and rat) as a result of the exon splicing. Generation of new antibodies 
specifically recognizing NCCSV allowed us to demonstrate the presence of these isoforms at 
the apical membrane of the DCT, as well as in urinary extracellular vesicles (uEVs) 
(Chapter 2). The presence of NCCSV in the uEVs was also confirmed by mass spectrometry. 
On average total NCC mRNA in the human kidney comprises ~45% of NCCSV and ~55% of 
NCC3. However, the ratio of NCCSV to NCC3 mRNA expression in human kidneys varied 
between 20-60%. These large differences in NCCSV to NCC3 ratio suggest that a splicing 
donor site at exon 20 (20a and 20b respectively) (56) is highly regulated. It has been shown 
that ~95% of human genes are alternatively spliced, including the NCC gene (69). The 
production of alternatively spliced mRNAs is diversely regulated by a variety of external 
stimuli. Mechanisms of alternative splicing are highly variable and not well understood (51). 
The differences in alternative spliced mRNAs can consequently impact abundance and/or 
function of a protein (51, 74), and are suggested to contribute to the development of various 
diseases, such as cancer and diabetes (2, 97, 100). In addition, altered splicing of genes is 
indicated to influence drug response (38). 
In order to assess the role of NCCSV, we have analyzed the NCCSV and NCC3 
abundance in uEVs in several physiological (water loading; Chapter 2) and 
pathophysiological (essential hypertensive and calcineurin inhibitor-treated patients; 
Chapters 3 and 5) conditions. Our findings showed a robust decrease in expression of 
NCC3, as well as NCCSV protein, in uEVs in response to water loading (Chapter 2). Water 
loading will result in transient extracellular volume expansion and decrease in serum 
osmolality, which are known to deactivate RAAS and reduce arginine vasopressin (AVP, 
antidiuretic hormone) release (12, 71, 80, 86, 88-90, 105, 106). However, in response to 
hypovolemia, RAAS levels are increased to induce renal Na+ reabsorption (83). AVP is 
mainly known for its water-retaining action on the CD by increasing the water channel 
aquaporin 2 (AQP2) abundance, phosphorylation, and membrane targeting (30). Vice versa, 
water loading is known to downregulate AQP2 to stimulate water excretion, hence 
decreasing the extra cellular volume (ECF) (98). Indeed, we showed that AQP2 abundance 
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in uEVs and urine osmolality was decreased after water loading. A growing body of evidence 
suggests an important role of AVP in activation of NCC3 that may contribute to the Na+ 
conservation in the DCT (64, 71). The decreased NCCSV abundance in water-loaded 
subjects is likely a result of decline in RAAS levels and AVP release. Thus, our results 
demonstrate that NCCSV, like NCC3, is highly regulated under physiological condition.  
The data presented in Chapter 3 demonstrates that the NCCSV also plays a role in 
pathophysiological conditions. Abundance of NCCSV and NCC3 in uEVs of essential 
hypertensive patients was increased upon chronic thiazide treatment, but not by valsartan. 
Valsartan is also a well-known anti-hypertensive drug that reduces blood pressure by 
antagonizing angiotensin II type I receptors (37). Our current data highlights that the blood 
pressure decrease correlates with NCCSV abundance in uEVs and plasma K+ levels of 
essential hypertensive patients treated with thiazides. As described above, the decline in 
plasma K+ levels upon thiazide treatment might be explained by the increased distal delivery 
of Na+ that results in increased K+ secretion. Combination of the observations that NCCSV is 
significantly expressed in the kidney, responsive to physiological stimuli such as water 
loading and involved in pathophysiological processes, denotes the key role of NCCSV in 
renal salt handling. 
 
Functional role of NCCSV 
Chapters 2 and 4 show that NCCSV exhibits thiazide-sensitive Na+ transport activity in both 
Xenopus oocytes and mammalian cells, similar to NCC3. Recently, a novel phosphorylation 
site in NCCSV at serine 811 (S811), solely present in NCCSV, was identified (35). The lack of 
S811 in rodents and rabbit hampered the progress and interest towards further 
investigations (35). Our studies described in Chapters 2 and 4 now reveal that NCCSV S811 
plays a key role in NCCSV but also NCC3 function (Fig. 2). First, a phosphorylation-deficient 
S811 mutant (NCCSV S811A) showed decreased transport activity. X. laevis oocytes 
expressing NCCSV S811A exhibited reduced 22Na+-uptake compared to oocytes expressing 
wild-type NCCSV (Chapter 2). This was confirmed in mammalian cells by fluorescence 
microscopy using the halide-sensitive YFP/mKate system as a measure for NCC activity 
(Chapter 4). Second, we demonstrated that co-expression of NCCSV S811A and NCC3 
results in a dominant negative effect on NCC3 function, while it does not affect the NCC 
abundance at the plasma membrane (Chapter 4). Together, these chapters indicate that 
S811 not only regulates NCCSV activity, but also affects the function of NCC3. 
We postulate that S811 exerts its effect via altered phosphorylation of threonine 
residues 60 (T60) and 55 (T55) in NCCSV and NCC3. These N-terminal residues are key 
phosphorylation sites and essential for NCC activity (22, 68, 99, 116) and plasma membrane 
abundance (43, 114). This is highlighted by a loss-of-function mutation at T60 in NCC that is 
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linked to Gitelman syndrome (48, 114). Moreover, it has been shown that defective T60 
phosphorylation corrects the phenotype of FHHt in mice (114). In NCC3, T60 is postulated as 
dominant phosphorylation site as the non-phosphorylated form of T60 (T60A) inhibited 
phosphorylation of adjacent residues T46 and T55 (78). Additionally, it was shown that the 
T60A mutant strongly inhibits NCC3 activity, while this was less prominent for the 
phosphorylation-deficient threonine 46 (T46A) and 55 (T55A) mutants (78). Several other 
studies have shown that T60 is an important site for NCC activity (68, 78, 114). Our findings 
demonstrate that S811, solely present in NCCSV, has a dominant-negative regulatory role on 
Na+ transport activity in both NCCSV and NCC3, as the S811A prevented the T60 and T55 
phosphorylation in NCCSV and NCC3.  
While it is known that T60 and T55 are phosphorylated via activation of WNK-SPAK 
signaling pathway (1, 68), the kinase involved in S811 phosphorylation remains to be 
elucidated. WNK4 inhibited NCCSV and NCC3 function independent of S811 (Chapter 2). 
Prediction software suggested that the amino acid sequence around S811 shows high 
similarity to a protein kinase A (PKA) consensus site. Therefore, potential hormones 
regulating the PKA pathway might be involved in regulating NCCSV-mediated Na+ 
reabsorption in DCT. There is a growing body of evidence demonstrating that NCC3 
abundance and phosphorylation is affected by protein kinase C (PKC) or PKA downstream 
of angiotensin II or AVP signaling, respectively (9, 64, 71, 90). After water loading, the 
decreased NCCSV abundance in uEVs and urine osmolality indicates, at least in part, that 
PKA signaling pathway might be involved in NCCSV regulation (Chapter 2). The effect of 
AVP is also demonstrated in the thick ascending limb of Henle’s loop that expresses the 
type 2 vasopressin receptor (V2R). Here, AVP stimulation leads to activation of cyclic AMP 
(cAMP) and PKA signaling that ultimately affects NKCC2 phosphorylation (109). 
Interestingly, V2R has also been detected in DCT, and micropuncture studies have shown 
that AVP increases Na+ absorption in DCT (9, 24, 25). The presented data in this thesis 
suggests that RAAS- as well as AVP-dependent signaling pathways might be involved in 
regulation of NCCSV. 
 
Regulation of NCC abundance at the plasma membrane 
Another way to regulate Na+ reabsorption in the kidney is to modulate NCC abundance at 
the plasma membrane. In Chapter 4, cell surface biotinylation of NCC-transfected cells 
revealed that a change in S811 phosphorylation of NCCSV does not affect the abundance of 
NCCSV at the plasma membrane, where NCC is functionally active. Moreover, there is no 
change in plasma membrane abundance of any of the NCC isoforms or mutants. These 
findings indicate that translocation of NCC to the plasma membrane or stability of NCC is not 
affected by S811; rather, intrinsic T60 and T55 phosphorylation of NCC is increased. 
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However, our study is in agreement with previous studies demonstrating that NCC3 surface 
abundance is not affected by the phosphorylation status of T60 in X. laevis oocytes 
(Chapter 4) (68). Similarly, the triple mutation of T55, T60 and S73 to alanine did not 
significantly change the NCC3 abundance at the plasma membrane (43). The relation 
between the T60 phosphorylation and membrane stability of NCC3 has been postulated 
(114). Although, several studies demonstrated a decreased abundance of NCC3 T60A in 
both the biotinylated fractions and input fraction, the ratio of biotinylated fractions to input 
was not reduced, suggesting unaltered abundance at the plasma membrane (43, 114). 
 
Figure 2 | Functional role of the novel phosphorylation site serine 811 (S811). 
The amino (N)-terminal domain of NCC contains several key phosphorylation sites (T55/T66) that are 
essential for NCC activity and plasma membrane abundance. S811 acts as a dominant regulatory site 
for phosphorylation of T60 and T55 in NCCSV and NCC3. The various interactions of the NCCSV 
regulatory pathway are shown as green arrows (stimulatory) or red lines (inhibitory). Phosphorylation 
is indicated with the symbol P. WNK4 (with no lysine kinase 4) is capable of activating SPAK 
(STE20/SPS1-related, proline alanine-rich kinase) and OSR1 (oxidative stress responsive protein 
type 1). Notably, the phosphorylation-deficient (S811A) mutant exhibits a decreased transport activity 
in NCCSV. WNK4 inhibits the function of NCCSV and both NCCSV mutants independent of S811. The 
Cl- channel CLC-Kb is responsible for efflux of Cl-. In low Cl- condition the intracellular Cl- 
concentration decreases, which subsequently stimulates WNK-SPAK/OSR1 signaling. 
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NCCSV and NCC3 form hetero and homodimers 
Chapter 4 describes the molecular mechanism by which NCCSV S811 exerts a dominant-
negative effect on NCC3. Our data shows that both the constitutively phosphorylated and 
non-phosphorylated NCCSV S811 mutants can form heterodimers with NCC3, indicating that 
the effect of S811 on phosphorylation of NCC3 can occur though interaction between the two 
isoforms. The phosphorylation status of S811 did not affect the dimerization of NCCSV and 
NCC3. Homodimerization of NCC3 proteins has been proposed in previous studies (21), and 
it was also found that most NCC3 proteins are present at the plasma membrane in a 
dimerized form (21, 33). However, previous studies observed the homodimerization of NCC3 
by using immunoblot analysis showing immunoreactive bands of ~130 kDa (monomer) and 
~260 kDa (dimer) (21, 33, 79, 103). Importantly, this work shows for the first time that NCCSV 
and NCC3 form heterodimers in living cells and that NCCSV competes with NCC3 to form a 
heterodimer. Our data suggest that the dimerization of NCC might already occur in the 
intracellular compartment before the proteins reach the plasma membrane. Furthermore, the 
intracellularly retained NCCSV mutants were also shown to dimerize with NCC3, suggesting 
that the phosphorylation status of S811 does not affect the interaction between NCCSV and 
NCC3 from an early stage. From its dimeric nature, NCC resembles NaKCl cotransporter 
(NKCC2) (33, 61), suggesting that other members of the family of electroneutral cation-
chloride cotransporters form similar oligomeric structures. Dimerization of transmembrane 
proteins is a common mechanism that precedes functional regulation of a protein. 
Previously, it was demonstrated that in the tyrosine kinase pathway, Erb2/Erb3 cross-
phosphorylate each other after dimerization (55, 91). The heterodimerization of NCCSV with 
NCC3, provides an indication that NCCSV S811 phosphorylation regulates the N-terminal T60 
and T55 of NCC3 via close interaction. 
 
uEVs as a source of urinary biomarkers 
Urine provides a source for the discovery of urinary biomarkers useful for detection of kidney 
diseases and for monitoring of treatment. uEVs, which also include exosomes, are 
nanosized vesicles (30–120 nm) that form when multivesicular bodies within the cell merge 
with the cell membrane and release internal vesicles into the extracellular space or pro-urine 
(76). These microvesicles are an appealing source for urinary biomarker, as they are 
normally secreted into the urine from all nephron segments, and its cargo reflects the 
physiological and pathophysiological state of the cell from which they were released (Fig. 
3A) (41, 104). In the field of urinary biomarker discovery uEVs have sparked a great surge of 
interest in recent years (60, 115). In this thesis, we designed a detailed protocol for isolation 
and standardization of uEVs in order to assess the NCC regulation in humans. Our 
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observations, in Chapters 2, 3 and 5, demonstrate that uEVs provide a unique and novel 
non-invasive tool to study the regulation of NCC in the human kidney. This assessment of 
NCC in uEVs represents an alternative method to guide anti-hypertensive therapy in patients 
with high blood pressure.  
 
Structural characterization of NCC in uEVs 
To determine whether NCC abundance in uEVs reflects NCC present in the epithelial cells 
of the DCT, several biochemical analyses were performed (Chapter 3). NCC is present in 
oligomeric structures in both uEVs and human kidney membrane fractions. This was 
demonstrated by immunoblots showing NCC proteins as complex bands of ~260 and ~130 
kDa, representing the dimeric and monomeric forms, respectively. Interestingly, uEVs or 
proteins isolated from urine or tissue, respectively, did not allow dissociation of the dimeric 
NCC complex in a monomeric form. This has been attempted by incubating the uEVs at 
temperatures up to 100 °C or exposing them to the reducing agents dithiothreitol (DTT) and 
β-mercaptoethanol (β-met). The NCC complexes of ~260 and ~130 kDa detected in the 
human uEVs are comparable to NCC expression in human kidney membrane fractions, 
indicative of NCC derived from epithelium lines the DCT. Furthermore, N-glycosidase F was 
used to assess glycosylation since it has previously been demonstrated that NCC is N-
glycosylated in rat kidney. The N-glycosylation is essential for the cell surface expression, 
thiazide sensitivity and activity of NCC (39). Our study in Chapter 3 indicated that NCC in 
uEVs is glycosylated similarly to kidney membrane fractions. In addition, both the dimeric 
and monomeric NCC forms in uEVs and human kidney membrane fractions were insensitive 
to endoglycosidase H (Endo H) digestion, indicating that NCC in uEVs is present as a 
matured protein with complex glycosylation. Proteins that are sensitive to Endo H digestion 
are suggested to be retained in the endoplasmic reticulum and pre-Golgi complex without 
further processing (20, 32, 81). For example, it was shown that a part of the NCC 
monomeric band of Xenopus oocytes was sensitive to Endo H digestion (20, 39), suggesting 
the presence of unprocessed NCC protein. Together, this suggests that the NCC protein in 
uEVs represents a mature plasma membrane protein. Therefore, NCC in uEVs can be used 
as representative of NCC in human kidney membrane fractions. 
 
NCC abundance in uEVs predicts the anti-hypertensive response to thiazides 
In the studies presented in Chapters 3 and 5, uEVs were used as a tool to study NCC 
regulation in essential hypertensive patients and kidney transplant recipients treated with 
calcineurin inhibitors (CNIs), including cyclosporine A and tacrolimus. In addition, both the 
essential hypertensive and CNI-induced hypertensive patients were treated with thiazide 
diuretic to assess their NCC abundance in uEVs and blood pressure response to thiazides. 
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In addition to uEV-NCC analysis, clinical parameters and blood pressure were assessed in 
the patients. Our study demonstrated that chronic treatment with CNIs increases both total 
NCC (tNCC) and phosphorylated NCC (pNCC) abundance in uEVs of kidney transplant 
recipients. In Chapter 5, tNCC and pNCC refers to all three NCC isoforms in uEVs of kidney 
transplant recipients. This observation indicates that the CNI-induced increase in NCC 
abundance and phosphorylation (activity) might be involved in the pathogenesis of 
hypertension in kidney transplant recipients. Furthermore, we propose that analysis of NCC 
abundance in uEVs might predict the blood pressure response to thiazide diuretics. Thiazide 
treatment decreased the blood pressure in several essential and CNI-induced hypertensive 
patients, referred to as the “responders” (Fig. 3B). The uEV analysis in these kidney 
transplant recipients demonstrated that pre-treatment abundances of tNCC and pNCC in 
uEVs correlate with the blood pressure response to thiazide diuretics (Chapter 5). The 
observed increase in tNCC and pNCC abundance after thiazide treatment is consistent with 
data obtained in animal models (65, 66). Of note, when separating the group of patients into 
thiazide responders (a decrease of ≥ 5 mmHg in blood pressure) and non-responders (a 
decrease of < 5 mmHg in blood pressure), it becomes clear that NCC abundance was 
mainly increased in responders. This is in line with several previous studies demonstrating 
that prolonged thiazide treatment enhances NCC abundance in rodent kidney (65, 66). 
Moreover, chronic thiazide infusion in mice upregulated the binding density of [3H] 
metolazone, an indirect measure of NCC activity, thereby also confirming the increased 
NCC abundance after thiazides (11). The augmented abundance of NCC in the DCT, which 
is reflected by an increased abundance of NCC in uEVs, might be the result of 
compensatory mechanisms. These compensatory mechanisms are potentially mediated by 
the RAAS or/and K+ balance, which counteract reduced NCC function by the thiazide 
treatment (93). This compensatory response could, therefore, partly contribute to diuretic 
resistance (28). Similarly, chronic administration of the diuretics furosemide and amiloride, 
which block NKCC2 and ENaC, respectively, was shown to enhance the abundance of 
these proteins in rodent kidney (44, 65).  
Interestingly, a decrease in pNCC and pNCC/tNCC ratio upon thiazide treatment was 
observed in the non-responders (Chapter 5). This might be explained by the fact that the 
blood pressure response to thiazides is accompanied by altered plasma K+ levels or/and 
RAAS activation resulting in different NCC excretion patterns in uEVs. Recently, it has been 
demonstrated that aldosterone treatment increased the tNCC and pNCC abundance in uEVs 
of hypertensive patients, possibly driven by changes in plasma K+ levels (111). Our studies 
show that alterations in blood pressure correlate with NCC abundance and plasma K+ levels 
of hypertensive patients treated with thiazides. Moreover, the serum K+ concentrations were 
lower in responders compared to non-responders (Chapters 3 and 5). These reduced 
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plasma K+ levels observed in responders may explain the increase in NCC abundance in 
uEVs of hypertensive patients following thiazide treatment. A recent study revealed that a 
modest decrease in plasma K+ levels, within the narrow physiological range of 3.5–5.0 
mmol/L, can already increase NCC abundance and activity (101). Furthermore, it has been 
demonstrated that K+ depletion, as well as renal K+ loss, stimulate NCC phosphorylation (40, 
108). In contrast to thiazide diuretics, valsartan did not enhance the abundance of NCC in 
uEVs derived from essential hypertensive patients, nor did it change plasma K+ levels in 
these patients (Chapter 3). The lack of NCC response and unaltered serum K+ levels in 
valsartan-treated patients indicate that NCC activation is partly dependent on plasma K+-
mediated stimulation (10). The upstream regulatory pathways of NCC stimulation (such as 
RAAS) are still intact during thiazide treatment and may stimulate NCC abundance and 
phosphorylation, while its function is still blocked by thiazides. The renin levels were 
elevated in thiazide-treated patients. In addition, it has been shown that high dietary Na+ 
ingestion contributes to non-responsiveness to the thiazide treatment (diuretic resistance) 
(75). Patients with resistant hypertension who consumed a low Na+ diet showed significantly 
increased plasma renin levels (75) 
Collectively, these observations indicate that the CNI-induced increases in NCC 
abundance and phosphorylation are involved in the pathogenesis of hypertension in kidney 
transplant recipients. Furthermore, the blood pressure response correlates with NCC 
abundance in uEVs and plasma K+ levels of hypertensive patients treated with thiazides. 
Ultimately, our results show that NCC abundance in uEVs could be used as a biomarker to 
predict the blood pressure response to thiazide diuretics. 
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Figure 3 | NCC abundance in uEVs predicts the anti-hypertensive response to thiazides. 
(A) Schematic diagram from collection of urine to the detection of specific proteins in urinary 
extracellular vesicles (uEVs). (B) Pre-treatment NCC abundance in uEVs isolated from hypertensive 
patients who did or did not respond to thiazides. The immunoblot and densitometry of tNCC in uEVs 
of hypertensive patients before the treatment with thiazide diuretics. Responders (n = 10) refer to 
patients who had a significant anti-hypertensive response (≥ 5 mmHg reduction in blood pressure) to 
treatment with thiazide diuretics. Non-responders (n = 8) did not have an anti-hypertensive response 
to thiazides (a decrease of < 5 mmHg in blood pressure). uEVs were isolated before the treatment 
with thiazides. tNCC abundance were significantly higher in responders compared to non-responders. 
 
Effects of a high Na+-low K+ diet on renal electrolyte handling 
Chapter 6 shows that a diet that is high in Na+ and low in K+ is not only involved in NCC 
regulation and pathogenesis of hypertension, but it is also associated with electrolyte 
disturbances. Our findings show that this diet has significant effects on renal calcium (Ca2+) 
handling, while not affecting the magnesium (Mg2+) balance. The high Na+-low K+ diet 
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enhances NCC abundance and activity, which subsequently increases the blood pressure 
(26, 101, 102). Similarly, patients with FHHt suffer from hypertension that results from gain-
of-function of NCC (45, 85, 110, 113). In addition, patients with FHHt are characterized by 
decreased renal Na+ and K+ excretion and increased renal Ca2+ excretion, while  their Mg2+ 
balance is not affected (70). In contrast, patients with Gitelman syndrome resulting from 
loss-of-function of NCC, have augmented renal Na+, K+, and Mg2+ wasting and reduced renal 
Ca2+ excretion (17, 29, 34, 47). Moreover, hypertensive patients treated with high-dose of 
thiazide diuretics may develop  hypokalaemia, hypomagnesaemia and hypocalciuria (8, 19, 
72), resembling the electrolyte disturbances observed in patients with Gitelman syndrome. 
The molecular mechanism explaining the renal Mg2+ handling in patients with FHHt and 
Gitelman syndrome is still not known. These data suggest that renal Mg2+ handling is mainly 
affected when NCC abundance or/and activity is decreased, while higher NCC activity due 
to a high Na+-low K+ diet or in FHHt patients does not result in Mg2+ imbalance. In addition to 
the cause of NCC related diseases, the duration of high Na+-low K+ diet is also known to 
show this discrepancy in Mg2+ handling. Serum and urine Mg2+ levels were not changed 
upon 4 days of diet in mice. In contrast, a previous study demonstrated increased urinary 
Mg2+ excretion in rats fed a high Na+ diet (46). This discrepancy could be due to the period 
of the diets (7 days versus 4 days), suggesting a time-dependent effect. 
Interestingly, the presented work described in Chapter 6 reveals a prompt 
enhancement in renal Ca2+ and phosphate (Pi) excretion in response to high Na+-low K+ diet. 
Alterations in the gene and protein expression of players involved in Ca2+ and Pi transport 
indicates that high Na+ intake inhibits proximal tubular reabsorption. We propose that the 
distal part of the nephron is unable to recover for the loss of Ca2+ and Pi by the proximal 
tubule, while the mechanism is sufficient to maintain Mg2+ homeostasis. Excessive renal 
excretion of Ca2+ and Pi are important risk factors for stone formation, as ~10% of all kidney 
stones are calcium-phosphate stones (112). Vice versa, several reports have shown that low 
Na+ and high K+ intake lowers the risk and progression of kidney stones (15, 31, 54, 82, 94). 
Previously, it has been postulated that a low K+ diet-mediated renal Ca2+ loss is NCC 
dependent (102). The Ca2+ excretion was increased when mice were fed high Na+ and low 
K+ diet, while this effect on renal Ca2+ loss was absent in NCC knock out mice (102). 
Interestingly, in NCC knock out mice, the excessive Ca2+ excretion caused by only high Na+ 
diet was not diminished, but only the effects of dietary K+ on Ca2+ excretion were reversed in 
mice lacking NCC (102). This suggests that thiazide-treated or Gitelman syndrome patients 
might benefit from K+ supplementation to diminish their NCC linked hypocalciuria. The 
current findings add to a growing body of literature showing that high Na+ and low K+ diet 
induces hypercalciuria (13, 18, 102). However, the exact mechanism underlying the altered 
renal Ca2+ handling needs further investigation. 
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Impact of this thesis and future perspective 
This thesis highlights that NCCSV is significantly expressed in the kidney where it operates 
as a fully functional thiazide-sensitive NaCl-transporting protein. NCCSV is not a redundant 
protein since it plays an important role in (patho)physiological processes. Additionally, the 
phosphorylation site S811 in NCCSV acts as a dominant-negative regulatory site for 
phosphorylation of T55 and T60. These findings reveal a new regulatory mechanism of NCC 
function that might be critical in renal salt handling and could, therefore, play an important 
role in the pathogenesis of essential hypertension. Hence, it is relevant to study the 
regulation of NCCSV in vivo in several pathophysiological conditions. The generation of 
NCCSV knock-in mice models that express solely NCCSV and/or co-express both NCCSV and 
NCC3 in DCT are crucial to increase our understanding. Furthermore, unraveling the 
molecular signaling pathway and kinases that are involved in the phosphorylation of S811 
might give more insight into the regulation of NCCSV. Although, WNKs play an important role 
in the maintenance of the Na+ balance, their abundant expression in different segments of 
the kidney makes it less effective to exploit them as therapeutic targets. However, utilizing 
the downstream kinases that are specifically involved in NCC regulation might be crucial to 
develop novel therapeutic strategies to combat the dysregulation of blood pressure. In 
addition, uEV analysis may have clinical utility as a non-invasive biomarker for a variety of 
physiological and pathological conditions. Notably, our data demonstrates that uEVs can be 
used as a non-invasive tool to guide anti-hypertensive therapy in patients with hypertension 
and may help to individualize anti-hypertensive treatment. An unresolved question in the 
uEV-field is whether the abundance of protein per uEV varies, or whether the number of 
uEVs is regulated. However, normalizing spot urines by creatinine for uEV analysis is 
currently an accepted approach (87, 104, 111, 117). Currently, the abundance of the uEV 
marker CD9 is often used to analyze whether normalization by urinary creatinine results in a 
similar number of uEVs for immunoblotting (3, 76, 87). Despite these methods (3, 76, 87), 
techniques that allow uEV counting will be necessary to address this point more 
conclusively. Furthermore, the development of high-throughput assay for uEV analysis will 
be necessary for further clinical applications.  
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Inleiding 
Hoge bloeddruk (hypertensie) is een risicofactor voor hart- en vaatziekten, en chronisch 
nierfalen en verhoogt hiermee het risico op sterven. Met een prevalentie van 1,4 miljard 
mensen, ofwel 1 op de 3 volwassenen wereldwijd, is hypertensie één van de meest ernstige 
volksgezondheidsproblemen. Opmerkelijk genoeg is de helft van de patiënten met 
hypertensie niet op de hoogte van hun conditie, en daarom wordt hypertensie vaak aangeduid 
als 'de stille moordenaar'. Bovendien is de oorzaak in ~90% van de patiënten met hypertensie 
niet bekend en het wordt dan ook wel ‘essentiële hypertensie’ genoemd. 
Bloeddruk wordt gehandhaafd door een samenspel tussen bepaalde delen van de 
hersenen (de hersenstam), de nieren en het hart. De nieren regelen voor een belangrijk deel 
het vocht- en het zoutgehalte in ons lichaam, en dragen daarmee bij aan de hoogte van de 
bloeddruk. De nier is opgebouwd uit ongeveer 1 miljoen nefronen, de functionele eenheden 
van de nier. Ze filteren het bloed en zorgen voor de uitscheiding van afvalstoffen en ‘overtollig’ 
zout en vocht via de urine. Elk nefron bestaat uit een glomerulus (een kluwen hele kleine 
bloedvaatjes), het kapsel van Bowman (een kapsel dat om de glomerulus heen ligt) en een 
nierbuis (tubulus). Na filtratie van het bloed in de glomerulus ontstaat er voorurine die door 
de nierbuis stroomt. Er vindt dan een uitwisselingsproces van opname en afgifte van water en 
zouten plaats tussen de voorurine en het bloed, dat in kleine bloedvaatjes rondom de nierbuis 
stroomt. Het laatste gedeelte van nierbuis speelt een sleutelrol in de regulatie van bloeddruk 
door het beïnvloeden van natrium (Na+) en kalium (K+) uitwisseling. Dit deel bestaat uit het 
distaal convoluut (DCT), de verbindingsbuis (CNT) en de verzamelbuis. De opname, ofwel 
resorptie, van Na+ in dit deel van de nierbuis staat onder controle van specifieke 
transporteiwitten, de NaCl cotransporter (NCC) en het epitheliale Na+ kanaal (ENaC). NCC 
komt specifiek voor in de DCT, met name in het vroege deel van de DCT (DCT1) en lokalisatie 
neemt geleidelijk af langs het latere deel van de DCT (DCT2). De lokalisatie van ENaC neemt 
geleidelijk toe van DCT2 naar CNT en verzamelbuis. Opname van Na+ door NCC in DCT1 
bepaalt de hoeveel Na+ die doorstroomt naar DCT2, CNT en verzamelbuis en daarmee heeft 
NCC een indirecte rol op Na+ opname via ENaC. De opname van Na+ via ENaC is gekoppeld 
aan de afgifte (excretie) van K+ via het transporteiwit ROMK. Er zijn verschillende hormonen 
die dit netwerk van opname en afgifte van Na+ en K+ regelen. Het hormonale renine-
angiotensine-aldosteron-systeem (RAAS) is een belangrijke component hierin en speelt een 
essentiële rol in de regulatie van de bloeddruk. 
 Het belang van NCC in regulatie van Na+ en K+ wordt gekenmerkt door de onderliggende 
moleculaire mechanismen van pseudohypoaldosteronisme type 2 (familiale hyperkaliëmische 
hypertensie; FHHt), Gitelman syndroom en thiazidediuretica. FHHt is een erfelijke ziekte die 
wordt veroorzaakt door mutaties in het WNK4, WNK1, CUL3 of KLHL3 gen. Deze genen zijn 
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op hun beurt uiteindelijk weer verantwoordelijk voor de activiteit van de NCC. Patiënten met 
FHHt lijden aan hypertensie en hyperkaliëmie ten gevolge van een verhoogde activiteit van 
de NCC. Beide symptomen van patiënten met FFHt, hypertensie en hyperkaliëmie, kunnen 
worden gecorrigeerd door een lage dosis thiazidediuretica. Thiazidediuretica remmen NCC in 
de DCT. Dit zorgt voor de verhoogde Na+ afgifte, wat vervolgens leidt tot verlaging van de 
bloeddruk. Verschillende richtlijnen adviseren thiazidediuretica als de eerstelijnsbehandeling van 
hypertensie. Vanwege het remmende effect van thiaziden op NCC-activiteit zal er meer Na+ bij de 
DCT2, CNT en verzamelbuis terecht komen. Deze segmenten zullen vervolgens meer Na+ via 
ENaC opnemen. Als gevolg hiervan wordt er meer K+ via ROMK uitgescheiden, wat uiteindelijk 
resulteert in een te lage K+ concentratie in het bloed. Gitelman syndroom is een erfelijke 
aandoening, veroorzaakt door mutaties in het NCC gen. Ook hebben patiënten met Gitelman 
syndroom een te lage K+ concentratie in het bloed, veroorzaakt door het verlies van NCC 
functie. Recentelijk is aangetoond dat de K+ concentratie in het bloed, onafhankelijk van 
hormonale effecten, de NCC functie kan moduleren. Het Westers dieet, dat veel Na+ en weinig 
K+ bevat, kan de bloed K+ concentratie verlagen, wat vervolgens leidt tot verhoging van de NCC 
activiteit, zelfs als er sprake is van hypertensie. Het lichaam probeert de K+ balans te 
handhaven ten koste van een hoge bloeddruk. Dit kan een belangrijke oorzaak zijn van de 
hypertensiepandemie. Daarom kan niet alleen het beperken van de dagelijkse Na+ inname, 
maar ook het verhogen van K+ inname, nuttig zijn voor de behandeling en preventie van 
hypertensie. 
 
Het bestuderen van nieuwe NCC-isovormen 
Alternatieve splicing variant van NCC (NCCSV) 
Sinds de ontdekking van NCC in de mens in 1996, is het aangetoond dat er drie vormen van 
NCC in de menselijke nier aanwezig zijn, die ook wel de NCC isovormen genoemd. Hoewel 
veel studies in de afgelopen decennia het belang van NCC voor de zoutbalans en bloeddruk 
hebben benadrukt, hebben deze studies zich geconcentreerd op de kortste NCC isovorm 
(NCC3). De NCC isovormen 1 en 2, gezamenlijk aangeduid als NCC splicing variant (NCCSV), 
zijn tot nu toe niet bestudeerd. NCCSV komt uitsluitend tot expressie in mensen en hogere 
primaten. Met het genereren van een nieuw antilichaam dat specifiek NCCSV herkent, hebben 
we aangetoond dat NCCSV (net als NCC3) gelokaliseerd is op het apicale membraan van 
cellen in de DCT (hoofdstuk 2). De aanwezigheid van NCCSV werd ook bevestigd in 
exosomen. Dit zijn kleine blaasjes, ook aangeduid als extracellulaire vesikels, die door 
lichaamscellen worden afgescheiden in bloed en urine. Hierdoor kunnen exosomen 
geïsoleerd worden uit de urine. Exosomen bevatten de bouwstenen van de oorspronkelijke 
cellen, waaronder eiwitten en RNA en ze kunnen gebruikt worden voor de analyse van NCC 
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eiwitten en zijn representatief voor de cellen in de DCT. Uit de resultaten bleek dat het totale 
mRNA van NCC in de menselijke nier gemiddeld voor ~45% uit NCCSV RNA en voor ~55% 
uit NCC3 RNA bestaat. Echter, als we deze verhouding in mRNA expressie tussen NCCSV en 
NCC3 in menselijke nieren per individu bekijken, dan zien we dat het varieert tussen 20-60%. 
Deze grote verschillen in de ratio NCCSV:NCC3 suggereren dat splicing van het NCC gen 
gereguleerd wordt. Er is daarnaast aangetoond dat ~95% van de menselijke genen gespliced 
wordt, inclusief het NCC gen.  
Om de rol van NCCSV in verschillende fysiologische en pathofysiologische condities te 
onderzoeken is er eerst een methode ontwikkeld voor het bestuderen van NCC in de 
exosomen verkregen vanuit menselijke urine. In hoofdstuk 2 is de fysiologische rol van 
NCCSV bestudeerd door analyse van NCC expressie in exosomen bij proefpersonen die 
overmatig veel water (0,5 L in 30 min) hadden ingenomen. Onze bevindingen toonden een 
sterke afname aan in eiwittenexpressie van NCCSV en NCC3 in de urinaire exosomen, als 
gevolg van overmatige waterinname (hoofdstuk 2). Forse waterinname resulteerde in een 
stijging van het bloedvolume en een afname in serum osmolaliteit, wat leidt tot RAAS 
inactivatie en afgifte van vasopressine (antidiuretisch hormoon) door de hersenen. De 
verminderde eiwitexpressie van NCCSV in de proefpersonen is daarom waarschijnlijk een 
gevolg van RAAS inactivatie en verhoogde afgifte van vasopressine. Zo toonden onze 
resultaten aan dat NCCSV, net als NCC3, sterk gereguleerd wordt onder fysiologische 
condities. 
De hoofdstukken 3 en 5 richten zich op de pathofysiologische rol van NCCSV in patiënten 
met essentiële hypertensie en patiënten die behandeld worden met calcineurineremmers. In 
hoofdstuk 3 wordt aangetoond dat NCCSV een rol speelt in de pathogenese van essentiële 
hypertensie. Expressie van NCCSV en NCC3 in urinaire exosomen van essentieel 
hypertensieve patiënten was verhoogd na het gebruik van thiazidediuretica, maar niet na de 
behandeling met valsartan. Valsartan behoort tot de angiotensine-II-blokkers en is bekend als 
bloeddrukverlagend middel. Onze resultaten toonden aan dat de bloeddrukverlaging na 
gebruik van thiazidediuretica correleert met de expressie van NCCSV in urinaire exosomen en 
met de K+ concentratie in het bloed van essentieel hypertensieve patiënten. Daling in K+ 
concentratie in het bloed van de patiënten behandeld met thiazidediuretica kan leiden tot een 
verhoging van de Na+ concentratie in het distale deel van het nefron, wat vervolgens resulteert 
in verhoogde K+ afgifte. De combinatie van de waarnemingen in dit proefschrift, zoals een 
significante eiwitexpressie van NCCSV in de nier en betrokkenheid van NCCSV bij fysiologische 
en pathofysiologische processen, duidt op een sleutelrol voor NCCSV in het reguleren van de 
water- en zouthuishouding. 
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Functionele rol van NCCSV 
In hoofdstuk 2 en 4 was de thiazidegevoelige transportactiviteit van NCCSV in zowel oocyten 
als menselijke embryonale niercellen onderzocht. Recentelijk is er een nieuw residu 
geïdentificeerd (serine 811, S811), uitsluitend aanwezig in NCCSV, dat gemodificeerd kan 
worden via fosforylatie. De afwezigheid van NCCSV in muizen, ratten en konijnen heeft de 
voortgang en belangstelling voor verdere onderzoeken belemmerd. De studies in dit 
proefschrift onthullen dat NCCSV-S811 niet alleen een sleutelrol speelt in NCCSV, maar ook in 
NCC3 functie. Fosforylering-deficiënte S811-mutant (NCCSV-S811A) toonde een verminderde 
transportactiviteit in oocyten en menselijke embryonale niercellen. Hoofdstuk 4 laat ook zien 
dat co-expressie van NCCSV S811A en NCC3 resulteert in een remmend effect van NCCSV 
S811A op NCC3 functie. Samengevat beschrijft dit hoofdstuk dat S811 niet alleen de activiteit 
van NCCSV reguleert, maar ook de functie van NCC3 beïnvloedt. Daarnaast hebben wij voor 
het eerste aangetoond dat NCCSV en NCC3 interacties aangaan en zogenaamde 
heterodimeren vormen in menselijke embryonale niercellen. Dimerisatie van membraan-
eiwitten is een gemeenschappelijk mechanisme dat voorafgaat aan de functionele regulatie 
van een eiwit. Onze bevinding van heterodimerisatie van NCCSV en NCC3 suggereert dat 
NCCSV-S811 op deze wijze de activiteit van NCCSV en NCC3 kan beïnvloeden. Daarnaast zien 
we dat de dimerisatie van NCC al intracellulair kan optreden, nog voordat de eiwitten de 
plasmamembraan bereiken.  
 
Urinaire exosomen als bron van biomarkers 
Exosomen worden continu uitgescheiden in de urine en daarom vormen ze een makkelijk 
toegankelijke bron van biomarkers voor nierziekten. Bovendien is het verzamelen van urinaire 
exosomen voor de patiënt minimaal belastend. In dit proefschrift hebben we een 
gedetailleerde methode ontwikkeld om NCC eiwitten in urinaire exosomen te kunnen 
analyseren. Hoofdstukken 2, 3 en 5 laten zien dat urinaire exosomen als een unieke en non-
invasieve methode kunnen worden gebruikt om de NCC regulatie in de menselijke nier te 
bestuderen. Daarnaast biedt het analyseren van NCC in urinaire exosomen een alternatieve 
methode om patiënten met hypertensie te begeleiden bij anti-hypertensieve therapie. Urinaire 
exosomen kunnen daarom bijdragen aan een effectieve en persoonlijke behandeling van 
hypertensie. 
 
NCC in urinaire exosomen voorspelt de respons van de patiënt op thiazidediuretica 
Hoofdstukken 3 en 5 richten zich op het analyseren van NCC in urinaire exosomen van 
essentieel hypertensieve patiënten en patiënten die een niertransplantatie ondergaan hebben 
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en behandeld zijn met calcineurineremmers. In beide hypertensieve patiëntengroepen was de 
expressie van NCC in de urinaire exosomen en de bloeddrukrespons op thiazidediuretica 
geanalyseerd. Onze studie heeft aangetoond dat chronische behandeling met 
calcineurineremmers zowel de expressie van totaal NCC (tNCC) als de gefosforyleerde 
(actieve) vorm van NCC (pNCC) verhoogt in urinaire exosomen van patiënten die een 
niertransplantatie hebben ondergaan. Deze bevindingen geven aan dat de toename in de 
expressie van NCC die geïnduceerd is door calcineurineremmers mogelijk betrokken is bij de 
pathogenese van hypertensie in deze patiëntengroep. We weten dat er interindividuele 
variatie in de gevoeligheid voor thiaziden bestaat. Opmerkelijk genoeg onze resultaten laten 
zien dat het analyseren van NCC expressie in urinaire exosomen alvorens de behandeling 
met thiaziden de bloeddrukrespons op thiazidediuretica kan voorspellen. Dit betekent dat voor 
de behandeling met thiazidediuretica, de exosoom-analyse kan helpen bij het vast stellen van 
individuele gevoeligheid voor de behandeling met thiaziden en zo onnodige thiazidediuretica 
gebruik voorkomen kunnen worden. Het is ook interessant om te onderzoeken of urinaire 
exosomen alvorens de behandeling met andere diuretica dan thiaziden de bloeddrukrespons 
kan voorspellen. Dit proefschrift toont eveneens aan dat veranderingen in de bloeddruk 
correleren met de NCC eiwitexpressie en de K+ concentratie in het bloed van hypertensieve 
patiënten die behandeld zijn met thiazidediuretica. Daarnaast is gebleken dat een hoge Na+ 
inname bijdraagt aan een ongevoeligheid voor de behandeling met thiaziden. 
 
Effecten van een Westers dieet op renale elektrolythomeostase 
Het is bekend dat een Westers dieet de NCC activiteit stimuleert, wat leidt tot verhoogde 
bloeddruk. Hoofdstuk 6 laat zien dat een Westers dieet niet alleen bij de NCC regulatie en 
pathogenese van hypertensie betrokken is, maar ook met andere stoornissen in de zoutbalans 
wordt geassocieerd. Uit onze bevindingen blijkt dat het Westerse dieet aanzienlijke effecten 
heeft op de renale calcium (Ca2+) en fosfaat (Pi) regulatie, zonder dat het de balans van 
magnesium (Mg2+) beïnvloed wordt. We laten zien dat het Westerse dieet resulteert in een 
verhoogde renale afgifte van Ca2+ en Pi in de urine. De hypothese is dat de opname van Ca2+ 
en Pi in het eerste deel van het nefron, de proximale tubulus, lager is als gevolg van hoge Na+ 
opname in dit deel van het nefron. Waarschijnlijk kan het distale deel van het nefron het 
ontstane renale verlies in Ca2+ en Pi niet herstellen, terwijl er wel voldoende capaciteit is om 
Mg2+ balans te handhaven. Overmatige uitscheiding van Ca2+ en Pi door de nieren is een 
belangrijke risicofactor voor het ontwikkelen van nierstenen. Verschillende studies hebben 
aangetoond dat lage Na+ en een hoge K+ inname het risico en de progressie van nierstenen 
kan verminderen. Gezamenlijk dragen deze bevindingen bij aan een groeiend aantal studies 
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die aantonen dat een dieet bestaande uit weinig Na+ en veel K+ een voordelige invloed kan 
hebben op onze gezondheid.  
Impact van dit proefschrift en toekomstperspectief 
Dit proefschrift benadrukt dat NCCSV in aanzienlijkemate in de nier aanwezig is en dat het 
fungeert als een volledig functioneel NaCl-transporterend eiwit. NCCSV is duidelijk geen 
overbodig eiwit, aangezien hier aangetoond is dat het een belangrijke rol speelt in 
(patho)fysiologische processen in de mens. Bovendien functioneert S811 in NCCSV als een 
dominant-negatieve regulator van de NCC activiteit. Deze bevindingen onthullen een nieuw 
mechanisme voor de regulatie van NCC functie, dat belangrijk kan zijn bij de zouthuishouding 
en daarom een belangrijke rol zou kunnen spelen in de pathogenese van essentiële 
hypertensie. Het is relevant om de regulatie van NCCSV in verschillende pathofysiologische 
omstandigheden te bestuderen met behulp van muismodellen. Het inbrengen van NCCSV gen 
in muismodellen die uitsluitend NCCSV en/of NCCSV en NCC3 in de nier tot expressie brengen 
is cruciaal om onze kennis verder te kunnen vergroten. Bovendien kan het ontrafelen van 
kinase eiwitten die betrokken zijn bij de fosforylering van S811 meer inzicht geven in de 
regulatie van NCCSV. Het is bekend dat WNK kinases NCC op residuen anders dan S811 
kunnen fosforyleren. Hoewel WNK kinases een mogelijk therapeutische alternatief bieden, de 
expressie van deze kinases in verschillende segmenten van de nier maakt het minder effectief 
om ze te gebruiken als therapeutische doelen. Het vinden van een kinase dat specifiek de 
fosforylatiestatus van S811 en dus NCC activiteit in de DCT zou kunnen beïnvloeden, lijkt 
essentieel om nieuwe therapeutische strategieën te ontwikkelen zodat de bloeddruk beter 
gecontroleerd kan worden. Hoewel thiazidediuretica vaak de eerste keuze zijn voor het 
verlagen van de bloeddruk, verhogen zij vaak het urinezuurgehalte van het bloed met 
uiteenlopende negatieve gevolgen.  
In dit proefschrift hebben we ook aangetoond dat urinaire exosomen als non-invasief 
hulpmiddel gebruikt kunnen worden om anti-hypertensieve therapie bij patiënten met een 
hoge bloeddruk te begeleiden. Exosoom-analyse kan helpen bij het personaliseren van anti-
hypertensieve behandeling. Urine is niet alleen een belangrijke bron van biomarkers voor de 
prognose van anti-hypertensieve therapieën, maar mogelijk ook voor de diagnose van 
verschillende nierziekten. Het ontstaan en de voortschrijding van nierziekten kan hiermee 
worden beperkt. In de toekomst kan het wellicht voor sommige ziekten een nierbiopt overbodig 
maken. Recentelijk zijn er methoden ontwikkeld om urinaire exosomen makkelijker en sneller 
te kunnen onderzoeken. Echter, voor de verdere klinische toepassingen zijn de ontwikkeling 
van high-throughput assays voor exosoom-analyse noodzakelijk. Exosomen zijn dus 
veelbelovend, maar hun klinische toepassing zal in de toekomst verder ontwikkeld moeten 
worden.
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List of abbreviations 	
AQP2   Aquaporin-2  
ATP   Adenosine triphosphate 
AVP   Arginine vasopressin 
C-terminal  Carboxy-terminal 
Ca2+   Calcium  
cAMP   Cyclic AMP 
CD   Collecting duct 
cDNA   Complementary DNA 
CKD   Chronic kidney disease  
Cl-   Chloride 
CLC-Kb  Cl- channel 
CNIs   Calcineurin inhibitors 
CNT   Connecting tubule 
CsA   Cyclosporine A 
CUL3   Cullin 3  
DCT    Distal convoluted tubule   
DCT1   Early part of the DCT 
DCT2   Later part of the DCT 
DASH   Dietary Approaches to Stop Hypertension  
DMEM   Dulbecco's modified eagle's medium 
DNA   Deoxyribonucleic acid  
DTT   Dithiothreitol 
ECF   Extracellular fluid 
EDTA   Ethylene diamine tetraacetic acid  
eGFP   Enhanced green fluorescent protein 
eGFR   Estimated glomerular filtration rate 
EGTA   Ethylene glycol tetraacetic acid  
ENaC   Amiloride-sensitive epithelial Na+ channel 
Endo H   Endoglycosidase H  
ESRD   End stage renal disease  
FHHt   Familial Hyperkalemic Hypertension 
FLIM   Fluorescence lifetime imaging microscopy  
FRET   Förster resonance energy transfer  
GFP   Green fluorescent protein  
GFR   Glomerular filtration rate  
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HCT   Hydrochlorothiazide  
HCTZ   Hydrochlorothiazide  
HEK293  Human embryonic kidney  
IB   Immunoblotting  
IHC   Immunohistochemistry  
K+   Potassium 
KDa   Kilo dalton 
KLHL3   Kelch-like 3  
KS-WNK1  Kidney-specific WNK1 
mDCT   Mouse distal convoluted tubule  
Mg2+   Magnesium  
MQ   Milli-Q water  
MR   Mineralocorticoid receptor 
mRNA   Messenger ribonucleic acid  
MS   Mass spectrometry  
MS/MS   Tandem MS  
N-terminal  Amino-terminal 
Na/K-ATPase  Na+/K+ pump 
Na+   Sodium 
NaCl   Salt 
NAMIS   Nijmegen Anti-hypertensive Management Improvement Study  
NaPi   Sodiumphosphate symporters 
NCC    Thiazide-sensitive NaCl cotransporter 
NCC1-3   Isoforms 1, 2 and 3 of the thiazide-sensitive NaCl cotransporter 
NCC1/2   Isoforms 1 and 2 of the thiazide-sensitive NaCl cotransporter  
NCC3   Isoform 3 of the thiazide-sensitive NaCl cotransporter  
NCC3   NaCl cotransporter isoform 3  
NCCSV   NaCl cotransporter isoform 1 and 2  
NCCSV   NCC splice variant 
NHE3   Na+/H+ exchanger type 3 
NKCC2   Furosemide-sensitive NaKCl cotransporter 
NT-proBNP  N-terminal of the prohormone brain natriuretic peptide  
OSR1   Oxidative stress responsive protein type 1 
PCR   Polymerase chain reaction 
PHAII   Pseudohypoaldosteronism type II  
Pi   Phosphate 
PKA   Protein kinase A 
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PKC   Protein kinase C 
pNCC   Phosphorylated thiazide-sensitive NaCl cotransporter 
pNCC1-3  Phosphorylated total thiazide-sensitive NaCl cotransporter  
PNGase F  N-glycosidase F 
PROBE  Prospective open-label and blinded end-point  
PT   Proximal tubule 
PVDF   Polyvinylidene difluoride  
RAAS   Renin-angiotensin-aldosterone system  
RNA   Ribonucleic acid 
ROMK  Renal outer medullary K+ channel 
RT   Reverse transcriptase 
RT-PCR  Real time PCR  
S811   Serine 811  
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM   Standard error of the mean  
SGK1   Serum and glucocorticoid-inducible kinase 1 
SPAK   STE20/SPS1-related proline alanine-rich kinase 
T55   Threonine 55  
T60   Threonine 60  
Tac   Tacrolimus  
TAL   Thick ascending limb of Henle’s loop 
tNCC   Total thiazide-sensitive NaCl cotransporter 
uEVs   Urinary extracellular vesicles  
V2R   Type 2 vasopressin receptor 
Val   Valsartan  
WNK   With no lysine   
YFP   Yellow fluorescent protein  
β-met   β-mercaptoethanol 
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Curriculum vitae  
Omar A.Z. Tutakhel was born in Kabul, Afghanistan, 
on 20 February 1988. After graduating from high 
school in 2006 at Merlet College in Grave, The 
Netherlands, he studied Life Sciences for four years 
at the HAN University in Nijmegen, The Netherlands. 
He obtained his Bachelor major in Microbiology and 
minor in Biochemistry. In 2010, he decided to pursue 
his interest in health sciences and enrolled in the 
Master of Biomedical Sciences (dual major 
Toxicology and Human Pathobiology) at Radboud 
University in Nijmegen, The Netherlands. For his first Master internship, he performed an 
internship at the departments of Pharmacology-Toxicology and Physiology under the 
supervision of Prof. dr. Roos Masereeuw and Prof. dr. Joost G.J. Hoenderop. During this 
internship, he investigated the regulation of sodium-dependent phosphate transporters in a 
conditionally immortalized human proximal tubule cell line. He performed his second Master 
internship in 2013 at the department of Biochemistry, Université de Montréal, Canada, 
where he studied the genome-wide expression profiling of the response to nicotinamide in 
Candida albicans using RNA sequencing. The same year, after obtaining his Master’s 
degree, Omar joined the department of Physiology of the Radboud university medical center 
(Radboudumc) as a PhD candidate. Under the supervision of Prof. dr. René J.M. Bindels, 
Prof. dr. Joost G.J. Hoenderop, Dr. Jenny van der Wijst and Dr. Ewout J. Hoorn, he studied 
the novel molecular and functional implications of the NaCl cotransporter in hypertension. 
Additionally, his PhD research demonstrated that urinary exosomes can be used as a non-
invasive tool to guide anti-hypertensive therapy in patients with hypertension. Subsequently, 
as postdoctoral researcher at the department of Physiology of the Radboudumc, Omar is 
dedicated to clinically utilize urinary exosomes as a non-invasive biomarker for a variety of 
(patho)physiological conditions. During his graduation research, Omar’s work was selected 
for poster presentations at the American Society for Nephrology (ASN) in USA and 
EURenOmics Heidelberg Meeting in Germany. Additionally, he obtained a NVBMB Travel 
Award to attend the Experimental Biology (EB) Meeting in USA. Moreover, he was awarded 
with the ‘Best Oral Presentation Award’ at the 23rd edition of the PhD retreat of the Radboud 
Institute for Molecular Life Sciences (RIMLS). He successfully followed the PhD training 
programme of the RIMLS and supervised 16 students from Biomedical Sciences, Medicine, 
Medical Biology and Molecular Mechanisms of Disease Bachelor’s and Master’s studies.
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Research data management  
Appropriate research data management is important for safeguarding scientific integrity, 
open science, safekeeping of valuable datasets and the reuse of data. The data obtained 
during my PhD at the Radboud university medical center (Radboudumc) are archived 
according to the Findable, Accessible, Interoperable and Reusable (FAIR) principles (1). At 
the beginning of my PhD we introduced a digital lab book called Labguru, which is centrally 
stored and daily backed up on the local server of Radboudumc. The primary (raw) and 
secondary (processed) data that were generated, have been stored on Labguru and local 
server of the department of Physiology and viewed by the associated principal investigators 
(PIs). Both the local server of our department and Labguru are supported by the Information 
and Communications Technology (ICT) of Radboudumc. Primary and secondary data of all 
projects that were stored the local server were weekly backed-up on the university servers. 
The data archives on the Labguru and local server are accessible by the associated 
scientific staff members. However, once the data are locked, the staff members can only 
view (= download) data files of the archive from Labguru and the local server, but not edit or 
remove any archived file. In Chapter 2, 3, and 5, human studies were conducted according 
to the principles expressed in the Declaration of Helsinki. All participants gave written 
informed consent for the use of their data and samples. The study protocols, including the 
data management plan were approved by the associated Medical Ethics Committee of the 
Radboudumc and Erasmus Medical Center. Animal studies in Chapter 5 and 6 were 
approved by the Central Animal Laboratory and the Animal Ethics Board of the associated 
Universities. Published data generated or analyzed in this thesis are included in published 
articles and its additional files are available from the associated corresponding authors on 
request. To ensure general accessibility of the data, all file names, all primary and 
secondary data, metadata, descriptive files and program code and scripts used to produce 
the final results such as figures, tables, statistical analyses were documented according to 
the protocol of the department of Physiology.  
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Oral and poster presentation are indicated with a * and # after the name of the activity, respectively  
RIMLS Portfolio 
Name PhD student:    Omar A.Z. Tutakhel 
Department:                Physiology 
Research School:       Radboud Institute for  
                                      Molecular Life Sciences 
 
 
PhD period:          01-09-2013 – 31-08-2017 
Promotors:                   Prof. dr. R.J.M. Bindels 
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                              Prof. dr. E.J. Hoorn, Erasmus MC 
Copromotor:        Dr.  J. van der Wijst  
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Mijn wereldreis begon in Afghanistan in een zeer dynamische periode. Door mijn constant 
veranderende leefomgeving gedurende mijn vlucht periode waarbij ik door 17 landen gereisd 
heb in 10 jaar, heb ik veel geleerd. In deze reis van mijn leven wil ik alle mensen van harte 
bedanken die mij hebben gevormd, bijgestaan, mij lieten en leerden glimlachen in het leven 
ondanks de vele moeilijkheden waarmee we te maken hadden. Met dit proefschrift sluit ik een 
zeer leerzame en positieve deel van mij leven af. Ik hoop dat ik met dit proefschrift mijn 
steentje heb kunnen bijdragen aan de kennis van zouttransport in de nier en hiermee wil ik 
graag mijn promotoren, collega’s, vrienden en families bedanken.  
Ten eerste wil ik mijn promotoren prof. dr. René Bindels, prof. dr. Joost Hoenderop en prof. 
dr. Ewout Hoorn en copromotor dr. Jenny van der Wijst veel bedanken voor hun steun en 
vertrouwen. Ik dank mijn promotieteam ook voor alle kansen en mogelijkheden die ze mij de 
afgelopen jaren hebben gegeven. Ik heb genoten van mijn tijd op afdeling Fysiologie. René, 
ik bewonder jouw gedrevenheid, ambitie, energie en inspanning voor de afdeling Fysiologie 
en het RIMLS. Dankzij jouw kennis, organisatievaardigheden, efficiëntie en proactieve 
houding staat de afdeling Fysiologie hoog in het vaandel van in de (inter)nationale 
onderzoeksgemeenschap. Elke keer als ik ergens tegen aanliep, kon ik snel bij je terecht. 
Dankzij jouw begeleiding is dit proefschrift geworden wat het nu is. Ik heb ontzettend veel van 
je geleerd en ik hoop nog heel veel van je te mogen leren aankomende tijd bij de afdeling 
Fysiologie. Joost, jouw passie, inzet en enthousiasme voor onderzoek was zeer motiverend 
en leerzaam. Bedankt voor je meedenken en adviezen gedurende mijn onderzoek. Jou inzet 
in het succesvol afronden van mijn PhD speelt een belangrijke rol. Bedankt voor je 
ondersteuning en vertrouwen in de afgelopen jaren. Ewout, ik vind het een groot voorrecht 
om samen met jou te mogen werken. Het was zeer cruciaal voor mijn PhD om kennis, ideeën 
en expertise tussen beide afdeling uit te wisselen. Onze gezamenlijke inspanning hebben tot 
mooie publicaties geleid. Ik ben je daarvoor ontzettend dankbaar! We hopen deze 
samenwerking in de toekomst succesvol door te zetten. Jenny, je hebt mij ontzettend veel 
geholpen met het schrijven van dit proefschrift. Ik heb veel geleerd van jouw directe 
begeleiding en moleculaire kennis. Dankzij jou inzet en kennis zijn hoofdstukken 4 en 6 van 
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 رھﻧﻣﺎی ﺗداوی دﻗﯾق ﻓﺷﺎر ﺑﺎﻻی ﺧون را از طرﯾق ﻣﻌﺎﯾﻧﮫ ادرار ﻧﺷﺎن ﻣﯾدھد. اﮔزوزوماﺳﺗﻔﺎده 
 ﺗﺷﺧﯾص ﺑﯾﻣﺎریﺑﮫ طور ﻣداوم از طرﯾق ادرار دﻓﻊ ﻣﯽ ﺷوﻧد و ﺑﮫ ھﻣﯾن ﺗرﺗﯾب آﻧﮭﺎ ﯾﮏ ﻣﻧﺑﻊ  اﮔزوزوم
 ﯾنﭘروﺗﺋ ﯾلو ﺗﺣﻠ ﯾﮫﺗﺟز یﺑرا ﯾقروش دﻗ ﯾﮏﻧﺎﻣﮫ، ﻣﺎ  ﯾﺎنﭘﺎ ﯾندر ا .ھﺎی ﮐﻠﯾوی ھﺳﺗﻧد ﺑﯾﻣﺎری یﺑرا
ﻧﺷﺎن ﻣﯽ دھد  ۵و  ٣، ١ﻓﺻل در اﯾن ﭘﺎﯾﺎن ﻧﺎﻣﮫ، . ﯾمﮐرده ا ﯾﺟﺎدا یادرار یھﺎ مدر اﮔزوز CCN یھﺎ
ﮐﮫ اﮔزوزوم ھﺎی ادراری ﺑﮫ ﻋﻧوان ﯾﮏ روش ﻣﻧﺣﺻر ﺑﮫ ﻓرد و ﻏﯾر ﺗﮭﺎﺟﻣﯽ ﺑرای ﻣطﺎﻟﻌﮫ ﺗﻧظﯾم 
ھﺎی ادراری  مزاﮔزودر  CCNدر ﮐﻠﯾﮫ اﻧﺳﺎن اﺳﺗﻔﺎده ﻣﯽ ﺷود. ﻋﻼوه ﺑر اﯾن، ﺗﺟزﯾﮫ و ﺗﺣﻠﯾل  CCN
درﻣﺎن ﺿد ﻓﺷﺎر ﺧون را  و ،ﮕزﯾن ﺑرای ﻧظﺎرت ﺑر ﺑﯾﻣﺎران ﻣﺑﺗﻼ ﺑﮫ ﻓﺷﺎر ﺧون ﺑﺎﻻﯾﯾﮏ روش ﺟﺎ
  CCNادرار ﻣﯽ ﺗواﻧد ﺑﮫ درﻣﺎن ﻣوﺛر و ﺷﺧﺻﯽ ﻓﺷﺎر ﺧون ﺑﺎﻻ ﮐﻣﮏ ﮐﻧد. در اﮔزوزومﻓراھم ﻣﯽ ﮐﻧد. 
ﺗﯾﺎزﯾد  .ﮑﻧدﯾﮏ ھﺎی ﺗﯾﺎزﯾد را ﭘﯾش ﺑﯾﻧﯽ ﻣﯾﺑﮫ دﯾورﺗ ﺑﯾﻣﺎران ﯽﺷﺧﺻ ﻓﺎﯾدهاﮔزوزوم ھﺎی ادراری در
اوﻟﯾن داوای  اﺳت ﮐﮫ ﺑرای ﻓﺷﺎر ﺑﺎﻻی ﺧون اﺳﺗﻔﺎده ﻣﯾﺷود. ﺗﯾﺎزﯾد دﯾورﺗﯾﮏ دﯾورﺗﯾﮏ ﯾﮑﯽ از دوا ھﺎی
. ﺑﮫ اﯾن طرﯾق درا ﺑﻧد ﻣﯾﺳﺎز CCNاﺳت ﮐﮫ ﺑرای ﻓﺷﺎر ﺑﻠﻧد داده ﻣﯾﺷود. ﺗﯾﺎزﯾد دﯾورﺗﯾﮏ دروازه ھﺎی 
ب ھﻣﭼﻧﺎن از ﺑدن ﺧﺎرج ﻣﯾﺷود. ﺑﮫ اﯾن طرﯾق ﻓﺷﺎر ﺧون را آﺳودﯾم دﻓﻊ ﮐﻠﯾﮫ ﻣﯾﺷود. و ﺑﺎ دﻓﻊ ﺳودﯾم 
ﺑﮫ ﺗﯾﺎزﯾد ھﺎ وﺟود دارد. ﺷﺎﯾﺎن ذﮐر  ﺧون ﻓﺷﺎرﮐﺎھش ﻣﺎ ﻣﯽ داﻧﯾم ﺗﻧوع ﺑﯾن ﻓردی در  ﮐﺎھش ﻣﯾدھد.
ﻗﺑل از درﻣﺎن  ھﺎی ادراریاﮔزوزوم در  CCNاﺳت، ﻧﺗﺎﯾﺞ ﻣﺎ ﻧﺷﺎن ﻣﯾدھد ﮐﮫ ﺗﺟزﯾﮫ و ﺗﺣﻠﯾل ﺑﯾﺎن 
ن ﺟﺎﻟب اﺳت ﮐﮫ ﺎ. ھﻣﭼﻧﯾورﺗﯾﮏ ھﺎی ﺗﯾﺎزﯾدی ﭘﯾش ﺑﯾﻧﯽ ﮐﻧدﺑﮫ د را ﺗﯾﺎزﯾدی ﻣﯽ ﺗواﻧﯾد ﭘﺎﺳﺦ ﻓﺷﺎر ﺧون
ﺑﺗواﻧﻧد ﭘﺎﺳﺦ ﻓﺷﺎر ﺧون را  ﺗﺎﺑررﺳﯽ ﺷود  یھﺎی ادرار مﻗﺑل از درﻣﺎن ﺑﺎ دﯾورﺗﯾﮏ ھﺎی دﯾﮕر، اﮔزوز
 ﭘﯾش ﺑﯾﻧﯽ ﮐﻧﻧد.
  
 .آﯾﻧدهﺗﺄﺛﯾر اﯾن ﭘﺎﯾﺎن ﻧﺎﻣﮫ و دﯾدﮔﺎه 
ﻣﯽ ﺗواﻧد ﺑﮫ ﻋﻧوان اﺑزار ﻏﯾر ﺗﮭﺎﺟﻣﯽ ھﻣراه اﮔزوزم ھﺎی ادراری در اﯾن ﭘﺎﯾﺎن ﻧﺎﻣﮫ، ﻣﺎ ﻧﺷﺎن دادﯾم ﮐﮫ 
ﺑﺎ درﻣﺎن ﺿد ﻓﺷﺎر ﺧون در ﺑﯾﻣﺎران ﻣﺑﺗﻼ ﺑﮫ ﻓﺷﺎر ﺧون ﺑﺎﻻ ﻣورد اﺳﺗﻔﺎده ﻗرار ﮔﯾرد. ﺗﺟزﯾﮫ و ﺗﺣﻠﯾل 
درﻣﺎن ﺿد ﻓﺷﺎر ﺧون. ادرار ﻧﮫ ﺗﻧﮭﺎ ﻣﻧﺑﻊ ﻣﮭم  ﺑﮫ ﺷﺧﺻﯽﮐﻧد ﻣﯽ ﺗواﻧد ﮐﻣﮏ  اﮔزوزم ھﺎی ادراری
ﺑرای ﭘﯾش آﮔﮭﯽ درﻣﺎن ھﺎی ﺿد ﻓﺷﺎر ﺧون اﺳت، ﺑﻠﮑﮫ ھﻣﭼﻧﯾن ﺑرای ﺗﺷﺧﯾص ﺑﯾﻣﺎری  ﺗﺷﺧﯾص ﺑﯾﻣﺎری
ھﺎی ﻣﺧﺗﻠف ﮐﻠﯾوی اﺳت. اﯾن ﻣﻣﮑن اﺳت ﺷروع و ﭘﯾﺷرﻓت ﺑﯾﻣﺎری ھﺎی ﮐﻠﯾوی را ﻣﺣدود ﮐﻧد. در 
ﮐﻠﯾﮫ ﻏﯾر ﺿروری ﺑﺎﺷد. ﺑﮫ ﺗﺎزﮔﯽ روش ھﺎﯾﯽ ز uرﻓﺗن ﭘﺎرﭼﮫ اآﯾﻧده، ﻣﻣﮑن اﺳت ﺑرﺧﯽ از ﺑﯾﻣﺎری ھﺎ 
ھﺎی ادراری ﺑﮫ ﮐﺎر ﮔرﻓﺗﮫ ﺷده اﺳت. ﺑﺎ اﯾن ﺣﺎل، ﺑرای ﺑرﻧﺎﻣﮫ ھﺎی ﮐﺎرﺑردی  مﺑرای ﺑررﺳﯽ اﮔزوز
ﺿروری اﺳت. ﺑﻧﺎﺑراﯾن  اﮔزوزمﺑﺎﻟﯾﻧﯽ ﺑﯾﺷﺗر، ﺗوﺳﻌﮫ آزﻣﺎﯾش ھﺎی ﺑﺎ ﮐﺎراﯾﯽ ﺑﺎﻻ ﺑرای ﺗﺟزﯾﮫ و ﺗﺣﻠﯾل 
ﺷﻔﺎﺧﺎﻧﮫ ھﺎ در آﯾﻧده ﺑﺎﯾد در ﮐﻠﯾﮫ ﺗﺷﺧﯾص ﺑﯾﻣﺎری ﺎﺑ اﮔزوزمده اﺳﺗﻔﺎ اﻣﯾدوار ﮐﻧﻧده اﺳت، اﻣﺎ اﮔزوزوم
 ﺗﺣﻘﯾﻘﺎت ﺷود.
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 .ﺑﻧﺎم ﺧداوﻧد ﯾﮑﺗﺎ و ﻧﮭﺎﯾت ﻣﮭرﺑﺎن
 
 .ﻣﻘدﻣﮫ
 .ﻓﺷﺎر ﺧون
ﯾﮏ ﻋﺎﻣل ﺧطر ﺑرای ﺑﯾﻣﺎری ھﺎی ﻗﻠﺑﯽ ﻋروﻗﯽ و ﻧﺎرﺳﺎﯾﯽ ﻣزﻣن ﮐﻠﯾﮫ اﺳت و در ﻧﺗﯾﺟﮫ  ﻓﺷﺎر ﺧون ﺑﺎﻻ
ﺑزرﮔﺳﺎﻻن در ﺳراﺳر  ٣ در ١ﻣﯾﻠﯾﺎرد ﻧﻔر ﯾﺎ  ۴.١ را اﻓزاﯾش ﻣﯽ دھد. ﺑﺎ ﺷﯾوع ﮫ ﻣرگﺧطر اﺑﺗﻼ ﺑ
ﻋﻣوﻣﻲ اﺳت. ﻗﺎﺑل ﺗوﺟﮫ  ﻲﯾﮑﻲ از ﺟدي ﺗرﯾن ﻣﺷﮑﻼت ﺳﻼﻣﺗ ﺑﮫ اﯾن ﺧﺎطر ،دارد ﺟﮭﺎن، ﻓﺷﺎر ﺧون
اﺳت ﮐﮫ ﻧﯾﻣﯽ از ﺑﯾﻣﺎران ﻣﺑﺗﻼ ﺑﮫ ﻓﺷﺎر ﺧون ﺑﺎﻻ از وﺿﻌﯾت ﺧود آﮔﺎھﯽ ﻧدارﻧد و ﺑﻧﺎﺑراﯾن ﻓﺷﺎرﺧون 
ﺑﯾﻣﺎران ﻣﺑﺗﻼ ﺑﮫ ﻓﺷﺎرﺧون  ٪٠٩ ﺗﻘرﯾﺑﺎد. ﻋﻼوه ﺑر اﯾن ﻋﻠت اﻏﻠب ﺑﮫ ﻋﻧوان "ﻗﺎﺗل ﺧﺎﻣوش" ﻧﺎﻣﯾده ﻣﯽ ﺷو
 ﻧﺎﺷﻧﺎﺧﺗﮫ اﺳت.
 
ﮐﻠﯾﮫ ھﺎ و ﻗﻠب ﻧﮕﮭداری ﻣﯽ ﺷود. ﮐﻠﯾﮫ ھﺎ ﻋﻣدﺗﺎ  ،ﻓﺷﺎر ﺧون ﺗوﺳط ﺗرﮐﯾﺑﯽ از ﺑﺧش ھﺎی ﺧﺎص ﻣﻐز
رطوﺑت و ﺷوری را در ﺑدن ﻣﺎ ﮐﻧﺗرل ﻣﯽ ﮐﻧﻧد و درﻧﺗﯾﺟﮫ ﺑﺎﻋث اﻓزاﯾش ﻓﺷﺎر ﺧون ﻣﯽ ﺷوﻧد. ﮐﻠﯾﮫ از 
و ﺑﯾش  ﻣﯽ ﮐﻧﻧد ﺻﺎفﻣﯾﻠﯾون ﻧﻔرون، واﺣد ھﺎی ﻋﻣﻠﮑردی ﮐﻠﯾﮫ ﺗﺷﮑﯾل ﺷده اﺳت. آﻧﮭﺎ ﺧون را  ١ﺣدود 
)درھم  ﭘس از ﻓﯾﻠﺗر ﮐردن ﺧون ﺑﮫ ﮔﻠوﻣرول. از طرﯾق ادرار ﻓراھم ﻣﯽ ﮐﻧﻧدرااز ﺣد ﻧﻣﮏ و رطوﺑت 
را از طرﯾق ﻟوﻟﮫ ھﺎی ﮐﻠﯾﮫ ﺟرﯾﺎن ﻣﯽ دھد. ﻓرآﯾﻧد  ادرار ،و ﺑرھم ﮐردن رگ ھﺎی ﮐوﭼﮏ ﺧوﻧﯽ(
و ﺧون وارد رگ ھﺎی ﺧوﻧﯽ در اطراف ﻟوﻟﮫ ﮐﻠﯾﮫ اﺗﻔﺎق  ادرارﻟﮫ ﺟذب و ﺗﺣوﯾل آب و ﻧﻣﮏ ﺑﯾن ﻣﺑﺎد
 و  aN(+) ﺳودﯾمﻣﯽ اﻓﺗد. ﻗﺳﻣت ﻧﮭﺎﯾﯽ ﻟوﻟﮫ ﮐﻠﯾﮫ ﻧﻘش ﻣﮭﻣﯽ در ﺗﻧظﯾم ﻓﺷﺎر ﺧون ﺗوﺳط ﺗﺄﺛﯾر ﺗﺑﺎدل 
اﺳت. ﺿﺑط، و   C(TN)ﻟوﻟﮫ اﺗﺻﺎل  و )TCD( اﯾﻔﺎ ﻣﯽ ﮐﻧد. اﯾن ﻗﺳﻣت ﺷﺎﻣل ﭘﯾﭼش دﯾﺳﺗﺎل K(+)ﭘﺗﺎﺳﯾم 
                       رﻛﻠوراﯾد ﻛوﺗراﻧﺳﭘوﺗ ﺳودﯾم ﺑﮫ طرﯾق در اﯾن ﺑﺧش از ﻟوﻟﮫ ﮐﻠﯾﮫ ﺳودﯾمﯾﺎ ﺗﺣﻠﯾل، از 
 CCN .ﻣﯽ ﺷود ادرار طرﯾق از ﺗﺣت ﮐﻧﺗرل)CaNE( اﭘﯾﺗﻠﯾﺎل ﺳودﯾم  ﺳودﯾم و ﮐﺎﻧﺎل ھﺎی )CCN(
ﺗﻌﯾﯾن ﻣﯾزان ﺳودﯾم در  ﺳودﯾمﻣﯾزان  TCD. در اﺳت TNCﺧﺎص در   CaNE اﺳت و TCD درﺧﺎص 
. دارد CaNEاز طرﯾق  ﺳودﯾمﻣﺳﺗﻘﯾم در ﺟذب ﻏﯾر ﻧﻘش  CCNدر ﻧﺗﯾﺟﮫ  . ﺑﻧﺎﺑر اﯾنﻣﯽ ﺷود TNC
ﻣﯽ ﺷود. ھورﻣون ھﺎی ﻣﺗﻌددی  KMORاز طرﯾق  ﭘﺗﺎﺳﯾمﺑﮫ اﻧﺗﺷﺎر )دﻓﻊ(  CaNEاز طرﯾق  ﺳودﯾمﺟذب 
-آﻧژﯾوﺗﺎﻧﺳﯾن-ﺳﯾﺳﺗم رﻧﯾنل ﻣﯽ ﮐﻧد. ورا ﮐﻧﺗر ﭘﺗﺎﺳﯾمو  ﺳودﯾموﺟود دارد ﮐﮫ اﯾن ﺷﺑﮑﮫ از ﺷﺑﮑﮫ ھﺎی 
ﺑﻧﺎﺑراﯾن ﮐم ﺧوردن ﻧﻣﮏ و زﯾﺎد  ﻧﻘش ﻣﮭﻣﯽ در ﺗﻧظﯾم ﻓﺷﺎر ﺧون دارد. )SAAR( آﻟدوﺳﺗرون ھورﻣوﻧﯽ
ﺑﺎﯾد ﯾﺎداور ﺷوﯾم ﮐﮫ  ﺧطر اﺑﺗﻼ ﺑﮫ ﭘرﻓﺷﺎری ﺧون را ﮐﺎھش دھد. و ﺧوردن ﭘﺗﺎﺳﯾم ﺷﻧﺎﺧﺗﮫ ﺷده اﺳت
ﺗﺎزه و ﺧﺷﮏ ﻣوﺟود ﻣﯾﺑﺎﺷد از ﺟﻣﻠﮫ ﻣﺎﻧﻧد ﮐﯾﻠﮫ، ﻣﺎﻟﺗﮫ، اب  ﭘﺗﺎﺳﯾم ﺑﮫ ﻣﻘدار زﯾﺎد در ﺗرﮐﺎرھﺎ و ﻣﯾوﺟﺎت
.وﻏﯾره ﺑﺎدام ﻧﺎ﷼، ﺳﺑزی ﭘﺎﻟﮏ، ﺑﺎدﻧﺟﺎن روﻣﯽ، ﮐﺷﻣش،
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 ﻣوﺟودﯾت ﭘﮫ ادرار ﮐﯽ د وﯾﻧﯽ ﻟور ﻓﺷﺎر دﻗﯾق ﻻر5ود دې. (semosoxE)د ا(زوزوم 
 ﯾﻧﯥﺳرﭼ ﻟﭘﺎره  Rﻧﺎروﻏ ﺷﮑل د ادرارو ﭘﮫ واﺳطﮫ دﻓﻊ ﮐﯾژی. ﻧو Fﮑﮫ د ﺑډوډو د اCزوزوم ﭘﮫ دواﻣدار
 ﯾلﺗﺣﻠ اCزوزوﻣو ادرارو د _ﯾﻧوﻧوﭘرو CCNد  ﯥﭘﮫ د ﻣﺛﺎل ﮐ ږﻣو ﻟﯾﮏ ﮐﯽ،ﭘﮫ دی ﭘﺎی  .دي ﯾصﺗﺷﺧ د
ﻓﺻﻠوﻧﮫ ﭼﮫ د ادرارو اCزوزوم   ۵، ٣، ٢ﺟور ﮐری  .ید ړیﮐ ﯾﺎرﺗ ﯾﺗودواﺿﺢ ﻣ ﯾوﻟﭘﺎره ﺗﺟزﯾﮫ د  او
  CCNﮐﯽ اﺳﺗﻔﺎده Cﯾږی، ﺳرﺑﯾره ﭘر دی ید ﯾو ﻻرiود او ﯾو ﻏﯾر ﯾرﻏﻠﯾز ﭘﮫ ﺗوCﮫ د اﻧﺳﺎن ﭘﮫ ﺑډوډ ﮫi
اCزوزوﻣو ﺗﺟزﯾﮫ ﺗﺣﻠﯾل د وﯾﻧﯽ  ادرارو د _ﯾﻧوﻧوﭘرو CCN ﻣطﺎﻟﻌﮫ د ادرارو ﭘﮫ اCزوزوم ﯾوﻻرiود ده.
درﻣﻠﻧﮫ ﮐﯽ   ﻟور ﻓﺷﺎرﻧﺎروﻏﺎن او د ھﻐوی درﻣﻠﻧﯽ ﻧظﺎرت ﮐوی. د ادرارو اCزوزوم د ﻟور ﻓﺷﺎر ﻣوﺛره
ل ﮐﯽ وراﻧدﻧﯾﮫ د ادرارو ﭘﮫ اCزوزوم ﮐﯽ د ﻧﺎروغ Fواب د ﺗﯾﺎزﯾد دﯾورﺗﯾﮏ ﭘﮫ ﻣﻘﺎﺑ CCN ﻣرﺳﺗﮫ ﮐوی.
ﺗﯾﺎزﯾد دﯾورﺗﯾﮏ ھﻐﮫ دوا ده ﭼﮫ د وﯾﻧو د ﻟور ﻓﺷﺎر د ﭘﺎره اﺳﺗﻔﺎده ﮐﯾږی. ﺗﯾﺎزﯾد دﯾورﺗﯾﮏ ﻟوﻣرﻧﯽ  ﮐوی.
دروازی ﺑﻧدوی. ﭘﮫ ھﻣدی   CCNدارو ده ﭼﮫ د ﻟور ﻓﺷﺎر ﻧﺎروﻏﺎﻧو ﺗﮫ ورﮐول ﮐﯾږی. ﺗﯾﺎزﯾد دﯾورﺗﯾﮏ د
اوﺑو ھم د ﺑدن vﺧﮫ راوFﯽ، او ﭘﮫ ﻧﮫ ورﺳﺗﮫ  اﻧﺗﻘﺎلد  aN+د ﺑډوډو ﭼﺧﮫ دﻓﻊ ﮐﯾږی. د  aN+ﻻره ﮐﯽ 
ﻣوﻧږ ﭘوھﯾwو ﭼﮫ ﺣﺳﺎﺳﯾت د ﺗﯾﺎزﯾد دﯾورﺗﯾﮏ ﭘﮫ ﻣﻘﺎﺑل ﮐﯽ ﭘﮫ  ھﻣدی دول د وﯾﻧﯽ ﻓﺷﺎر ﺗﯾﺗوی.
د ادرارو ﭘﮫ  CCNاﺷﺧﺎﺻوﮐﯽ ﻣوﺟود دی. زﻣوﻧږ ﻧﺗﺎﯾﺞ iﯽ ﺗﺣﻠﯾل او ﺗﺟزﯾﮫ د درﻣﻠﻧﯽ ﻧﮫ ﻣﺧﮑﯽ د 
دی ﻣﻌﻧﯽ ده ﭼﮫ د اCزوزم ﺗﺟزﯾﮫ  دا ﭘﮫ ﮐوی._ﮑل ا اCزوزوم  ﮐﯽ ﮐوﻟﯽ ﺷﯽ ﭼﮫ ﺗﯾﺎزﯾد دﯾورﺗﯾﮏ ﺗﺎﺳﯾر
او ﺗﺣﻠﯾل ﮐوﻟﯽ ﺷو ﭼﮫ ﻏﯾری ﺿروری اﺳﺗﻔﺎده ﻧﮫ ﯾﯽ ﻣﺧﻧﯾوی وﮐرو او ھم ﺟﺎﻟﺑﮫ ده ﭼﮫ ﻣﺧﮑﯽ ﻟﮫ دی 
ﭼﮫ د ﻧورو دﯾورﺗﯾﮏ ﭘﮫ واﺳطﮫ درﻣﻠﻧﮫ وﺷﯽ د ادرارو اCزوزوم ﻣﻌﺎﯾﻧﮫ ﺷﯽ، ﺗر vو ﺗﯾﺎزﯾدو ﻧﮫ وﮐوﻻی 
 ﺷﯽ د ﻟور ﻓﺷﺎر Fواب وراﻧدوﯾﻧﮫ وﮐری.
 
 او د راﺗﻠوﻧﮑﯽ ﭘس ﻣﻧظر. د ﭘﺎی ﻟﯾﮏ اﻏﯾز
ﭘﮫ دی ﭘﺎی ﻟﯾﮏ ﮐﯽ ﻣوﻧږ و iودﻟﮫ ﭼﮫ ادرارو اCزوزم ﮐوﻟﯽ ﺷﯽ ﭼﮫ د ﻏﯾر ﺑرﯾدCر ﭘﮫ ﺷﮑل د ﻟور ﻓﺷﺎر 
ﺿد ادوﯾﮫ ﺳره ﯾو Fﺎی د وﯾﻧﯽ ﻟورﻓﺷﺎر ﻧﺎروﻏﺎﻧو ﮐﯽ اﺳﺗﻔﺎده ﮐﯾږی. اCزوزوم ﺗﺣﻠﯾل او ﺗﺟزﯾﮫ ھﻐﮫ 
ﻣﮭﻣﮫ ﻣﻧﺑﮫ ده  ﯾصﺗﺷﺧ ار ﻧﮫ ﯾوازی دﮐﺳﺎﻧو ﺳره ﭼﮫ د ﻓﺷﺎر ﺿد دواﯾﯽ اﺧﻠﯽ ﻣرﺳﺗﮫ ﮐوی. اCزوزم ادر
ﭼﮫ د ﻟورﻓﺷﺎر ﺿد ﺗداوی iﯽ.  ﺑﻠﮑﮫ د ﻣﺧﺗﻠﻔو ﺑډوډو او ﻧﺎروﻏﯾو د ﺗﺷﺧﯾص د ﭘﺎره ھم ﻣﮭم دی. دا 
اﺧﯾﺳﺗل  ﮐری. او ﭘﮫ راﺗﻠوﻧﮑﯽ د ﺑﯾوﭘﺳﯽ )د ﺑډوډو ﺗوﺗﮫ( _ﮑلﻣﻣﮑن د ﺑډوډو ﻧﺎروﻏﯽ د ﭘﯾل او ﭘرﻣﺧﺗz ا
 اCزوزم د ﺑرﺳﯽ ﻟﭘﺎره ﭘﮫ ﮐﺎر اﺧﯾﺳﺗل ﺷوی ده. ھم ﺿرور ﻧوی. د اوس ﻣﺧﺗﻠﻔﯽ طرﯾﻘو Fﺧﮫ د ادرارو
  ﺑﺎﯾد vرﯾﻧﮫ وﺷﻲ. اCزوزوم د ﺎدهﻔﺑﯾﺎ ھم ﭘﮫ راﺗﻠوﻧﮑﯽ د روﻏﺗوﻧون ﮐﯽ دا اﺳﺗ
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 .ﭘﮫ ﻧﺎﻣﮫ یﺧدا Cوﻧﮑﯽاو ﺑ ید ﻟو
 
 د ﭘﺎﯾﻠﯾﮏ ﻟﻧډﯾز.
 د وﯾﻧﯥ ﻓﺷﺎر.
د وﯾﻧﯥ ﻟوړ ﻓﺷﺎر د زړه د ﻋروﻗﻲ ﻧﺎروﻏﯾو د ﺧطر او د ﺑډوډي د ﻧﺎروﻏﯾو ﯾو ﻟوی ﻻﻣل دی، ﭼﯥ ﭘﮫ 
 ١ﻣﯾﻠﯾﺎردو ﮐﺳﺎﻧو ﯾﺎ د ﻟوﯾﺎﻧو  ۴،١ﻧړۍ ﮐﯥ د وﯾﻧﯥ ﭘﮫ ﻓﺷﺎر د ﭘﺎﯾﻠﮫ ﮐﯥ ﯾﯥ ﻣرګ ﭘﯾCﯾدﻻی ﺷﻲ. ﭘﮫ Wوﻟﮫ 
ﮐﺳﺎﻧو اﺧﺗﮫ ﮐﯾدﻧﮫ ﯾوه ﻋﻣوﻣﻲ روﻏﺗﯾﺎﯾﻲ ﺳﺗوﻧزه ده. دا د ﭘﺎم وړ ده ﭼﯥ د وﯾﻧﯥ ﭘﮫ ﻓﺷﺎر ﻧﯾﻣﺎﯾﻲ  ٣ﭘﮫ 
اﺧﺗﮫ ﮐﺳﺎن د fﺎن ﻟﮫ وﺿﻌﯾﺗﮫ ﺧﺑر ﻧدي، ﻧوfﮑﮫ د وﯾﻧﯥ ﻓﺷﺎر د ﭘټ وژوﻧﮑﻲ ﭘﮫ ﻧﺎم ھم ﯾﺎدﯾږي. ﺑرﺳﯾره 
 ﻏﺎﻧو ﻻﻣل ﻧﺎﭘﯾژاﻧده دی. ﻧﺎرو ٪٠٩ﭘر دې، د 
 
د وﯾﻧﯥ ﻓﺷﺎر د ﺧﺎص ﻣﻐز، ﺑډوډو او زړه ﭘﮫ واﺳطﮫ ﺳﺎﺗل ﮐﯾږي. ﺑډوډي ﭘﮫ وﺟود ﮐﯥ رطوﺑت او ﻣﺎﻟnﮫ 
ﻣﯾﻠﯾون ﻧﻔرون، د ﺑډوډي د  ١ﮐﻧWروﻟوي، ﭼﯥ ﭘﮫ ﭘﺎﯾﻠﮫ ﮐﯥ ﯾﯥ د وﯾﻧﯥ ﻓﺷﺎر ﻟوړﯾږي. ﺑډوډي د ﺷﺎ او ﺧوا 
اﺿﺎﻓﻲ ﻣﺎﻟnﮫ او رطوﺑت د ادرارو ﻟﮫ ﻻرې ﮐړﻧﯥ واﺣد uﺧﮫ ﺟوړ ﺷوﯾدي. ھﻐوی وﯾﻧﮫ دﻓﻊ ﮐوي او 
 )د وﯾﻧﯥ د ﮐوﭼﻧﯾو رwوﻧو wډوډوﻟو( ﺗﮫ وﯾﻧﮫ ﻓﻠﺗر ﮐړي، ادرار دﻓﻊ ﮐوي. وروﺳﺗﮫ ﻟﮫ ھﻐﯥ ﭼﯥ wﻠوﻣرول
 ﯾﻧ}ﺗرﻣ ﯾﻧﯥاو و Wﯾوﺑوﻧود  او اوﺑو ﺟذب او اﻧﺗﻘﺎل ﮐول nﯥد ﻣﺎﻟ .ﯾرﯾږيﺗ ېﻟﮫ ﻻر Wﯾوﺑوﻧو ﺑډوډو د
د  K(+) ﯾماو د ﭘوﺗﺎﺷ aN(+) وﯾﻧﯥ ﻓﺷﺎر ﭘﮫ ﺗﻧظﯾم ﮐﯥ د ﻣﺎﻟnﮫ د ﺑرﺧﮫ ~وروﺳﺗ ﺑډوډي د ﻟوﻟﯥد  .ﯾږيﮐ
او د ﻧCﻠوﻟو  (TCD)ﺑرﺧﮫ د دﯾﺳﺗﺎل ﭘﯾﭼش  ~وروﺳﺗ ﺑډوډي د ﻟوﻟﯥد دﻏﮫ  .ﻣﮭم رول ﻟري ﻲﮐ ﺗﺑﺎدﻟﯥ
 وﺟذﺑ aN+ د ()CCN ﻛﻠوراﯾد ﻛوﺗراﻧﺳﭘوﺗر ﯾمﺳودﻲ ﮐ ﭘدﻏﮫ ﺑرﺧﮫ . ﺑډوډيږيuﺧﮫ ﯾﺎ دﯾ (TNC)ﻟوﻟﮫ 
 (SAAR)د رﻧﯾن آﻧژﯾوﺗﺎﻧﺳﯾن آﻟدوﺳﺗرون ﺳﯾﺳﺗم  ﻣﮫﺎﻧ ﮫﭘھورﻣوﻧوﻧﮫ  .ﻣﮭم رول ﻟري ﻲﮐ لﮑوﺎرﺟاو ﺧ وﻟ
ﻧو fﮑﮫ ﻣﺎﻟnﯽ ﻟﮏ اﺳﺗﻔﺎده  د دﻏﯥ ﯾوه ﻣﮭﻣﮫ ﺑرﺧﮫ ده او د وﯾﻧﯥ ﻓﺷﺎر ﭘﮫ ﺗﻧظﯾم ﮐﮫ ډﯾر ﻣﮭم رول ﻟري.
ه او وﭼﮫ ﻣﯾوه رل د ﻟور ﻓﺷﺎر ﺧطر ﮐﻣوی. ﭘﮫ دﯾره اﻧدازه ﭘﺗﺎﺳﯾم ﭘﮫ ﺗرﮐﺎرﯾو، ﺗﺎزﮐول او ﭘﺗﺎﺳﯾم دﯾر ﺧو
 ﮐﯽ ﺷﺗﮫ ﻟﮑﮫ ﭘﮫ ﮐﯾﻠﮫ، ﻣﺎﻟﺗﮫ، د ﻧﺎ﷼ اوﺑﮫ، ﺳﺑزی ﭘﺎﻟﮏ، روﻣﯽ ﺑﺎﻧﺟﺎن، ﻣﻣﯾز، ﺑﺎدام او داﺳﯽ ﻧور.
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